PROTEOMIC IDENTIFICATION OF THE TRANSCRIPTION FACTORS IKAROS AND AIOLOS AS NEW MYC INTERACTORS ON CHROMATIN by C.V. Locarno
European School of Molecular Medicine (SEMM) 
University of Milan and University of Naples “Federico II” 
 	  
PhD degree in Systems Medicine (curriculum in Molecular Oncology) 
Settore disciplinare: BIO/11 
 
 
Proteomic identification of the transcription factors 
Ikaros and Aiolos as new Myc interactors on chromatin 
 
Chiara Veronica Locarno 
Matricola: R10755 
 
Center for Genomic Science IIT@SEMM, Milan 
 
 
Supervisor: Bruno Amati, PhD 
 IEO, Milan  
 
Added Supervisor: Arianna Sabò, PhD 





Academic year 2017-2018 
	   1	  
Table of contents 
 
List of abbreviations ........................................................................................................... 4 
List of figures ....................................................................................................................... 8 
List of tables ....................................................................................................................... 11 
Abstract .............................................................................................................................. 12 
1. INTRODUCTION ......................................................................................................... 13 
1.1 Myc ........................................................................................................................................ 13 
1.1.1 Myc discovery and structure ........................................................................................... 13 
1.1.2. Role of Myc in physiological and pathological conditions ............................................ 15 
1.1.3. Myc interactions on chromatin ....................................................................................... 17 
1.1.3.1. Myc binding to DNA ............................................................................................................ 17 
1.1.3.2. Mechanisms of transcriptional control by Myc .................................................................... 19 
1.1.4. Myc and cancer therapy ................................................................................................. 21 
1.2. B-cell development ............................................................................................................ 22 
1.2.1. Early development .......................................................................................................... 22 
1.2.2. Maturation ...................................................................................................................... 24 
1.2.3. Antibody production and memory ................................................................................. 25 
1.2.4. Role of Myc in B lymphopoiesis .................................................................................... 27 
1.3. Ikaros and Aiolos ................................................................................................................ 28 
1.3.1. Ikaros discovery and structure ........................................................................................ 28 
1.3.2. Function of Ikaros and Aiolos in hematopoiesis ............................................................ 30 
1.3.3. Expression pattern of Ikaros family members ................................................................ 32 
1.3.4. Ikaros and Aiolos role in B lymphocyte development ................................................... 33 
1.3.4.1. Priming of the lymphoid lineage ........................................................................................... 33 
1.3.4.2. Ikaros role in early B cell progenitors ................................................................................... 34 
1.3.4.3. Role of Aiolos in mature B cells ........................................................................................... 35 
1.3.5. Mechanisms of action ..................................................................................................... 35 
1.3.6. Pathologies and therapies ............................................................................................... 38 
	   2	  
Aim of the project ............................................................................................................... 40 
2. MATERIALS AND METHODS ................................................................................. 41 
2.1. Cell lines ................................................................................................................... 41 
2.2. Cell transfection ....................................................................................................... 42 
2.3. Cell transduction ...................................................................................................... 43 
2.4. Proliferation assays .................................................................................................. 43 
2.5. Chromatin proteomics (ChroP) ........................................................................................ 44 
2.5.1. Chromatin Immunoprecipitation (ChIP) ........................................................................ 44 
2.5.2. In-gel digestion for MS .................................................................................................. 45 
2.5.3. Liquid chromatography and tandem Mass Spectrometry (LC-MS/MS) ........................ 46 
2.5.4. Protein identification by MaxQuant software and data analysis .................................... 47 
2.6. ChIP-qPCR ............................................................................................................... 48 
2.7. Western Blot (WB) .................................................................................................. 48 
2.8. Co-Immunoprecipitation (coIP) ............................................................................... 49 
2.9. ChIP-sequencing (ChIP-seq) .................................................................................... 49 
2.10. ChIP-seq analysis ................................................................................................... 50 
2.11. RNA extraction and analysis: quantitative PCR (qPCR) and RNA-seq. ............... 51 
2.12. RNA-seq data analysis ........................................................................................... 51 
2.13. Motif analysis ......................................................................................................... 52 
2.14. Functional annotation ............................................................................................. 52 
2.15. List of primers ................................................................................................................... 53 
3. RESULTS ....................................................................................................................... 54 
3.1. Identification of Myc interactors through mass spectrometry analysis ...................... 54 
3.1.1. Myc modulation in p493-6 cells ..................................................................................... 54 
3.1.2. Setting of the label-free ChroP technique. ..................................................................... 56 
3.1.3. Identification of new Myc interactors ............................................................................ 59 
3.1.4. Validation of Myc interactors ......................................................................................... 62 
	   3	  
3.2. Ikaros, Aiolos and Myc interaction in p493-6 cells ....................................................... 64 
3.2.1. Ikaros and Aiolos coimmunoprecipitate with Myc ........................................................ 64 
3.2.2. Genome-wide distribution of Ikaros, Aiolos and Myc ................................................... 69 
3.2.3. Identification of direct Myc-regulated genes. ................................................................ 79 
3.3. Combined activation of Ikaros and Myc in BH1 cells .................................................. 81 
3.3.1. IkarosER and Tet-Myc inducible system ....................................................................... 81 
3.3.2. Ikaros and Myc have an opposite effect on cell proliferation ........................................ 89 
3.3.3. Transcriptional effect of Ikaros and Myc induction ....................................................... 92 
4. DISCUSSION .............................................................................................................. 101 
4.1. Identification of new Myc interactors using a MS-based approach. ......................... 101 
4.2. Interplay between Ikaros/Aiolos and Myc .................................................................... 104 
5. APPENDIX .................................................................................................................. 110 
5.1. Experimental design ......................................................................................................... 110 
5.2. Materials and methods ..................................................................................................... 112 
5.2.1. Cell culture ................................................................................................................... 112 
5.2.2. SILAC ChroP ............................................................................................................... 112 
5.2.3. MS analysis .................................................................................................................. 112 
5.2.4. siRNA tranfection ......................................................................................................... 112 
5.2.5. Luciferase and resazurine measurement ....................................................................... 113 
5.3. Results ................................................................................................................................ 114 
5.3.1. Setting of the SILAC ChroP ......................................................................................... 114 
5.3.2. SILAC MS results ........................................................................................................ 116 
5.3.3. Integration of the MS data ............................................................................................ 117 
5.3.4. Functional screen set up ............................................................................................... 119 
5.4.5. Screen results ................................................................................................................ 122 
References ........................................................................................................................ 124 
Acknowledgment..............................................................................................................143 
	   4	  
List of abbreviations 
	  
AchR   acetylcholine receptor 
ACN   acetonitrile 
ALL   acute lymphoblastic leukemia 
Bcl-2/6  B cell lymphoma 2/6 
BCR   B cell receptor 
BET   bromodomain and extra-terminal motif proteins 
Brd4   bromodomain containing 4 
BrdU   5'-Bromo-2'Deoxyuridine 
bHLH-LZ  basic helix-loop-helix leucine zippr 
BPTF   bromodomain PHD Finger transcription factor 
BSA   bovine serum albumin 
CBP   CREB binding protein 
CDK9   cyclin dependent kinase 9 
cDNA   complementary DNA 
CHD4   chromodomain helicase DNA binding protein 4 
coIP   coimmunoprecipitation 
CtBP   C-terminal binding protein	  
CTD   C-terminal domain 
CtIP   CTBP-interacting protein 
ChIP   chromatin immunoprecipitation 
ChroP   chromatin proteomics 
CK2   casein kinase 2 
CLP   common lymphoid progenitors 
CMP   common myeloid progenitors 
	   5	  
CpG   cystein-phosphate-guanin 
DC   dendritic cells 
DEG   differentially expressed gene 
DN   dominant negative 
DNA   deoxyribonucleic acid 
Dox   doxycycline 
EBF1   early B-cell factor 1 
E-box   enhancer box 
EBV   Epstein-Bar virus 
eRPKM  exonic reads per kilobase per milion 
EtOH   ethanol 
ELP   earliest lymphocytes progenitors 
FA   formaldehyde 
FACS   fluorescence-activated cell sorting 
FC   fold change 
FT   flowthrough 
GC   germinal center 
GFP   green fluorescent protein 
GO   gene onthology 
GSEA   gene set enrichment analysis 
HAT   histone acetyltransferase 
HCC   hepatocellular carcinoma 
HDAC   histone deacetylase 
HSC   hematopoietic stem cells 
IFRD2   interferon related developmental regulator 2 
Igll1   immunoglobulin lambda like polypeptide 1 
IkarosER  Ikaros estrogen receptor 
	   6	  
IL7   interleukin 7 
IP   immunoprecipitation 
LC-MS/MS  liquid chromatography coupled with tandem mass spectrometry 
LFQ   label free quantification 
LMPP   lymphoid-primed multipotent progenitor 
Max   Myc-associated factor x 
MB I-II-III –IV Myc box I-II-III-IV 
MCM2-7  minichromosome maintenance protein 2-7 
Mga   Max gene-associated protein 
Miz-1   Myc-interacting zinc finger protein 1 
MPP   multipotent progenitors 
mRNA   messenger ribonucleic acid 
MS   mass spectrometry 
Myc   myelocytomatosis 
MZ   marginal zone  
NCL   nucleolin 
NF-Y   nuclear transcription factor Y 
NGS   next generation sequence 
NK   natural killer cell 
Npm   nucleophosmin 
NuRD   nucleosome remodeling deacetylase complex 
NURF   nucleosome remodeling factor 
OHT   4-hydroxytamoxifen 
Ph+   Philadelphia chromosome 
PI   propidium iodide 
PIC   preinitiation complex 
P-TEFb  positive transcription elongation factor b 
	   7	  
Pol II   RNA polymerase II 
qPCR   quantitative polymerase chain reaction 
Ras   rat sarcoma virus oncogene 
RNA   ribonucleic acid 
ROS   reactive oxygen species 
RT-PCR  reverse transcriptase polymerase chain reaction 
SDS-PAGE  sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
SLC   surrogate light chain 
SMAD2/3  Sma- and Mad-related protein 2/3 
SP1/SP3  specificity protein 1 
STAT5  signal transducer and activator of transcription 5 
SWI/SNF  SWItch/Sucrose Non-Fermentable 
TAD   transcriptional activation domain 
TBP   TATA-box binding protein 
TCR   T cell receptor 
Tdt   terminal deoxynucleotidyltransferase 
Tet   tetracycline 
TFA   trifluoroacetic acid 
TFII-I   general transcription factor II, I 
TRIM28  tripartite motif containig 28 
TRRAP  transformation/transcription domain associated protein 
TSS   transcription start site 
VDJ   variable-diversity-junction 
WDR5   WD repeat domain 5 
YY1   Yin and Yang 1 Protein 
v-myc   viral myelocytomatosis 
WB   western blot	    
	   8	  
List of figures 
FIGURE 1. STRUCTURE OF MYC FAMILY PROTEINS ............................................................... 14 
FIGURE 2. MYC TRANSCRIPTIONAL ACTIVATION FUNCTIONS ............................................... 15 
FIGURE 3. B CELL DEVELOPMENT ......................................................................................... 24 
FIGURE 4. PLASMA CELL DEVELOPMENT .............................................................................. 26 
FIGURE 5. MYC ROLE IN B LYMPHOPOIESIS .......................................................................... 28 
FIGURE 6. IKAROS ISOFORMS ................................................................................................ 30 
FIGURE 7. P493-6 CELL LINE ................................................................................................ 55 
FIGURE 8. MYC LEVEL MODULATION IN P493-6 CELLS ......................................................... 56 
FIGURE 9. LABEL FREE CHROP SCHEME ............................................................................... 57 
FIGURE 10. PRELIMINARY CHIP CONTROL: QPCR ............................................................... 58 
FIGURE 11. PRELIMINARY CHIP CONTROL: WB. .................................................................. 58 
FIGURE 12. LABEL FREE CHROP RESULTS. ........................................................................... 60 
FIGURE 13. TOP CANDIDATES SELECTED FROM THE LABEL FREE CHROP RESULTS ............... 61 
FIGURE 14. VALIDATION OF MYC INTERACTORS BY CHIP-WB IN P493-6 CELLS ................. 63 
FIGURE 15. MYC, IKAROS AND AIOLOS COIMMUNOPRECIPITATION IN P493-6 CELLS ........... 65 
FIGURE 16. MYC, IKAROS AND AIOLOS COIMMUNOPRECIPITATION IN DIFFERENT CELL LINES
 ..................................................................................................................................... 66 
FIGURE 17. COIMMUNOPRECIPITATIONS IN HEK293T CELLS .............................................. 68 
FIGURE 18. COIMMUNOPRECIPITATION IN BA/F3 CELLS ....................................................... 68 
FIGURE 19. CHIP-QPCR ON MYC-CHIP AND H3K27AC-CHIP ............................................ 69 
FIGURE 20. CHIP-SEQ PEAK NUMBERS AND ANNOTATION .................................................... 70 
FIGURE 21. MOTIF ANALYSIS ON SEQUENCES UNDERLYING IKAROS, AIOLOS AND MYC 
PEAKS. .......................................................................................................................... 71 
FIGURE 22. BOUND GENES OVERLAP AND FUNCTIONAL ANNOTATION. ................................. 73 
FIGURE 23.  TARGET GENE TRACKS ...................................................................................... 74 
	   9	  
FIGURE 24. VALIDATION OF IKAROS AND AIOLOS BOUND REGIONS BY CHIP-QPCR ........... 75 
FIGURE 25. IKAROS GENOME-WIDE ENRICHMENT ................................................................. 75 
FIGURE 26. OVERLAP OF IKAROS, AIOLOS AND MYC PEAKS IN P493-6 CELLS ...................... 77 
FIGURE 27. INTENSITY AND DISTRIBUTION OF CHIP-SEQ PEAKS ........................................... 78 
FIGURE 28. MYC DEREGULATED GENES IN P493-6 CELLS ..................................................... 79 
FIGURE 29. FUNCTIONAL ANALYSIS OF MYC DEGS IN P493-6 CELLS  ................................. 80 
FIGURE 30. PERCENTAGES OF DEGS AND NO DEGS BOUND BY IKAROS, AIOLOS AND MYC 
IN P493-6 CELLS ........................................................................................................... 81 
FIGURE 31. GENERATION OF THE BH1 CELL LINE ................................................................ 82 
FIGURE 32. GFP LEVEL IN BH1 CELLS ................................................................................. 83 
FIGURE 33. EFFECTS OF IKAROS LEVELS ON BH1 CELL GROWTH ......................................... 84 
FIGURE 34. EFFECT OF IL7 ON BH1 CELL GROWTH .............................................................. 84 
FIGURE 35. REGULATION OF IKAROS TARGET GENES IN BH1 CELLS .................................... 85 
FIGURE 36. INDUCIBLE EXPRESSION OF TET-MYC IN BH1 CELLS. ........................................ 86 
FIGURE 37. IKAROSER AND MYC COIMMUNOPRECIPITATION IN BH1 CELLS ....................... 87 
FIGURE 38. BH1 TREATMENT CONTROLS ............................................................................. 88 
FIGURE 39. GROWTH CURVES....... ....................................................................................... 90 
FIGURE 40. BRDU INCORPORATION ...................................................................................... 90 
FIGURE 41. EVALUATION OF CELL DEATH ............................................................................ 91 
FIGURE 42. DEG IDENTIFIED IN BH1 CELLS UPON IKAROSER AND/OR TET-MYC INDUCTION
 ..................................................................................................................................... 93 
FIGURE 43. CORRELATION HEATMAP OF RNA-SEQ SAMPLES UPON IKAROSER AND/OR MYC 
ACTIVATION IN BH1 CELLS .......................................................................................... 94 
FIGURE 44. CORRELATION PLOTS OF GENE EXPRESSION UPON IKAROSER OR IKAROSER PLUS 
MYC ACTIVATION IN BH1 CELLS .................................................................................. 94 
FIGURE 45. IKAROS AND MYC COMMON TARGET GENES IN BH1 CELLS ............................... 96 
	   10	  
FIGURE 46. GENES ANTI-REGULATED AND CO-REGULATED BY IKAROSER AND MYC IN BH1 
CELLS ........................................................................................................................... 97 
FIGURE 47. SILAC CHROP SCHEME ................................................................................... 111 
FIGURE 48. GROWTH CURVE WITH SILAC MEDIUM ........................................................... 114 
FIGURE 49. INCORPORATION TEST. ..................................................................................... 115 
FIGURE 50. MYC ENRICHMENT IN SILAC CHROP EXPERIMENTS ....................................... 116 
FIGURE 51. SILAC MS RESULTS. ....................................................................................... 117 
FIGURE 52. LABEL-FREE AND SILAC MS RESULTS ........................................................... 118 
FIGURE 53. ENLARGED LIST OF MYC INTERACTORS. .......................................................... 119 
FIGURE 54. FUNCTIONAL SCREEN SETUP ............................................................................. 121 
FIGURE 55. PRELIMINARY CONTROLS ................................................................................. 122 




	   11	  
List of tables 
TABLE 1. LIST OF PRIMERS.. ................................................................................................. 53 
TABLE 2. LISTS OF GENES ANTI-REGULATED AND CO-REGULATED BY IKAROS AND MYC...100 
 
SUPPLEMENTARY TABLE 1. LIST OF IKAROS AND MYC COMMON DEGS IDENTIFIED IN BH1 
CELLS AND RELATIVE LOG2(FOLD CHANGE) VALUES IN ALL THE CONDITIONS AND TIME 
POINTS.................................................................................................................. (EXCEL FILE) 
  
SUPPLEMENTARY TABLE 2. COMPLETE LIST OF  MYC INTERACTORS IDENTIFIED IN OUR MS 





	   12	  
Abstract 
	  
Myc is a transcription factor that plays a key role in many cellular functions. When 
deregulated, it becomes a potent oncogene and a hallmark of many human cancers. 
Although its activity has been proven to strongly depend on many cofactors, we are still far 
from a comprehensive understanding of Myc’s mechanisms of action in transcriptional 
control. Moreover, since Myc itself is not easily druggable, targeting its cofactors or 
downstream effectors may constitute a more promising therapeutic strategy in Myc-driven 
tumors. Here, we have used the Chromatin Proteomics (ChroP) technology to identify new 
Myc interactors. Among the list of identified candidates, we have chosen to focus our 
attention on two lymphocyte specific transcription factors, Ikaros and Aiolos. We validated 
the interaction of Myc with these factors and started to study its functional meaning. Our 
working hypothesis is that Myc and Ikaros/Aiolos antagonize each other on chromatin at 
selected target loci. We were able to identify a subset of genes regulated in opposite 
manners by Ikaros and Myc, involved mainly in cell cycle regulation, metabolism of lipids 
and metabolic stress response; the next step will be to study more in depth the mechanisms 
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1. Introduction 
	  
1.1 Myc 	  
1.1.1 Myc discovery and structure 	  
The c-myc oncogene was discovered as the cellular homologue of a viral oncogene isolated 
from the MC29 chicken virus (v-myc) (Sheiness & Bishop, 1979; Sheiness et al., 1978; 
Vennstrom et al., 1982). The MC29 virus causes myeloid cells transformation that results 
in myelocytomas, hence the name c-myc (myelocytomatosis).  The	  Myc	   family	   includes	   three	   related	   genes,	   c-­‐,	   N-­‐	   and	   L-­‐myc,	  encoding	   the	   basic-­‐helix-­‐loop-­‐helix	   leucine	  zipper	   transcription	   factors	   c-­‐Myc,	  N-­‐Myc	  and	  L-­‐Myc.	   c-­‐Myc	  (hereafter	  Myc)	   is	  broadly	  overexpressed	   in	  both	  blood-­‐borne	  and	  solid	   tumors,	  N-­‐Myc	  in	  solid	  cancers	  of	  neural	  origin	  such	  as	  neuroblastoma	  and	  glioma	  (Schwab et al., 
1984),	  and	  L-­‐Myc	  in	  small	  cell	   lung	  carcinomas	  (Nau et al., 1985; Wasylishen & Penn, 
2010).	  Myc is 439 aminoacids in length and can be schematically divided into three main 
parts, organized in the same way in all the members of the family (figure 1), as follows:  
1) an N-terminal transcriptional activation domain (TAD): this region is mostly 
unstructured (Andresen et al., 2012) and is required to sustain Myc-dependent cell 
transformation (Stone et al., 1987) and transcriptional activities, when fused to a DNA 
binding domain (Kato et al., 1990). Moreover, it also includes two conserved regions 
called Myc-boxes (MB): MBI, that contains a degron responsible of Myc ubiquitination 
and degradation, and MBII, implicated in protein-protein interactions and transcriptional 
activation (Conacci-Sorrell et al., 2014; Tansey, 2014); 
 2) a central part containing the nuclear localization sequence, together with a region rich 
in proline, glutamic acid, serine and threonine (PEST) and the conserved Myc box regions 
called MBIII and MBIV; 
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3) a C-terminal basic helix-loop-helix leucine zipper (bHLH-LZ) domain, a region of about 
100 amino acids that mediates dimerization with the partner protein Max (Myc-associated 
factor x) and DNA binding.  
Max is also a member of the bHLH-LZ family and, to date, is the only known dimerization 
partner of Myc. The Myc/Max interaction is essential for DNA binding and, in particular, 
to recognize the E-box consensus sequence CACGTG (or variant thereof) (Blackwell et 
al., 1993; Blackwell et al., 1990). Max is thus fundamental to accomplish the majority of 
Myc activities, such as transcriptional regulation and cell transformation (Amati et al., 
1993a; Amati et al., 1992). While, at least at physiological levels, Myc cannot form 
homodimers, Max can do it and can also form heterodimers with other bHLH-LZ proteins, 
including the MXD proteins and Mga (Diolaiti et al., 2015). These interactions may 
antagonize the function of Myc at different levels: they may sequester Max in complexes 
other than the Myc/Max heterodimers, may compete for the same binding sites on DNA, 
and may recruit transcriptional repressors to common target loci (Grandori et al., 2000; 
Nair & Burley, 2003). 
 
	  
Figure 1. Structure of Myc family proteins. At the top of the image, a generic Myc protein is represented 
with the transcriptional activation domain, the central portion, the nuclear localization sequence (N) and the 
DNA binding domain. Below, the three members of the family with the conserved Myc box regions are 
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1.1.2. Role of Myc in physiological and pathological conditions 	  
Myc is a pleiotropic transcription factor that plays a fundamental role in several cellular 
functions such as cell cycle regulation, cell growth, apoptosis, cell differentiation and 
development (figure 2). One of its main functions is the regulation of cell proliferation. In 
fact, Myc activation is sufficient to induce quiescent cells to re-enter the cell cycle and can 
make cycling cells proliferate more rapidly and independently from growth factors (Amati 
et al., 1998). It also activates the expression of genes involved in mRNA maturation, 
ribosomal and mitochondrial biogenesis, nucleic acid synthesis and protein translation, 
providing the energy required by a cell to replicate (Arabi et al., 2005; Gomez-Roman et 
al., 2003; Iritani & Eisenman, 1999).  
 
Figure 2. Myc transcriptional activation functions. Summary of the main pathways activated by the 
Myc/Max dimer (from Kress 2015). 
 
Due to its crucial role in regulation of cell growth, cell transformation and tumorigenesis, 
Myc activity is strictly controlled in physiological conditions, at every step from gene 
expression to post-transcriptional modifications. Indeed, its expression is generally low in 
adult tissues and mainly restricted to cells with proliferative or regenerative potential.  
To prevent uncontrolled cell proliferation as a consequence of Myc overexpression, Myc 
itself can induce apoptosis (Evan et al., 1992), either via the activation of p53 through the 
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upregulation of Arf (Zindy et al., 1998) or in a p53-independent way by regulating the 
balance between pro-apoptotic and anti-apoptotic proteins (Eischen et al., 2001). Loss of a 
tumor suppressor, such as p53 or Arf, or the activation of a second oncogene can abolish 
Myc-dependent apoptosis and favor tumorigenesis. For example, Bcl-2 overexpression 
inhibits Myc-mediated apoptosis but does not affect Myc-induced proliferation, providing 
an example of oncogene cooperation in sustaining tumor development	  (Bissonnette et al., 
1992; Fanidi et al., 1992; Strasser et al., 1990).  
Failure in Myc regulation induces a cascade of oncogenic signals that contribute to 
tumorigenesis and tumor maintenance, such as uncontrolled cell proliferation and growth, 
increased protein biogenesis, metabolic changes (Gabay et al., 2014). One way in which 
Myc deregulation occurs is by chromosomal translocation. This is characteristic of 
Burkitt’s lymphoma, where the Myc gene is translocated under the control of the Igµ heavy 
chain enhancer, resulting in very high levels of Myc expression in B cells (Dalla-Favera et 
al., 1982). In other cancer types, instead, Myc is subjected to gene amplification (Little et 
al., 1983; Vita & Henriksson, 2006). Although mutational changes in the c-Myc coding 
sequence, often leading to stabilization of the Myc protein, are observed in a fraction of 
tumors (in particular Burkitt’s lymphoma) (Bahram et al., 2000; Hemann et al., 2005), 
these are not obligatory and are generally secondary to a translocation event. Moreover, 
deregulated Myc expression in cancer can also occur in the absence of c-Myc alterations, 
due to mutations in upstream regulatory pathways such as Wnt, Notch and others (Meyer 
& Penn, 2008). In tumor cells, Myc can promote metabolic changes aimed to support a 
rapid growth, for example by enhancing the expression of genes involved in glucose 
uptake and glycolysis; indeed, Myc-transformed cells often become glucose and glutamine 
addicted (Gao et al., 2009; Hsieh et al., 2015; Shim et al., 1998). Moreover, Myc can 
improve angiogenesis, helping the tumor to develop its own vasculature (Baudino et al., 
2002; Dews et al., 2009), can induce epithelial to mesenchymal transition (Smith et al., 
2009; Trimboli et al., 2008) and adhesion independence (Frye et al., 2003), thus favoring 
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metastasis. An aberrant proliferation can also result in “replication stress”, collapse of 
DNA replication forks at fragile sites, followed by double strand breaks and chromosomal 
abnormalities (Felsher & Bishop, 1999; Prochownik & Li, 2007; Rohban & Campaner, 
2015). Finally, Myc can be implicated in DNA damage and instability through the 
induction of reactive oxygen species (ROS) (Vafa et al., 2002).  
Besides driving tumor initiation and progression, Myc is essential for tumor maintenance 
(Gabay et al., 2014). In several mouse models of Myc-driven malignancies, tumor cells 
become addicted to continuous Myc overexpression, as switching Myc off can result in 
growth arrest, apoptosis and differentiation. This is true not only in Myc driven tumors but 
also in cancers driven by other oncogenes like Ras (Felsher et al., 2010; Li et al., 2014; 
Soucek et al., 2013).  
	  
1.1.3. Myc interactions on chromatin 
 
1.1.3.1. Myc binding to DNA 
 
As we said, Myc requires the dimerization with Max to bind DNA and activate or repress 
the expression of its target genes. Myc/Max binding sites on DNA have been broadly 
studied thanks to the advent of the chromatin immunoprecipitation (ChIP) and more 
recently of ChIP-seq technique, and some common characteristic have been described: 
- Myc-binding sites are always associated with open chromatin, characterized by the 
presence of specific histone marks such as H3K4me3 or H3K27ac, the presence of 
the basal transcription machinery and hypersensitivity to digestion by DNaseI 
(Guccione et al., 2006); other important genomic features often associated with 
Myc binding sites are CpG island, that are themselves sites of active chromatin, and 
the presence of Pol II (Fernandez et al., 2003; Zeller et al., 2006). 
- The Myc/Max dimer is not only bound at E-box sequences and it can bind both 
promoters and distal sites (mostly active enhancers) according to its expression 
	   18	  
level: at physiological levels, it preferentially binds to high-affinity, E-box 
containing promoters, while when it is overexpressed, it can also “invade” lower 
affinity sites even devoid of any E-box as far as they reside in an active chromatin 
state (Sabò et al., 2014, Zeller et al., 2006). 
In our group, a model describing Myc/Max binding to DNA has been proposed. In this 
model, the Myc/Max dimer recruitment to the open chromatin is facilitated by protein-
protein interactions with other chromatin-associated proteins; this leads to a first 
interaction with the double helix that is sequence independent, followed by a “scanning” 
phase of the DNA sequence that ends with the stabilization of the Myc/Max dimer in 
correspondence of high-affinity sites (Sabò & Amati, 2014). The fact that only a small 
fraction of all the Myc/Max bound regions contains the E-box consensus site strengthens 
the hypothesis that, besides DNA sequence specificity, Myc could be recruited to 
chromatin also through the interaction with other proteins as well as non sequence-specific 
interactions with DNA. For example, Myc binding is mainly found on pre-engaged 
RNAPol2 (Pol II) promoters, thus it is possible that Myc is recruited on DNA through 
components of the general transcriptional machinery; moreover, Myc is reported to interact 
with Pol II itself as well as with other general regulators such as TFII-I (Roy et al., 1993), 
TBP (Hateboer et al., 1993) and P-TEFb (Eberhardy & Farnham, 2002; Rahl & Young, 
2014). 
An example of the critical role played by protein-protein interactions in Myc target 
recognition is unveiled by WDR5, a component of many complexes involved in histone 
methylation, which mediates Myc recruitment on chromatin (Thomas et al., 2015). ChIP-
seq experiments showed that Myc signal overlaps well with WDR5 binding, while this co-
localization strongly decreases if the protein-protein interaction is disrupted (Thomas et al., 
2015). Similarly, Myc interaction with BPTF, a core component of the NURF chromatin-
remodeling complex, appears to be implicated in Myc target recognition: BPTF 
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knockdown, in fact, results in reduced Myc binding to chromatin and impaired activation 
of Myc transcriptional program (Richart et al., 2016).  
 
1.1.3.2. Mechanisms of transcriptional control by Myc  	  
The mechanisms through which Myc is able to activate and repress transcription are not 
completely defined yet. Since Pol II is the enzyme responsible for the transcription of 
protein-coding genes, the interplay between Myc and Pol II has been widely studied. The 
transcription cycle includes a first step (transcription initiation) in which Pol II is recruited 
at gene promoters, a second step (transcription elongation) in which the C-terminal domain 
(CTD) of Pol II must be phosphorylated by the CDK9/P-TEFb complex in order to have a 
successful processivity, and a third step (transcription termination) that concludes 
transcription through Pol II dissociation.  Many studies showed that Myc is able to recruit 
P-TEFb to its target genes, thus facilitating Pol II elongation (Bouchard et al., 2004; 
Eberhardy & Farnham, 2001; Rahl & Young., 2014). More recently, Pol II recruitment was 
shown to be the primary step in Myc-activated transcription, followed by pause-release (de 
Pretis et al., 2017). 
The capacity of Myc to recruit the general transcription factor P-TEFb and to increase Pol 
II processivity, together with its widespread genomic distribution, has been the basis of a 
new model in which Myc was proposed to act as a general amplifier of transcription at all 
the active sites, rather than as a regulator of specific target genes. This effect would also 
explain the increase in RNA quantity per cell (“RNA amplification”) that is often observed 
upon Myc overexpression (Lin et al., 2012; Nie et al., 2012). Our group, instead, 
demonstrated that Myc can only regulate a specific set of genes in response to 
environmental stimuli, arguing that Myc-dependent transcriptional regulation and RNA 
amplification, when present, are two distinct processes. In this case, the global increase in 
RNA level would be a secondary effect following the regulation of Myc target genes, as 
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many of these genes are themselves involved in RNA biosynthesis and processing (Kress, 
Sabò, & Amati, 2015; Sabò et al., 2014).  
The observation that Myc can invade most of the promoters located in open chromatin 
when overexpressed, but that only a small part of them is transcriptionally regulated, 
suggests that Myc binding to DNA is not sufficient to determine gene regulation, but that 
the interaction with other effectors is needed. For examples, Myc can recruit different 
histone acetyltransferase (HAT) containing complexes. Interaction with the adaptor protein 
TRRAP (McMahon et al., 1998), in particular, allows the recruitment of the STAGA 
(Zhang et al., 2014) and NuA4 (Frank et al., 2003) complexes that include the HAT 
subunits GCN5/PCAF and TIP60, respectively. Moreover, Myc can also interact with the 
CBP and EP300 HATs (Vervoorts et al., 2003). Myc has been reported to bind different 
components of the SWI/SNF complex (Cheng et al., 1999; Stojanova et al., 2016), which 
regulates transcription by remodeling chromatin in an ATP-dependent manner. In 
particular, the bHLH-LZ domain of Myc directly interacts with INI1/hSNF5, a key 
component of SWI/SNF complex, and this allows Myc mediated expression of reporter 
genes in vitro (Cheng et al. 1999). Myc can also interact with transcriptional repressors 
such as Sin3a, Sin3b (Garcia-Sanz et al., 2014) and components of the NuRD chromatin 
remodeler complex, including HDAC1 (Garcia-sanz et al., 2014), HDAC2, TRIM28 and 
CHD4 (Koch et al., 2007). 
Myc-dependent repression is less characterized than activation, and is mostly related to 
Myc binding to chromatin through other transcription factors, among which Miz-1 
(Peukert et al., 1997) SP1/SP3 (Gartel et al., 2001), NF-Y (Izumi et al., 2001) 
SMAD2/SMAD3 (Feng et al., 2002), YY1 (Shrivastava et al., 1993). The most studied 
mechanism regards Myc-interacting zinc finger protein 1 (Miz-1) which activates 
transcription by the association with p300 and nucleophosmin (Npn); Myc association with 
Miz-1 is able to displace Miz1 coactivators thus blocking the activation of target genes 
(Staller et al., 2001). It has been shown that Myc/Miz-1 complexes can recruit the 
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methylases Dnmt3 to the cdkn1a promoter, thus inducing DNA methylation and silencing 
of the target genes (Brenner et al., 2005); moreover, Myc is able to recruit the HDAC3 
deacetylase (Kurland & Tansey, 2008), but whether the recruitment of corepressors and the 
formation of heterochromatin are common mechanism for Myc-dependent gene repression 
remains to be determined.  
 
1.1.4. Myc and cancer therapy 	  
Myc deregulation is one of the most common features of many cancer cells; moreover, the 
fact that many tumors become Myc-dependent makes the inhibition of Myc activity 
appealing for anticancer drugs. Unfortunately, Myc itself is not an easy target, in fact 
transcription factors, as a class of proteins, lack an active site that can be blocked by small 
molecules (Horiuchi et al., 2014; McKeown & Bradner, 2014). 
Many strategies have been studied to interfere with Myc-dependent transcriptional activity 
at different levels. For example, Myc function can be impaired by acting on its interaction 
with Max (Amati et al., 1993a; Amati, et al., 1993b; Amati et al., 1992). Omomyc is a 
dominant negative, mutated version of Myc that can either form homodimers or 
heterodimers with Myc or Max, thus it can interfere with Myc activities at different levels: 
by sequestering Myc away from Max or by occupying the Myc/Max binding sites as 
inactive Omomyc homodimers (Jung et al., 2017; Soucek et al., 2008). Several small 
molecule inhibitors of Myc/Max dimerization as well as molecules that impair Myc/Max 
binding to DNA have also been developed (Koh et al., 2016).  
Another example is provided by inhibitors of BET bromodomain proteins that recognize 
specific acetylated lysine residues in the N-terminal tails of histones and modulate gene 
expression by recruiting transcriptional regulators on chromatin. In particular, Brd4 was 
shown to directly interact with the positive elongation factor complex b (P-TEFb); the 
observation that also Myc regulates the pause release of Pol II at promoters by recruiting 
P-TEFb, settled the rationale to explore the effects of Brd4 inhibition on Myc 
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transcriptional program. Actually, blocking Brd4 function with small molecule inhibitors 
such as JQ1, i-BET and MMS417, have been shown to inhibit Myc-dependent 
transcription, but also to negatively regulate Myc expression in several systems. (Delmore  
et al., 2011; Donato et al., 2017; Mertz et al., 2011; Zuber et al., 2011) Finally, a recent 
work identified WDR5 as a critical factor in pancreatic cancer proliferation, thus building 
the rationale to consider inhibitors of the Myc-Wdr5 interaction for therapies (Carugo et 
al., 2016). Altogether, the above evidences suggest that, although direct pharmaceutical 
inhibition of Myc is a difficult goal, targeting upstream or downstream signals and protein-
protein interactions could be an alternative strategy to inhibit Myc’s oncogenic activity. 
 
 
1.2. B-cell development 	  
1.2.1. Early development 	  
Hematopoiesis is the process through which the blood system is originated and maintained. 
In adult mammals, hematopoiesis begins from the few hematopoietic stem cells (HSC) that 
populate a specific niche in the bone marrow. These cells are mainly quiescent and 
characterized by the ability to self-renew; their direct progeny is composed by multipotent 
progenitors (MPP) that loose the self-renewal ability, but retain the potential to 
differentiate into various lineages. Indeed, the commitment of MPP can results either in the 
formation of common myeloid progenitors (CMP) or in the formation of lymphoid-primed 
multipotent progenitor (LMPP) which are the precursors of the earliest lymphocytes 
progenitors (ELP). In the ELP, Rag1 and Rag2 start to be expressed to allow the 
D(diversity)H-J(junction)H rearrangement at the immunoglobulin heavy-chain locus. ELP 
are thought to originate early T lineage progenitors (ETP) in the thymus and common 
lymphoid progenitors (CLP) in the bone marrow. From the latter, all the lymphoid cells 
can originate, such as B-cells, T-cells and Natural killer (NK). The first identifiable B cell 
precursors are recognized thanks to the expression of the B220 surface marker and are 
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called pre/pro B cells (or fraction A, according to the Hardy classification) (figure 3) 
(Hardy et al., 1991; Li et al., 1996). The heavy-chain DJ rearrangement terminates in the 
early pro-B cell phase (fraction B/C). This is followed by the heavy-chain V(variable)DJ 
recombination that results in the surface expression of the Igµ heavy chain as part of the 
pre-B cell receptor (pre-BCR). The functional µ heavy chain will pair with a surrogate 
light chain (SLC) and, together with the Igα/β heterodimer will form the pre-B cell 
receptor (pre-BCR) on the surface of pre-BI cells (Fraction C’). The SLC is encoded by the 
Igll1 (λ5) and Vpreb genes, and is similar to the final light chain but it is not variable 
(Melchers et al., 1993). The expression of the pre-BCR is proposed to be responsible of 
positive and negative selection of pre-B cells: only cells that express a functional µ heavy 
chain that is able to couple with a SLC are maintained. These events block the 
rearrangement mechanism to avoid that different heavy chains are produced (allelic 
exclusion) and compels the transition to the proliferative large pre-BII cell stage (fraction 
D) (Hess et al., 2001; Mårtensson et al., 2010; Melchers et al., 2000). Finally, the pre-BCR 
receptor promotes its own down-regulation, by silencing the genes coding for the SLC in 
order to start the recombination of the κ or λ Ig light chain; at this point, cells stop their 
proliferation and become small resting pre-B cells. The light chain, combined with the µ 
heavy chain, will form the IgM molecule that will be expressed on the surface of immature 
B cells (fraction E), constituting the B-cell receptor (BCR) (Ferreiros-Vidal et al., 2013; 
Mårtensson et al., 2007; Pieper et al., 2013). 
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Figure 3. B cell development.  Surface markers and the rearrangement status of immunoglobulin genes are 
reported for each stage of B lymphopoiesis (from Busslinger 2004). 
 
1.2.2. Maturation 	  
Only a small percentage of immature B cells will continue the maturation pathways, while 
most of them are negatively selected already in the bone marrow to avoid the development 
of auto-reactive, mature B cells (Pelanda & Torres, 2012). There are three possible 
mechanisms of negative selection: receptor editing, clonal deletion or anergy. The accepted 
model is that if an immature B cell strongly recognizes an auto-antigen, it starts a new 
round of recombination to change the BCR in order to avoid the self-reactivity (receptor 
editing); if it fails, it is eliminated (clonal deletion). Some cells that recognize only weakly 
an auto-antigen, could be positively selected, but if they recognize a self-antigen in the 
periphery, they become non-responsive (anergic) (Cancro & Kearney, 2004; Carsetti et al., 
1995). Non-autoreactive cells can reach the spleen and proceed with the maturation. 
Nevertheless, they are also subjected to a positive selection, meaning that BCR expression 
must reach a certain level, inducing a tonic signal that promote the differentiation toward 
the next stage (King & Monroe, 2014; Levine et al., 2000; Melchers et al., 1995). 
Peripheral immature B cells are called transitional B cells. A transitional B cell could 
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differentiate either in a marginal zone (MZ) B cell or in a follicular B cell (Pillai & 
Cariappa, 2009). A small fraction of transitional B cells reaches the splenic marginal zone 
and is retained there as non-recirculating marginal zone B cells. These cells contribute to 
the first immunological response, since they are quickly activated. In accordance to this, 
their location is strategic for the recognition of blood-borne antigens and they mostly 
recognize antigens in a T-cell independent way (Allman & Pillai, 2008). 
Follicular B cells, instead, are recirculating B cells and constitute the most abundant 
fraction of mature B cells. They migrate through blood and lymph and mainly home to the 
follicles in secondary lymphoid organs (B zone lymph nodes, Peyer’s patches and spleen), 
that are located next to the T cell zones. Indeed, follicular B cells are preferentially 
activated by the interaction with T helper lymphocytes, even if they are also able to 
recognize blood-borne antigens in a T-cell independent manner (Allman & Pillai, 2008).  
Another peculiar group of mature B cells, called B1 cells, exists. B1 cells are mainly found 
in peritoneal and pleural cavities and in the gut lamina propria. They are thought to follow 
an independent development pathway by originating from progenitors that are abundant in 
fetal liver but absent in adult bone marrow; in accordance to this, they are characterized by 
a unique self-renewing ability. B1 cells quickly respond to antigen in a T-cell independent 
manner and are a source of “natural” IgM, low affinity antibodies that contribute to the 
first lane response against an antigen: once B1 cells are activated, they migrate to the 
spleen or gut and become antibody-secreting plasma cells (Allman & Pillai, 2008; Casola 
et al., 2004).  
 
1.2.3. Antibody production and memory 	  
In presence of an antigen, the first cells that become active antibody producers (plasma 
cells) are B1 and marginal zone B cells. Circulating follicular B cells that encounter an 
antigen in a T-cell dependent or independent way, can also form extra-follicular foci of 
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plasmablasts where they undergo proliferation and secrete antibody in a couple of days 
after immunization. These kind of plasma cells are short-lived and do not have somatically 
mutated Ig genes, but provide a quick clearance of the antigen (Shapiro-Shelef & Calame, 
2005). 
As a second option, activated follicular B cells can establish a germinal center (GC), where 
they undergo affinity maturation and class-switch recombination while proliferating. In 
particular, it is possible to distinguish a dark zone in which B cells (called centroblasts) 
proliferate and undergo somatic hypermutation and a light zone in which B cells (called 
centrocytes) are subsequently selected according to their interaction with the antigen. The 
germinal centers allow the production of both plasma cells and memory cells with high 
affinity BCR. Differently from plasma cells, memory cells do not secret antibodies 
immediately, but are ready to react very quickly after a subsequent encounter of the 
antigen. Some plasma cells can migrate to the bone marrow to become long-lived plasma 
cells (Cyster, 2010; Nutt et al., 2015) (figure 4). 
	  
 
Figure 4. Plasma cell development. B1 cells, Marginal-zone B cells and Follicular B cells can develop into 
cells producing low affinity antibodies. Follicular B cells that form a germinal center can develop into high 
affinity plasma cells or memory B cells (from Shapiro 2005). 
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1.2.4. Role of Myc in B lymphopoiesis 	  
Myc has been shown to play an important role in B-cell lymphopoiesis and to be 
deregulated in many B cell malignancies. Myc expression level changes in a strictly 
regulated manner during B cell development and maturation, defining the balance between 
proliferative and resting periods (Delgado & Leon, 2010). Myc-deficient embryos die at 
around day 10 and defective hematopoiesis seems to be the main reason for this lethality 
(Davis et al., 1993). Conditional deletion of Myc in the HSC compartment results in an 
accumulation of HSCs, caused by a failure in the normal differentiation process; on the 
contrary, enforced Myc expression causes a decrease in HSC numbers, while increasing 
proliferation of progenitors and cell differentiation (Wilson et al., 2004). Thus, Myc seems 
to control the balance between self-renewal and differentiation in HSCs (Delgado & Leon, 
2010; Wilson et al., 2004). 
Later, during B cells differentiation, Myc expression is induced by the pre-BCR and 
interleukin 7 (IL7) signaling to burst pro-B cell proliferation, while it is downregulated 
again in small resting pre-B cells. Constitutive expression of Myc results in an 
accumulation of pre-B cells and a consequent reduction in mature B cells numbers. Thus, 
at this stage, Myc seems to be required for the pro-B to pre-B cell transition (Habib et al., 
2007; Iritani & Eisenman, 1999; Yasuda et al., 2008). 
When mature B cells are activated by the encounter with an antigen, Myc expression 
becomes fundamental for the formation of the germinal center (Calado et al 2012). During 
the germinal center reaction, two areas are distinguishable in the GC: a dark zone in which 
B cells are proliferating and a light zone where B cells are positively selected by the 
interaction with the antigen. Surprisingly, c-Myc is found to be expressed only in a small 
fraction of B cells located in the non-proliferative light zone, while it is down-regulated by 
Bcl-6 in most of the other cells (Calado et al., 2012; Dominguez-Sola et al., 2012). 
Subsequently, Myc downregulation is required to proceed toward differentiation into 
plasma cells. In particular, Myc is downregulated by Blimp-1 (B lymphocyte-induced 
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maturation protein-1), a master regulator of terminal B cells differentiation. Ectopic 
expression of Myc at this stage, blocks terminal differentiation into plasma cells, often 
leading to tumorigenic effects (Lin et al., 2000).  
In summary, the role of Myc in lymphopoiesis depends on cell stage: it drives 
differentiation in HSCs and early B cell progenitors, while it inhibits terminal 
differentiation of mature B cells (figure 5). 
	  
Figure 5. Myc role in B lymphopoiesis. During B cell development, Myc plays a crucial role in regulating 
cell proliferations. In particular, Myc promotes differentiation of hematopoietic stem cells (HSC) and pro-B 
cells, while must be downregulated to allow B cell differentiation into plasma cells.  
 
 
1.3. Ikaros and Aiolos 	  
1.3.1. Ikaros discovery and structure 	  
Lymphocyte development and maturation is the result of tightly regulated events driven by 
specialized transcription factors, among which Ikaros and Aiolos, that will be the topic of 
this thesis. In the early 1990s, a protein able to bind the TdT promoter in T cells was 
identified and initially named LyF-1 (Lo et al., 1991); in parallel, the enhancer of the 
earliest definitive T cell differentiation marker, CD36δ, was used to screen a T cell 
expression library aimed at identifying transcription factors that prime T lymphocyte 
lineage in mice. A cDNA coding for an uncharacterized protein, that was able to bind and 
regulate this enhancer, was identified (Georgopoulos et al., 1992) and the corresponding 
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protein was named Ikaros. LyF-1 and Ikaros were then recognized to be the same protein 
(Hahm et al., 1994) and, few years later, the human ortholog was identified and cloned 
(Molnár et al., 1996). Ikaros is well conserved among species (Molnár et al., 1996) and is 
characterized by two groups of zinc-finger domains. The four zinc fingers in the N-
terminal constitute the DNA binding domain and determine the recognition of the binding 
motif, the core of which is defined as GGGAA. Two zinc-fingers are present at the C-
terminus and mediate omo- or hetero-dimerization with the other members of the family 
(Molnár & Georgopoulos, 1994; Sun et al., 1996).  
The gene encoding Ikaros (IKZF1) gives rise to a number of different protein isoforms due 
to alternative splicing or deletions (figure 6) (Georgopoulos et al., 1994; Hahm et al., 1994; 
Molnár & Georgopoulos, 1994; Molnár et al., 1996). The isoforms all share the two C-
terminal zinc fingers, but differ in the number of N-terminal zinc fingers: isoforms with 2 
to 4 zinc fingers in the N-terminal domain can bind DNA, even if with different affinities 
and functions, conversely, isoforms with only one or no zinc fingers in the N-terminal 
domain cannot bind DNA. Since heterodimers containing an active isoform together with 
an isoform that cannot bind DNA are transcriptionally inert, the latter are called dominant 
negative (DN) isoforms and are thought to be implicated in Ikaros self-regulation (Sun et 
al., 1996). Of particular interest, the DN isoform Ik6 (figure 6) is overexpressed in many 
cases of pre-B acute lymphoblastic leukemia (ALL), especially associated with BCR/ABL 
translocation. For this reason, it is particularly studied as a possible diagnostic marker as 
well as a putative therapeutic target (Mullighan et al., 2008; Zhou et al., 2013). 
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Figure 6. Ikaros isoforms. Schematic representation of Ikaros isoforms and their domains. E1-E7= exons; 
F1-F6= zinc fingers. * indicates dominant negative isoforms (generated by the mutant Ikzf1 gene in which 
exons 3 and 4 are deleted) (adapted from Sun et al 1996). 
 
1.3.2. Function of Ikaros and Aiolos in hematopoiesis 	  
To study the role of Ikaros in hematopoiesis, transgenic mice bearing Ikaros mutations or 
inactivation have been created (Cortes et al., 1999; Katia Georgopoulos et al., 1997; 
Nichogiannopoulou et al., 1998). In the first model used, a region of 8.5 kb including part 
of exons 3 and exon 4 of the Ikaros gene was deleted and substituted with a neomycin-
resistance cassette, resulting in the loss of three zinc fingers of the DNA-binding domain 
and production of a dominant negative isoform. This construct was inserted into embryonic 
stem cells and used to generate recombinant mice. In homozygous mice (DN-/-), B and T 
lymphocytes, as well as NK cells and progenitors, were absent at either fetal or postnatal 
stages, while the erythroid and myeloid compartments did not seem to be affected, 
indicating that Ikaros has a role at the very early stages of lymphopoiesis (Georgopoulos et 
al., 1994).  
In heterozygous mice (DN +/-), an apparently normal phenotype during the first three 
months was followed by development of T cells leukemia and lymphomas with 100% 
penetrance. T lymphocyte expansion started in the thymus, suggesting that it arose from 
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maturing lymphocytes, and was accompanied by loss of the wild type Ikzf1 allele, 
Conversely, no B cells were identified in spleen, lymph nodes or bone marrow. These 
results suggested that Ikaros plays a critical role not only in early development of 
lymphoid progenitors but also at later stages of T cell maturation (Winandy et al., 1995). 
To obtain a real Ikaros null mouse model, a 1.35 kb region at the C-terminal was removed, 
by substituting part of exon 7 with a neomycin resistance cassette: in this way, the 
dimerization domain and an activation domain that mediates transcriptional effects were 
eliminated in the germ line, leading to production of an inactive protein that is unstable and 
rapidly degraded, not detected at cellular level; moreover, this mutant has been shown to 
be transcriptionally inactive and do not display dominant negative effects (Sun et al., 1996; 
Wang et al., 1996). In this mouse model, thymocytes and their precursors were not 
detected during gestation, but appeared only 3-5 days after birth; moreover, although they 
expanded reaching almost a normal number, they did not follow the canonical 
differentiation pathway and were skewed toward a CD4+CD8- phenotype. Lymphnode 
development was also impaired and NK cells were absent, while the erythroid and myeloid 
compartments were normal or even increased. Moreover, B lymphocyte differentiation was 
completely blocked in these mice, with no detectable formation of B cells and their 
precursors (Wang et al., 1996).  
The results obtained with these models and, in particular, the fact that mice bearing the 
Ikaros DN isoform  (Georgopoulos et al., 1994, Winandy et al., 1995) showed a more 
severe effect than Ikaros null mice (Wang et al., 1996), suggested that Ikaros is necessary 
for fetal HSC differentiation and lymphocyte specification, but that its function in the late 
fetal and postnatal hematopoiesis can be at least partially rescued by other proteins, which 
are similarly inhibited by the dominant negative isoforms (Morgan et al, 1997). 
According with this hypothesis, Aiolos was identified as a zinc finger protein showing the 
highest similarity with Ikaros; the two transcription factors share a conserved structure and 
extended homology particularly through the DNA binding domain and the C-terminal 
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region (Caballero et al., 2007; Hosokawa et al., 1999; Morgan et al., 1997). To study 
Aiolos function in hematopoiesis, an Aiolos-null mouse model was generated by replacing 
exon 7 of the gene with a neomycin-resistance cassette, similarly to what had been done 
for Ikaros (Wang et al., 1996; Wang et al., 1998). Aiolos-null mice showed an 
accumulation of B cell precursors, increased B cell lymphomagenesis and auto-antibody 
production, while the number of recirculating B cells in bone marrow was reduced. Minor 
effects, instead, were visible in the T cell compartment. Thus, Aiolos is not required for 
early differentiation of B and T lymphocytes, but plays a more prominent role in B cell 
maturation (Wang et al., 1998).  
Ikaros and Aiolos can form heterodimers in differentiating and mature B and T 
lymphocytes. To analyze their functional interaction, mice with mutations in both the 
genes were studied; the results suggested that the two transcription factors collaborate to 
set threshold for the control of antigen-mediated lymphocyte proliferation (Cortes et al., 
1999). 
After Aiolos, other members of the Ikaros family have been identified, with a conserved 
dimerization and activation domain: Helios (Hahm et al., 1998), Eos/Dedalus (Honma et 
al., 1999) and Pegasus (Perdomo et al., 2000). 
 
1.3.3. Expression pattern of Ikaros family members 	  
Although Ikaros proteins share a high degree of similarity, their expression pattern is quite 
different. Ikaros can be detected from the earlier stages of embryogenesis in the yolk sac, 
fetal liver, thymus and hematopoietic stem cells. In adults, Ikaros expression is restricted to 
bone marrow, thymus and spleen, it is constantly expressed during all the stages of 
lymphopoiesis, while it is present at low level in erythroid and myeloid precursors and not 
in terminally differentiated erythrocytes, monocytes and macrophages (Georgopoulos et 
al., 1992; Nichogiannopoulou et al., 1998). Aiolos is not expressed in multipotent 
	   33	  
progenitors but is induced upon pre-BCR signaling in cycling pre-B cells and reaches the 
highest level in differentiated lymphocytes (Kioussis et al., 2007; Morgan et al., 1997).  
The other members of the family are more widely detectable. Helios is found at low levels 
in HSC and does not seem to be involved in B cell development, in fact its expression is 
restricted to the T lymphocyte lineage; moreover, Helios is also expressed in epidermal 
keratinocytes (Georgopoulos, 2017; Hahm et al., 1998; Kelley et al., 1998). Eos/Dedalus is 
expressed at low level in the immune and neuro-epithelial system, having a role both in the 
hematopoietic and nervous system (Honma et al., 1999; Rieder & Shevach, 2013). Finally, 
Pegasus expression is spread in different tissues, thus it may play functions outside the 
lymphoid compartment (Perdomo et al., 2000). 
 
1.3.4. Ikaros and Aiolos role in B lymphocyte development 	  
1.3.4.1. Priming of the lymphoid lineage  	  
Ikaros plays an important role in at least two defined stages or early lymphopoiesis, 
namely the development of LMPPs and at the transition to pre-B cell stage (Dovat, 2013). 
It has been hypothesized that Ikaros could drive the development of MLPPs by governing 
lineage regulators, such as Flt3 (Yoshida et al., 2006). In fact, Ikaros deficient progenitors 
lack Flt3 expression and MLPPs are present, but lose the potential to develop into B and T 
lymphocytes (Ng et al., 2007). HSCs can potentially develop into myeloid, erythroid or 
lymphoid lineage; the subsequent lineage restriction is dependent on the stabilization of the 
appropriate genetic program and concomitant inhibition of the alternative programs. For 
example, upon HSC restriction to MLPPs, the downregulation of erythroid transcripts is 
concomitant with the establishment of myeloid and lymphoid programs. This is dependent 
upon Ikaros, which initiates a cascade of lymphoid-promoting signals, comprising the 
expression of transcription factors such as Sox4, FoxP1 and signaling receptors such as 
Flt3 and Notch1, while negatively regulating genes implicated in self-renewal and 
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development of non-lymphoid lineages (Hu et al., 2016; Ng et al., 2009; Yoshida et al., 
2006). Thus, Ikaros not only provides an important contribution in priming lymphoid 
lineage, but it is also implicated in the repression of genes driving stemness and self-
renewal that, if deregulated, could lead to malignant cell growth.  
 
1.3.4.2. Ikaros role in early B cell progenitors 	  
A recent work dissected the role of Ikaros in early B cell progenitors and demonstrated that 
it specifically controls the transition from pro-B to pre-B cells, by inducing pre-BCR 
signaling. Without Ikaros, cells are blocked at an atypical pro-B cell stage, characterized 
by increased cell adhesion and defects in pre-BCR signaling (Schwickert et al., 2014).  Of 
notice, Aiolos is not able to compensate the lack of Ikaros in early lymphomagenesis, 
suggesting that the two factors have also non redundant functions (Schwickert et al., 2014). 
When the pre-B cell receptor complex is assembled and expressed on the cell surface, pre-
B cells undergo a massive proliferation step; to proceed toward the resting small pre-B cell 
stage, cells must exit the cell cycle, and start the rearrangement of the light chain. Ikaros 
family proteins are involved in this transition, which requires the suppression of pre-BCR 
signaling through down-regulation of the pre-BCR components, Igll1 (λ5) and Vpreb. 
Mechanistically, pre-BCR signaling induces a negative feedback loop through activation of 
Aiolos expression which, together with Ikaros, downregulates the expression of the pre-
BCR components, thus keeping pre-B cell proliferation under strict control (Joshi et al., 
2014; Kioussis, 2007; Ma et al., 2008; Thompson et al., 2007). Another way in which 
Ikaros could contribute in blocking cell proliferation at this differentiation stage is by 
binding to Myc promoter and repressing its transcription (Ma et al., 2010). 
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1.3.4.3. Role of Aiolos in mature B cells   	  
While Aiolos is absent or lowly expressed in early lymphocyte progenitors, it seems to 
play a fundamental role in mature and recirculating B cells, where it is expressed at high 
levels (Georgopoulos, 2017). In Aiolos null mice, B cells appear to be more sensible to 
BCR activation; that leads to cell proliferation (Wang et al., 1998) and results in an 
increased number of germinal centers, independently from immunization (Cariappa et al., 
2001). In a similar way, Ikaros loss in mature T cells facilitates their activation in response 
to T cell receptor (TCR) signals (Avitahl et al., 1999). Moreover, mice lacking Aiolos 
develop symptoms of Lupus Erythematosus, suggesting that Aiolos could be implied in the 
control of auto-immunity (Sun et al., 2003). In addition, Aiolos is involved in the 
production of high affinity long-lived plasma cells (Cortés & Georgopoulos, 2004) and 
other nonconventional B cells such as peritoneal B1 cells, marginal zone B cells and 
recirculating B cells (Wang et al., 1998).  
 
1.3.5. Mechanisms of action 	  
The first studies on Ikaros and Aiolos molecular functions revealed their capability to 
activate transcription of target genes by in vitro reporter assays (Georgopoulos et al., 1992; 
Molnár & Georgopoulos, 1994a; Morgan et al., 1997; Sun et al., 1996; Wargnier et al., 
1998). Subsequent in vivo studies confirmed this role: for example, Ikaros was shown to 
activate the CD8 gene either by increasing chromatin accessibility, thus facilitating the 
recruitment of other transcription factors, or by supporting the activity of already bound 
transcriptional regulators (Harker et al., 2002). Indeed, it was also proposed that Ikaros, 
instead of promoting gene activation per se, could act as a potentiator of other bona fide 
transcriptional activators (Koipally et al., 2002). Moreover, Ikaros and Aiolos are often 
found associated to centromeric heterochromatin, thereby suggesting that they could also 
have a role in gene repression, for example by relocating their target genes in proximity of 
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this transcriptionally inactive region (Brown et al., 1997; Cobb et al., 2000; Cortes et al., 
1999; Klug et al., 1998). Nevertheless, other complementary or alternative mechanisms 
could to be exploited by these transcription factors to regulate gene repression, as reported 
below (Sabbattini et al., 2001). 
Ikaros can interact with two chromatin remodeling complexes: the nucleosome remodeling 
and deacetylase (NuRD) complex and the SWItch/Sucrose Non-Fermentable (SWI/SNF) 
complex. Most of cellular Ikaros is associated with the NuRD complex (Kim et al., 1999; 
Sridharan & Smale, 2007) which contains the ATPase Mi-2b and the histone deacetylases 
HDAC1 and HDAC2. Therefore, NuRD can act both as an ATP-dependent chromatin 
remodeler and a histone deacetylase, leading to either opening or closing of the chromatin. 
Only a minor fraction of Ikaros has been found associated to the SWI/SNF complex 
containing Sin3/HDAC complex subunits (Busslinger, 2004; Kim et al., 1999). Although 
the interaction between Ikaros and chromatin remodeling complexes is well established, its 
functional consequences remain unclear. In vitro experiments showed that Ikaros and 
Aiolos, when fused to heterologous DNA binding domain, were able to support repression 
through HDACs recruitment (Koipally et al., 1999). Moreover, ChIP-seq experiments in 
thymocytes showed a variation of the NuRD complex genomic distribution upon Ikaros 
knockdown, thus supporting the idea of a functional relation between these factors 
(Oestereich & Einmann, 2012; J. Zhang et al., 2012). Further evidences suggested that, 
thanks to the interaction with the NuRD complex, Ikaros can regulate chromatin 
organization and accessibility and consequently affect transcription initiation (Bottardi et 
al., 2014). This idea is based on the observation that Ikaros can interact with P-TEFb (in 
particular with the CDK9 subunit) and recruit it on target gene promoters (Bottardi et al., 
2011; Bottardi et al., 2013). P-TEFb is also part of an elongation-competent form of the 
NuRD complex, that exists besides the most abundant form, not associated with P-TEFb. 
Ikaros interaction with the NuRD/P-TEFb complex could induce chromatin remodeling, 
facilitating the recruitment of general transcription factors such as TFIIB and TBP (which 
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Ikaros itself can directly interact with; Koipally & Georgopoulos, 2002) and the assembly 
of the preinitiation complex (PIC) (Bottardi et al. 2014). Subsequently, Ikaros was 
suggested to promote CDK9 dephosphorylation by recruiting PP1 with the consequent P-
TEFb activation; CDK9/P-TEFb can, in turn, phosphorylate the Pol II CDT inducing 
transcriptional elongation (Bottardi et al., 2014). Therefore, Ikaros could regulate gene 
activation by combining chromatin remodeling and Pol II elongation (Bottardi et al., 2014; 
Bottardi et al., 2015). Although this is an interesting hypothesis, the actual role of the 
Ikaros-NuRD/P-TEfb complex in transcriptional activation remains to be elucidated.  
On the other hand, the cooperation between Ikaros and the NuRD complex was also 
proposed to exert an opposite effect, favoring transcriptional repression. It was already 
demonstrated that Ikaros could compete with the transcriptional activator EBF1 to bind 
and regulate the Igll1 promoter (Thompson et al., 2007). A higher resolution study of the 
mechanism suggested that Ikaros could repress gene expression by interfering with Pol II 
recruitment. More in detail, Ikaros recruits the NuRD complex, where its ATPase subunit 
Mi-2b induces nucleosome invasion of the promoter; as a consequence, EBF1 binding is 
reduced and Pol II is evicted. Subsequently, HDAC1/2, are required to stabilize the 
repression and the recruitment of the Igll1 allele to pericentromeric heterochromatin sites. 
The same mechanism was observed also on the Myc promoter (Liang et al., 2017).  
Another way through which Ikaros may regulate target gene expression is through direct 
competition with other transcription factors. For example, Ikaros and STAT5 share many 
target genes that are inversely regulated. These two factors might exert their opposite 
regulation in two manners: by recruiting on chromatin different histone modifiers which 
regulate acetylation in an opposite way, or by directly competing for overlapping binding 
sites (Katerndahl et al., 2017). Ikaros competition with transcription factors for an 
overlapping binding site was also proposed for other target genes; for instance, Ikaros can 
repress TdT expression by competing with the Ets transcriptional activator to occupy the 
binding site present on TdT promoter (Trinh et al., 2001). Finally, Ikaros interaction with 
	   38	  
corepressors such as CtBP and CtIP, could also subtend a deacetylase-independent 
mechanism for gene repression (Koipally & Georgopoulos, 2000).  
In conclusion, Ikaros and Aiolos are transcription factors able to either activate or repress 
gene expression (Schwickert et al., 2014; Ferreiros-Vidal et al., 2013).  
 
1.3.6. Pathologies and therapies 	  
Studies on mice suggested a tumor suppressor role for Ikaros mainly in T cells: mice 
heterozygous for Ikaros DN mutation develop T cell lymphomas (in which the wildtype 
allele is lost) with 100% penetrance (Winandy et al., 1995). Nevertheless, in humans, 
Ikaros defects are identified only rarely in T cell malignancies. Interestingly, instead, 
Ikaros mutations are frequent in B cell Acute Lymphoblastic Leukemia (B-ALL). In this 
context, Ikaros deletions can result in haploinsufficiency, in a complete loss of Ikaros 
expression or in the expression of the dominant negative Ik6 isoform (Sun et al., 1996). 
These are the most frequently identified alterations and they preferentially appear in high 
risk B-ALL, characterized by the BCR/ABL translocation (Philadelphia chromosome, 
Ph+ALL), that constitute around 5% of pediatric B-ALL and 40% of adult B-ALL, or in 
Ph-like ALL. The presence of mutated Ikaros is considered a predictor of bad prognosis in 
both BCR/ABL positive and negative leukemia; moreover, it seems that certain Ikaros 
polymorphisms could define a predisposition to develop B-ALL (Mullighan et al., 2008; 
Mullighan et al., 2009). While the BCR/ABL translocation can also be linked to the 
development of chronic myelogenous leukemia (CML), Ikaros deletions are not identified 
in the chronic phase of this disease, while they are acquired during the progression to the 
blast crisis status (Mullighan et al., 2008).  
Following the above observations, restoration of Ikaros levels and function could be an 
interesting therapeutic strategy, and different approaches have been studied in this 
direction. For example, Casein Kinase2 (CK2) is a proto-oncogene overexpressed in 
hematological malignancies that phosphorylates Ikaros, inducing its degradation (Song et 
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al., 2015). Preliminary studies in vitro and in preclinical models using CK2 inhibitors, 
showed a stabilization of Ikaros level and promising anti-leukemic effects (Gowda et al., 
2017; Song et al., 2015). Another study shows that retinoids induce the upregulation of 
Ikaros expression and can reverse the leukemic phenotype in a pre-B ALL mouse model, 
thus it would be interesting to study more in depth their clinical effect on Ikaros-altered 
Ph+ ALL patients (Churchman et al., 2015).  
While Ikaros deletion and loss of function are frequent in pre-B ALL, mature B-cell 
lymphomas, such as multiple myeloma, bear high levels of this transcription factor. 
Multiple myeloma is a blood malignancy derived from plasma cells, antibody producer 
mature B cells in which both Ikaros and Aiolos are expressed at high levels. It has been 
shown that Lenalidomide, a drug that has been extensively used to treat multiple myeloma 
as well as other blood malignancies, induces the specific recruitment of Ikaros and Aiolos 
to the ubiquitin ligase Cereblon (CRL4CRBN), thus promoting their ubiquitination and 
degradation (Fink & Ebert, 2015; Kronke et al., 2014; Lu et al., 2014). Although the 
underlying mechanism is not known, Ikaros and Aiolos degradation in multiple myeloma 
results in downregulation of Irf4 and Myc, differently from what is observed during 
normal mouse-B cell development, suggesting a switch from a negative to a positive 
regulation of these target genes; thus, an hypothesis is that the regulation of this axis, 
directly or indirectly mediated by Ikaros and Aiolos, could explain the antiproliferative 
effect of the drug (Bjorklund et al., 2015). 
Apart from the widely studied role of Ikaros family in blood tumors, some recent works 
examine the less known function of these transcription factors in solid tumors. In 
particular, Aiolos emerged to be overexpressed in lung cancer, where it confers resistance 
to anoikis (Frisch & Schaller, 2014; Zhang et al., 2013; Zhu et al., 2017; Terada & Liu, 
2014), while pioneer studies on Ikaros role in hepatocellular carcinoma (HCC), suggest 
that patients affected by HCC have longer survival when Ikaros is present at higher level 
(Liu et  al., 2017; Tian et al., 2017; Zhang, 2014). 
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Aim of the project 
 
Myc deregulation is a hallmark of many human cancers and its function is essential for 
tumor maintenance. For this reason, it would be of great interest finding ways to inhibit 
Myc activity in the clinic. However, since Myc itself is not easily druggable, one 
possibility is to block Myc interaction with Max or other cofactors, impairing the 
regulation of its target genes. For this reason, the initial aim of our work was to identify 
new Myc interactors on chromatin, starting from a Mass Spectrometry-based approach in a 
human B-lymphocyte cell line. Among the Myc-interacting proteins identified, we focused 
our attention on two lymphocyte specific transcription factors, called Ikaros and Aiolos, to 
characterize their functional and molecular cooperation with Myc. 
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2. MATERIALS AND METHODS 
	  
2.1. Cell lines  	  
P493-6 cells (Pajic et al., 2000) were cultured in RPMI 1640 medium, with 10% 
tetracycline-free fetal bovine serum, 2 mM glutamine, 100 U/ml penicillin/streptomycin 
and 0.1 mM non-essential amino acids (NEAA, Lonza). For Low Myc conditions, p493-6 
cells were treated with 200 ng/ml tetracycline (Tet) (Sigma) for 8h. 
HEK293T cells were grown in DMEM medium, with 10% fetal bovine serum, 2 mM 
glutamine and 100 U/ml penicillin/streptomycin.  
BH1 cells were gently provided by the Kastner and Chan laboratory in France (Heizmann 
et al, 2013). Cells were amplified in IMDM medium, with 10% tetracycline-free fetal 
bovine serum, 2 mM glutamine, 100 U/ml penicillin/streptomycin, 50 µM beta-
mercaptoethanol and 7% supernatant of J558L cells producing IL7. To activate IkarosER, 
we added OHT to the medium at a final concentration of 400 nM and to induce Tet-Myc 
expression we added 400 ng/ml of doxycycline (Dox). 
Raji and Daudi Burkitt’s lymphoma cell lines were cultured in RPMI 1640 medium with 
10% fetal bovine serum, 2 mM glutamine, 1 mM Sodium Pyruvate, 10 mM Hepes and 100 
U/ml penicillin/streptomycin. 
Namalwa Burkitt’s lymphoma cell line was cultured in RPMI 1640 medium with 10% fetal 
bovine serum, 2 mM glutamine and 100 U/ml penicillin/streptomycin. 
Ramos Burkitt’s lymphoma cell line was cultured in MEM medium with 10% fetal bovine 
serum, 2 mM glutamine, 1 mM sodium pyruvate, 10 mM Hepes and 100 U/ml 
penicillin/streptomycin. 
Multiple myeloma cell lines (H929, MM1S, JJN3, KMS11) were cultured in RPMI 1640 
medium with 10% fetal bovine serum, 2 mM glutamine and 100 U/ml 
penicillin/streptomycin. 
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697 and REH pre-B ALL cell lines were cultured in RPMI 1640 medium, 20% fetal bovine 
serum, 2 mM glutamine and 100 U/ml penicillin/streptomycin. 
Sup-15 pre-B ALL cell line was cultured in McCoy’s medium with 20% fetal bovine 
serum, 2 mM glutamine, 100 U/ml penicillin/streptomycin. 
Ba/f3 cell line was cultured in RPMI 1640 medium with 10% fetal bovine serum, 10% 
supernatant of WEHI-3B cells, 2mM glutamine and 100 U/ml penicillin/streptomycin. 
 
2.2. Cell transfection 	  
3 x 106 HEK293T cells were plated in a 10 cm dish the day before the transfection. Cells 
were transiently transfected with pcDNA3 vectors expressing Ikaros, Aiolos or FLAG-
Myc in different combinations using the calcium phosphate protocol (Graham & van der 
Eb, 1973). 
To prepare the Ikaros and Aiolos vectors used for transfection, total RNA was extracted 
from p493-6 cells (Quick-RNATM MiniPrep, Zymo Research) and retrotranscribed into 
complementary DNA (cDNA) using the Reverse Transcriptase enzyme (ImProm-IITM, 
Promega). The cDNA corresponding to the entire Ikaros and Aiolos genes was amplified 
using the primers reported in table 1 and the p493-6 cDNA as template. The PCR product 
was run on agarose gel and the correct band was purified (QiAquick Gel Extraction kit, 
Quiagen) and inserted in the pcDNA3 vector using the XbaI and BamHI restriction 
enzymes (NEB); plasmids were then sequenced to check if they were correct. 
The pSLIK-Tet-Myc-Hygro vector was prepared with a two-step cloning protocol: first, 
hMyc cDNA was inserted into the pEN-Tmcs vector and then it was transferred into the 
pSLIK vector through the Gateway Recombination technology. The primers used to clone 
the hMyc cDNA are reported in table 1. 
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2.3. Cell transduction 	  
HEK293T cells were transfected with the pSLIK vector together with the packaging 
vectors psPax2 and pMD2.G to produce the lentiviral supernatant that was collected 48h 
later. 
Subsequently, 106 BH1 cells were resuspended in 1 ml of viral supernatant and centrifuged 
for 1.5h, 1800 rpm, for spin-infection. After 2h hours of recovery in the incubator, cells 
were resuspended in fresh medium and, 24h later, hygromycin was added for selection.  
 
2.4. Proliferation assays 	  
For the growth curves, 600000 BH1 cells were plated in 6-well plates with 2 ml of medium 
containing or not OHT and/or Dox. Cells were counted every two days, in triplicate, up to 
ten days.  
For the cell cycle analysis, BH1 cells were plated at a concentration of 300000 cells/ml in a 
6-well plate in presence or absence of OHT and/or Dox. 24h later, BrdU (B9285, Sigma) 
was added to each well at a final concentration of 10 µg/ml, for 20 minutes. Cells were 
then collected, washed with PBS and fixed with cold ethanol. After one wash in PBS 1% 
bovine serum albumin (BSA), cells were resuspended in 1 ml of denaturing solution (2N 
HCl) and left at room temperature for 20 minutes; subsequently, cells were neutralized 
with 3 ml 0.1 M NA2B4O7 pH 8.5 and washed with PBS 1% BSA. Cells are then stained 
with the anti-BrdU antibody (BD Bioscience) at a final concentration of 5 µg/ml for 1h 
light protected, washed again with PBS 1% BSA and incubated wit the secondary donkey-
anti-mouse antibody conjugated with ALexaFLuo647 (Invitrogen) at a final concentration 
of 20 µg/ml for 1h, light protected. Finally, cells are washed with PBS 1% BSA and 
resuspended in 500 µl of PBS with propidium iodide (PI, 2.5 µg/ml) and RNaseA 
(250µg/ml) overnight, before the acquisition with the MACSQuant® Analyzer. All the 
samples were then analyzed with the FlowJo X software. 
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2.5. Chromatin proteomics (ChroP) 	  
2.5.1. Chromatin Immunoprecipitation (ChIP) 	  
108 p493-6 cells were crosslinked with 1% Formaldehyde (FA) for 10 minutes; the reaction 
was blocked adding 125 mM glycine for 5 minutes. After a wash with PBS, cells were 
pelleted by centrifugation, shock-frozen in dry ice and conserved at -80°C until use.  
Thawed cells were resuspended in Lysis Buffer (150 mM NaCl, 15 mM TrisHCl pH 7.6, 
60 mM KCl, 2 mM EDTA, 0.5 mM EGTA, 0.3M sucrose, 0.4% NP-40) plus complete 
EDTA-free protease inhibitors (Roche), 1 mM DTT, 0.2 mM spermine, 1 mM spermidine, 
0.5 mM PMSF.  After a wash in Buffer D (15 mM NaCl, 15 mM TrisHCl pH 7.6, 60 mM 
KCl, 0.3 M sucrose), DNA digestion was performed with Micrococcal Nuclease (MNase), 
for 1h at 37°C in the proper buffer (20 mM Tris-HCl pH 7.6, 5 mM CaCl2); subsequently, 
the reaction was stopped adding EDTA at a final concentration of 50 mM and an aliquot of 
the sample was checked on agarose gel. 
IP buffer, composed of two parts of SDS buffer (100 mM NaCl, 50 mM Tris-HCl pH 8.1, 
0.5% SDS) and one part of Triton dilution buffer (100 mM Tris-HCl pH 8.5, 100 mM 
NaCl, 5 mM EDTA, 5% Triton X-100), plus protease inhibitors, was added after digestion 
and a rapid cycle of sonication was performed to completely break the nuclei. An aliquot 
was kept as input; 20 µg of antibodies were added to the rest (anti-Myc, N262, Santa Cruz; 
anti-rabbit IgG, Santa Cruz) and incubated overnight at 4°C. Immunocomplexes were 
recovered adding dynabeads (Life Technologies) for 4h and then washed five times with 
RIPA buffer (50 mM Hepes pH 7.6, 500 mM LiCl, 1 mM EDTA, 1% NP-40, 0.7% Na-
Deoxycholate) and once with TE 50mM NaCl. 10% of the material was processed to 
perform quantitative PCR and 10% was used for western blot; the rest of the material was 
decrosslinked, prepared for electrophoresis and loaded on a 4-12% pre-cast gel (NuPAGE 
Novex Bis-Tris Gel, Invitrogen). 
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2.5.2. In-gel digestion for MS 	  
In-gel digestion of the samples was performed as previously reported (Shevchenko et al., 
2006; Soldi & Bonaldi, 2014) with few modifications. 
Each lane of the gel was divided into 9 bands as shown in figure 11; each band was 
chopped in pieces of approximately 1x1 mm and transferred in microcentrifuge tubes. The 
gel pieces were washed with destaining buffer (25 mM NH4HCO3, 50% EtOH) at 25°C 
until the Blue Coomassie staining was completely removed. They were then dehydrated in 
100% EtOH and dried in a speed-vac. The samples were rehydrated in reduction buffer (10 
mM DTT, 50 mM NH4HCO3) and incubated 1h at 56°C. Afterwards, alkylation buffer (55 
mM iodoacetamide in 50 mM NH4HCO3) was added and samples were incubated for 45’ 
at 25°C, protected from light. The gel pieces were washed with digestion buffer (50 mM 
NH4HCO3 in ddH2O, pH 8) for 20’ at 25°C. The samples were again subjected to a couple 
of cycles of dehydration with EtOH and washed with digestion buffer, then they were dried 
in a speed-vac and rehydrated in the trypsin solution (12.5 ng/µl trypsin, Promega, in 50 
mM NH4HCO3) and incubated for 20’ at 4°C. Trypsin was then removed and digestion 
buffer was added for an overnight incubation at 37°C. The reaction was stopped adding 
trifluoroacetic acid (TFA); the samples were spinned down and the gel pieces were 
transferred in a new tube. The peptides were extracted from the gel by adding extraction 
buffer (3% TFA, 30% acetonitrile –ACN-) for 10’ at 25°C, shacking; gel pieces were 
spinned down and the supernatant was collected and added to the previous one (this 
operation was repeated twice). The same was done using 100% ACN. Finally, the 
collected supernatant was dried in a speed-vac to remove ACN. Lyophilized samples were 
desalted and concentrated on C18-Stage Tips (Rappsilber et al., 2007). The elution was 
carried out with a highly organic solvent (80% ACN) followed by lyophilisation. Prior to 
LC-MS/MS analysis, samples were resuspended in 1% TFA in ddH2O. 
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2.5.3. Liquid chromatography and tandem Mass Spectrometry (LC-
MS/MS) 	  
Samples were prepared and analyzed by Liquid Chromatography and Tandem Mass 
Spectrometry (LC-MS/MS) as previously described (Soldi & Bonaldi, 2013). 
Peptide mixtures were separated via nano-flow liquid chromatography (LC) using an 
Agilent 1100 Series (Agilent Technologies Waldbronn, Germany) coupled to a 7-tesla 
linear ion trap–Fourier transform–ion cyclotron resonance (LTQ-FT-ICR) Ultra mass 
spectrometer (Thermo-Fisher Scientific, Bremen, Germany). The nano-flow LC system 
was operated in a one-column set-up with a 15 cm analytical column (75 mm inner 
diameter, 350 mm outer diameter) packed with C18 resin (ReproSil, Pur C18AQ 3 mm, 
Dr. Maisch, Ammerbuch Germany). The sample was injected into an aqueous solution at a 
flow rate of 500 nl/min. Peptides were separated with a gradient of 0%–36% over 120 min 
followed by gradients of 36%–60% for 10 min and 60%– 80% over 5 min at a flow rate of 
250 nl/min. A nanoelectrospray ion source (Proxeon, Odense, Denmark) was used with a 
spray voltage of 2.4 kV. No sheath, sweep, or auxiliary gasses were used, and the capillary 
temperature was set at 190 °C. The mass spectrometer was operated in data-dependent 
mode to automatically switch between MS and MS/MS acquisition. In the mass 
spectrometer, full scan MS spectra (200–1650 m/z) were acquired with a resolution of 
100,000 at 400 m/z, setting an Acquisition Gain Control target of 1,000,000. The five most 
intense ions were isolated for fragmentation in the linear ion trap using collision-induced 
dissociation at a target value of 5000. Singly charged precursor ions were excluded. In the 
MS/MS method, a dynamic exclusion of 60 s was applied, and the total cycle time was 2 s. 
The collision gas pressure was 1.3 millitorr, and the normalized collision energy using 
wide band activation mode was 35%. The ion selection threshold is 250 counts with an 
activation q=0.25. An activation time of 30 ms was applied in MS/MS acquisitions. 
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2.5.4. Protein identification by MaxQuant software and data analysis 	  
MS analyses were performed as previously described (Soldi & Bonaldi, 2013) in 
collaboration with Tiziana Bonaldi’s group. 
Protein interactors from the cross-linking ChIPs were identified and quantified using 
MaxQuant software (version 1.3.0.5) (http://www.maxquant.org/downloads.htm). MS/MS 
spectra were recorded in “centroid” mode, and the six most abundant peaks per 100 Da 
mass intervals were selected for search. The MS/MS spectra were searched against a 
HUMAN 1401 database (51195 entries), using Andromeda search engine (Cox et al., 
2011) MaxQuant analysis included an initial search with a precursor mass tolerance of 20 
ppm, and the results were used for subsequent mass recalibration. Peptide identification 
was based on a main search with mass deviation of the precursor ion of 7 ppm, and the 
fragment mass tolerance was set at 0.5 Da. The mass accuracy of the precursor ions was 
improved by the time-dependent recalibration. Enzyme specificity was set to trypsin, 
allowing two missed cleavages and cleavage at the N-terminus of proline. A false 
discovery rate (FDR) of 0.01 for proteins and peptides is applied, and a minimum peptide 
length of 6 amino acids is required. Carbamidomethylation of cysteine was selected as a 
fixed modification, and oxidation of methionine and acetylation of the protein N-terminus 
were included as variable modifications. Peptide and protein identifications were 
performed automatically with MaxQuant using default settings. Additional option for 
Label Free Quantification (LFQ) and Match between run were selected. In particular, for 
the Match between run the precursor masses were matched in a 2-min retention time 
window (after realignment of the runs) based on the accurate mass measurement.  
Contaminants, hits to the reverse database (reversed) and proteins identified only by site 
were filtered out in each label-free Myc ChIP experiment. Proteins were accepted if they 
were identified with at least two peptides, one of which was unique, in each experiment. 
For each protein, the LFQ ratio was calculated dividing the LFQ value in the Myc ChIP 
over the LFQ value in the IgG ChIP. Proteins present in at least two out of three replicates 
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were selected as putative Myc interactors, considering all the proteins identified only in 
Myc-ChIP experiments, and also the proteins identified in both Myc-ChIP and IgG-ChIP 
with a LFQ ratio>=2.5. 
 
2.6. ChIP-qPCR 
To check the quality of the Myc-ChIP, we analyzed regions on Myc-bound promoters 
(Nucleolin, IFRD2) and a non-targeted region as a negative control (acetylcholine 
receptor). The qPCR mix was composed of 6 µl of DNA, 4 µl of 2 µM primers mix, 10 µl 
of Syber Green mix (Applied Biosystem), for a total volume of 20 µl. The primers used are 
listed in table 1. 
 
2.7. Western Blot (WB) 	  
Cells were resuspended in lysis buffer (150 mM NaCl, 1% NP-40, 0.5% Sodium 
Deoxycholate, 0.1% SDS, 50 mM Tris pH 7.5) supplemented with protease inhibitors 
(Roche) and sonicated; protein concentration was determined by Bradford-based Protein 
Assay kit (Bio-Rad). 
Cell lysates were loaded on a 12% polyacrylamide gel. After the electrophoresis, proteins 
were transferred on a nitrocellulose membrane that was blocked for 1h with 5% milk in 
TBS-T (10 mM TrisHCl, 100 mM NaCl, 0.1% Tween at pH 7.4) and subsequently 
incubated with the proper primary and secondary antibodies. The signal was detected using 
the Enhanced Chemioluminescence kit (Bio-Rad) and analyzed with ChemiDoc XRS+ 
imaging system and Image Lab software (Bio-Rad). 
Antibodies: anti-Myc (9E10), anti-Myc Y69 (ab32072, Abcam) anti-Ikaros (H-100, Santa 
Cruz), anti-Ikaros (A303-516A, Bethyl laboratories), anti-Aiolos (ab64400, Abcam), anti-
FLAG (ab1162, Abcam), anti-Vinculin (Sigma), anti-ACL (A303-866A, Bethyl 
laboratories), anti-DNA-PK (A300-516A-T, Bethyl laboratories), anti-Ruvbl1 (A304-716-
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A-T, Bethyl laboratories), anti-Ruvbl2 (A302-536A-T, Bethyl laboratories), anti-NCL 
(A300-711A-T, Bethyl laboratories), anti-Rbbp4 (ab79416, Abcam), anti-Ifi16 (sc8023, 
Santa Cruz), anti-CHD4 (A300-081A-T, Bethyl laboratories). 
 
2.8. Co-Immunoprecipitation (coIP) 	  
Endogenous Ikaros and Aiolos were immunoprecipitated in p493-6 cells, in HEK293T 
cells, in multiple myeloma cell lines and in Burkitt’s lymphoma cell lines using the 
sc13039 (H-100, Santa Cruz) and ab64400 (Abcam) antibodies respectively. Myc was 
immunoprecipitated with the N262 (sc764, Santa Cruz) antibody. 
Ikaros was immunoprecipitated in BH1 cells using the ab191394 (Abcam) antibody and in 
pre-B ALL cell lines using the anti-Ikaros antibody from Bethyl Laboratories (A303-
516A). 
30x106 cells were resuspended in 1ml of NHEN buffer (150 mM NaCl, 0.5% NP-40, 10% 
glycerol, 1 mM EDTA, 20 mM HEPES pH 7.5 and complete EDTA-free protease 
inhibitors (Roche) and briefly sonicated for 30 seconds with 30% amplitude. 2µg of the 
specific antibody was added to 2 mg of protein lysate and left for 3h at 4°C on a wheel. 
Sepharose beads conjugated with G protein (Invitrogen) were added for 2 additional hours 
to recover the immunocomplexes. After five washes with wash buffer (150 mM NaCl, 
0.1% Tween, 10% glycerol, 1 mM EDTA, 20 mM HEPES pH 7.5), the beads were 
resuspended in sample buffer, boiled at 95°C to elute the proteins and ran on SDS-PAGE 
for western blot analysis. 
 
2.9. ChIP-sequencing (ChIP-seq)  	  
The ChIP experimental protocol previously described in this session was followed with 
minor modifications. In particular, DNA was fragmented by 8 cycles (30” ON + 30” OFF, 
30% Amplitude) of sonication instead of being digested with MNase, in order to obtain 
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DNA fragments of a size between 200 and 300 bp. After overnight incubation with the 
antibody, G protein-conjugated beads (Invitrogen), pre-blocked with BSA and E. coli 
tRNA were added to the lysates for 2h at 4°C and then washed three times with Mixed 
Micelle buffer (150 mM NaCl, 20 mM Tris-HCl pH 8.1, 50 mM EDTA, 0.2% NaN3, 2% 
Triton-X 100, 0.2% SDS, 5% w/v sucrose), two times with buffer 500 (0.1% DOC, 1 mM 
EDTA, 50 mM HEPES, 500 mM NaCl, 1% Triton-X 100, 0.2% NaN3), two times with 
LiCl buffer (0.5% DOC, 1 mM EDTA, 250 mM LiCl, 0.5% NP-40, 10 mM Tris-HCl pH 8, 
0.2% NaN3) and once with TE buffer (10 mM Tris pH 8, 1 mM EDTA). Beads and inputs 
were then resuspended in 200 µl of TE with 2% SDS and decrosslinked overnight at 65°C. 
The day after, DNA was purified (PCR purification kit, Qiagen) eluted in 50 µl and dosed 
with the Qubit fluorimeter; an aliquot of DNA was diluted 1:5 and analysed by qPCR. 
 
2.10. ChIP-seq analysis 	  
ChIP-seq Next-Generation Sequencing (NGS) reads sequenced with the Illumina 
HiSeq2000 were filtered using the fastq_masker tool (setting the options to –q 20 – r N) of 
the FASTX-Toolkit 0.0.13.2 (http://hannonlab.cshl.edu/fastx_toolkit/). Their quality was 
evaluated and confirmed using the FastQC application 
(http://www.bioinformatics.barbraham.ac.uk/projects/fastqc/).  
ChIP-seq NGS reads were aligned to the hs19 genome through the BWA-0.6.2-r126 
aligner using default settings (Li & Durbin, 2010). Peaks were called using the MACS 
software (v2.0.9) (Zhang et al., 2008). Only peaks with P values <1 X 10-5 were retained 
(positive peaks). Normalized reads count within a genomic region was obtained by 
normalizing the number of reads in a particular region on the total number of aligned reads 
in the sequencing library. Peak enrichment was determined as log2(ChIPw - inputw), in 
which ChIPw and inputw is the normalized count of reads in the peak region in the ChIP 
and in the corresponding input sample. Promoters are defined as regions from -2 kb to +1 
	   51	  
kb around the TSS. All the alignments and peak calling were performed using HTS-flow, a 
web tool for the management and the analysis of NGS data (Bianchi et al., 2016). 
Bioinformatic analyses were performed in collaboration with Vera Pendino. 
 
2.11. RNA extraction and analysis: quantitative PCR (qPCR) 
and RNA-seq. 	  
Total RNA was purified onto RNeasy columns (Qiagen), or using the Maxwell ® 16 LEV 
simplyRNA cell kit.  
For qPCR analysis, the complementary DNA (cDNA) was synthetized using the ImPromII  
kit (Promega). 10 ng of cDNA were used for each qPCR reaction together with the FAST 
SYBER Green Master mix (Applied Biosystem) and 0.4 µM primers in a total volume of 
20 µl. 
For the RNA-seq, RNA quality was checked with the Agilent 2100 Bioanalyser (Agilent 
Technologies). Libraries for RNA-seq were then prepared with the TruSeq Stranded Total 
RNA sample Prep Kits (Illumina) following manufacturer instruction. RNA libraries were 
sequenced in a 50 bp pair-end mode with 60 milion reads depth. 
 
2.12. RNA-seq data analysis 	  
The samples sequenced with the Illumina HiSeq2000 were filtered using the fastq_masker 
tool (setting the options to –q 20 – r N) of the FASTX-Toolkit 0.0.13.2 
(http://hannonlab.cshl.edu/fastx_toolkit/). Their quality was evaluated and confirmed using 
the FastQC application (http://www.bioinformatics.barbraham.ac.uk/projects/fastqc/).  
NGS reads from the p493-6 samples were aligned to the hs19 reference genome, while the 
reads from the BH1 cells were aligned to the mm9 genome using the TopHat aligner 
(version 2.0.6) with default parameters (Trapnell et al., 2009). In case of duplicated reads, 
only one read was kept. Read counts were associated to each gene (gene annotation from 
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UCSC derived GTF gene) using the featureCounts software 
(http://bioinf.wehi.edu.au/featureCounts/). Absolute gene expression was defined 
determining the number of exonic reads per kilobase per million of total reads aligned on 
exons (eRPKM). Differentially expressed genes (DEGs) were identified using the 
Bioconductor package DESeq2 (Love et al., 2014) considering genes whose q-value 
relative to the control was lower than 0.05.   
All the alignments, absolute quantifications and identification of DEGs were performed 
using HTS-flow, a web tool for the management and the analysis of NGS data (Bianchi et 
al., 2016). Bioinformatics and statistical analysis, including heatmaps, hierarchical 
clustering of RNA-Seq data were performed using R and Bioconductor packages (R Core 
Team 2011). 
RNA-seq of p493-6 cells with high or low Myc level was performed on four biological 
replicates (cells treated and collected at different moments). RNA-seq of BH1 cells with 
different treatments was performed on three technical replicates (three aliquots of cells 
treated and collected at the same time). Bioinformatic analyses were performed in 
collaboration with Vera Pendino. 
 
2.13. Motif analysis 	  
Sequences of 200 bp around the summits of the peaks are considered for each ChIP-seq 
and analyzed with the MEME Suite web portal (v4.12.0) (Bailey et al., 2009), that uses 
different motif discovery tools such as DREME (Bailey, 2011) and MEME-ChIP 
(Machanick & Bailey, 2011). 
 
2.14. Functional annotation 	  
Functional annotation analysis to determine enriched classes of genes was performed using 
the Molecular Signature Database (MSigDB, v6.1) of the GSEA Broad Institute 
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(Subramanian et al., 2005), considering in particular the overlap with the Canonical 
Pathways and the Hallmark gene sets. 
2.15. List of primers 	  
	  




Gene name Specie Forward Reverse 
 Ikaros human  CGTAGGATCCACCATGGATGCTGATGAGGG  TACGTCTAGATTAGCTCATGTGGAAGC 
 Aiolos human  CGTAGGATCCACCATGGAAGATATACAAAC  TACGTCTAGATCACTTCAGCAGGGCTC 
 c-Myc human  CGTAACTAGTACCATGCCCCTCAACGTTAG  TACGGCGGCCGCTTACGCACAAGAGTTCC 
ChIP 
Gene name Specie Forward Reverse 
 Nucleolin human  TTTTGCGACGCGTACGAG  ACTAGGGCCGATACCGCC 
 IFRD2 human  CGTGCCCCAGCAGTCATT  GCAGTGGGCAGCGAGC 
 AchR human  CCTTCATTGGGATCACCACG  AGGAGATGAGTACCAGCAGGTTG 
 AMICA1 human  AGGAACCACAAGAAGGCTGA  GGGACCCTCTTACGTGACAA 
 SYK human  CTGTGTGGTTTGAGCGTGAT  ACATCCCTGGGCCATTAGAG 
 QPCTL human  ACCAATCCCCTGCCTACATC  GTTGGTTCCCCTGAGAATGG 
Gene expression 
Gene name Specie Forward Reverse 
 RPPO mouse/human  TTCATTGTGGGAGCAGAC  CAGCAGTTTCTCCAGAGC 
 TBP mouse  TAATCCCAAGCGATTTGCTG  CAGTTGTCCGTGGCTCTCTT 
 c-Myc human  GATTCTCTGCTCTCCTCGACGG  AGAAGGTGATCCAGACTCTGACC 
 c-Myc mouse  TTTTTGTCTATTTGGGGACAGTG  CATCGTCGTGGCTGTCTG 
 Ikaros mouse  TCCAGATGAAGGGGATGAGC  CTTTCTGGGTAAAGGAGGCC 
 St6Galnac4 human  TGGTCTACGGGATGGTCA  CTGCTCATGCAAACGGTACAT 
 Rrp9 human  AGAGACCGCACAGGAAAAGA  ACTTCTGCAACCTGCCTCTC 
 Igll1* mouse  GGACTTGAGGGTCAATGAAGCTC  GTGGGATGATCTGGAACAGGAG 
 Lig4* mouse  CATGTCCCCTTTGCAGACTT  TTTCTGTTCTTATGAAGGGCATC 
 Rag1* mouse  AGAGAGCAAGGAGAGAGTAGACAGCA  GGTGTTGAATTTCATCGGGTGC 
 Syk mouse  TTCAACCCCTATGAGCCAAC  GGCAGGGCTTCTCTCTGAA 
 Vpreb* mouse  CATCAGCCACCATTAGCATC  ACCCTGGTGCTTGTCTGAGT 
 Ccnd2* mouse  GATCCGAACGAGACCAAGAA  CCCTCTGGCTCACTTCTCAG 
 Blnk* mouse  GAGAGGGAACGGAGAGGACT   GGTTGTGCTGGTGACTGTTG 
*From Ferreiros-Vidal et al, 2013 
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3. RESULTS 
3.1 Identification of Myc interactors through mass spectrometry 
analysis  
 
3.1.1. Myc modulation in p493-6 cells 	  
As a system in which Myc levels can be easily modulated, thus facilitating the validation 
of Myc interactions and the study of their biological role, we chose to use the p493-6 line. 
P493-6 cells were derived from a human B cell line (EREB2-5), previously derived from 
primary human tonsil B-cells immortalized with a conditional form of the Epstein-Bar 
virus (EBV) protein EBNA2 (Kempkes et al., 1995). EBV infection initiates cell cycle 
entry of resting B lymphocytes in a way that is strictly dependent on the viral protein 
EBNA2. In particular, in the EREB2-5 cell line, the EBNA2 protein was engineered and 
fused with the ligand binding domain of the estrogen receptor, thus activation of EBNA2 
and cell proliferation depend on the presence of estrogens. In the absence of EBNA2 
activity, the endogenous Myc, that is shown to be an EBNA2 direct target, is not 
expressed; conversely, upon estrogen stimulation, EBNA2 regulates Myc expression 
inducing cell cycle entry (Kaiser et al., 1999). Subsequently, EREB2-5 cells were stably 
transfected with a vector expressing an exogenous Myc transgene under the control of a 
Tet-OFF system to obtain the final p493-6 cell line (figure 7); the suppression of Myc 
expression upon tetracycline (Tet) withdrawal treatment rapidly causes cell cycle arrest 
(Pajic et al., 2000). Since EBV infection is often associated with the onset of Burkitt’s 
lymphoma (BL) and since this cell line showed typical BL features in terms of cell 
morphology, expression of surface antigens and Myc expression level, p493-6 cells have 
commonly been considered an in vitro model of BL. 
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Figure 7. p493-6 cell line. Human B cells were immortalized with a conditional form of the 
Epstein-Bar Virus (EBV) protein EBNA2. Subsequently, they were stably transfected with a vector 
expressing an exogenous Myc transgene under the control of a Tet-OFF system (adapted from 
Pajic 2000). 
	  
This system would allow us to easily obtain a cell line with high or low Myc levels just 
adding Tet to the medium. In particular, we decided to compare cells proliferating in the 
absence of Tet (i.e. maximal Myc expression) with parallel cultures treated with Tet for 8h, 
in order to decrease Myc protein level of around ten times in the shorter time frame 
possible to avoid secondary effects due, for example, to the block of cell cycle. So, from 
now on, we will refer to “high Myc conditions” for untreated cells and “low Myc 
conditions” for cells treated with 200 ng/ml Tet for 8h (figure 8). 
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Figure 8. Myc level modulation in p493-6 cells. Exogenous Myc level is under the control of a Tet-off 
system. High Myc= non-treated cells; low Myc= cell treated for 8h with 200 ng/ml Tet.	  
 
3.1.2. Setting of the label-free ChroP technique. 	  
In order to identify new Myc interactors on chromatin, we took advantage of the 
Chromatin Proteomics (ChroP) technique that combines chromatin immunoprecipitation 
(ChIP) and Mass Spectrometry (MS) (Soldi & Bonaldi, 2014) (figure 9). We performed 
this experiment in p493-6 cells with high Myc level, using a label-free MS approach. 
Basically, we chemically crosslinked proteins and DNA with formaldehyde and performed 
immunoprecipitation using an antibody that specifically recognizes Myc, as usually done 
in chromatin immunoprecipitation (ChIP) experiments to identify protein-DNA 
interactions, but instead of Myc-associated DNA we analyzed Myc-associated proteins by 
mass spectrometry (figure 9).  
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Figure	  9.	  Label	   free	  ChroP	  scheme.	  Cells	  are	  crosslinked	  with	  formaldehyde	  (FA)	  and	  treated	  with	  MNAse	  to	  fragment	  DNA.	  Specific	  antibodies	  are	  added	  to	  the	  cell	  lysate;	  immune-­‐complexes	  are	  then	  recovered	  by	  adding	  beads	  and	  washed.	  Part	  of	  the	  material	   is	  kept	  for	  the	  controls	  (WB	  and	  qPCR),	  while	  the	  rest	  is	  loaded	  on	  a	  gel	  and	  processed	  for	  MS	  analysis	  
 
We first verified the quality of the immunoprecipitation by performing quantitative PCR 
(qPCR) and WB on part of the recovered material (DNA and protein, respectively). By 
ChIP-qPCR we verified that, in the Myc-ChIP, the recovery of DNA corresponding to 
promoters of known MYC targets (Nucleolin, IFRD2) (Sabò et al., 2014) was enriched 
compared to a negative control region (AchR promoter), while these levels were 
comparable to background with the mock IgG-ChIP (figure 10). Moreover, we verified by 
western blot that the Myc protein was only immunoprecipitated when the anti-Myc 
antibody was added, while it was not present in the non-specific IgG-ChIP (figure 11). 
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Figure 10. Preliminary ChIP control: qPCR. 10% of the material recovered after the immunoprecipitation 
was used to extract DNA and verify specific enrichment of known Myc bound regions (Nucleolin and 
IFRD2) in the Myc IP compared to the IgG IP. The non-bound acetylcholine receptor promoter (AchR) was 
used as negative control. Here it is shown one experiment representative of the three replicates. 
	  
 
Figure 11. Preliminary ChIP control: WB. 10% of the material recovered after the immunoprecipitation 
was used to perform a ChIP-WB, while the rest was loaded on gel, stained with coomassie blue and 
processed for MS analysis. Each lane was divided into 9 parts according to the molecular weight. IgH= 
immunoglobulin heavy chain of the antibody used for the IP; IgL= immunoglobulin light chain chain of the 
antibody used for the IP; FT=Flow Through. The loaded input and FT correspond to 2.5% of the material 
used for the IP. Here it is shown one experiment representative of the three replicates. 
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Although the western blot showed that we were recovering only a fraction of the Myc 
protein with the ChIP (as revealed by presence of Myc also in the unbound flow through 
samples), we judged the amount, specificity and quality of the immunoprecipitated 
material good enough to proceed with the mass spectrometry. On the same gel used to 
perform the ChIP-WB, we also loaded all of the remaining immunoprecipitated material 
for MS analysis: in this way, after development of the WB and coomassie blue staining, 
respectively, we could use the WB as a precise reference to identify the positions of Myc 
and Max on the gel (figure 11). Based on this, each lane of the coomassie gel has been 
divided into 9 different bands taking care of separating Myc (band 4) and Max (band 9) 
from the heavy and light chains (bands 5 and 8, respectively) of the antibody used for the 
immunoprecipitation, to avoid signal masking during MS analysis due to the high amount 
of IgG peptides (figure 11). Each band was cut and processed for MS analysis as described 
in the material and methods. We performed the ChroP experiment in triplicate, always 
comparing the Myc-ChroP with a mock, non-specific IgG-ChroP as negative control. 
  
3.1.3. Identification of new Myc interactors 	  
The MS data were analyzed with the MaxQuant software 
(http://www.maxquant.org/downloads.htm) and only proteins identified with at least two 
peptides, of which at least 1 is a unique peptide (a peptide that identifies a certain protein 
in an unambiguous way), have been selected as reliable, following the standard parameters. 
Proteins identified only in Myc-ChIP experiments or in both Myc-ChIP and IgG-ChIP but 
with a Myc/IgG ratio of protein amount (Label Free Quantfication, LFQ) ≥ 2.5 were 
considered putative Myc interactors. Using these criteria, we identified a total of 423 
candidates, 24 of which were in common within all the 3 experiments, while 51 were 
found in 2 out of 3 experiments (figure 12). 
 
	   60	  
	  
Figure 12. Label free ChroP results. The number of candidates identified in the three experiments was 
quite different (439 in the first replicate, 53 in the second and 102 in the third), nevertheless 24 proteins were 
present in all the replicates (1+2+3, red square), while 51 proteins were identified at least in two out of three 
experiments (1+2, 2+3, 1+3). Proteins written in blue are known Myc interactors; proteins written in green 
were identified as putative Myc interactors in other MS datasets (Koch et al., 2007; Agrawal et al., 2010), 
even if the interaction was not validated yet; proteins written in black are the new candidates, not previously 
reported as Myc ligands.  	  
As expected, Myc was always found with 12 peptides in all the three replicates and only in 
the Myc-ChIP samples. Several known Myc interacting proteins were identified in at least 
two independent experiments, validating the reliability of the results: components of the 
Tip60/NuA4 complex such as TRRAP (McMahon et al. 1998), EP400 (Tworkowski et al., 
2008), RUVBL1, RUVBL2 (Frank et al., 2003), as well as WDR5 (Thomas et al., 2015), 
HDAC1 (Garcia-Sanz et al., 2014), MCM2-7 (Dominguez-Sola et al., 2007), CHD4/Mi-2b 
(Koch et al., 2007). Moreover, some putative Myc interactors identified also in othe MS-
based studies, although not yet validated, were present in our lists: PSMA7, FBL, PRKDC, 
CCT5, TRIM28 (Koch et al., 2007), DDX17, YBX1, PGD, UBC, PTBP1 (Agrawal et al., 
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2010) (figure 12). Unexpectedly, Max was identified only in the first replicate (with 5 
peptides) but was missing in the others; this is probably due to technical problems related 
to the MS analysis, since Max is visible by ChIP-WB and its presence is necessary for Myc 
to bind the DNA regions (Amati et al., 1992) that resulted enriched by qPCR in our control 
experiment (figure 10). 
Looking at the proteins that were identified in at least two out of three experiments and 
considering in particular the proteins with a function that could be related to Myc 
transcriptional activity, some new interesting candidates emerged: IKZF3, IKZF1, RBBP4, 
SUPT16H, SSRP1, IFI16, YWHAQ, SFN (figure 13).  
 
	  
Figure 13. Top candidates selected from the label free ChroP results. Proteins identified in at least two 
out of three replicates, the function of which could be related to Myc transcriptional activity. Different 
subunits of the same complexes and families are found; already known Myc interactors are indicated in blue. 	  
RBBP4 is a subunit of the NuRD complex (Allen et al., 2013) and several NuRD subunits, 
including HDAC1/2, TIP48/49 and TRIM28, were already identified as Myc interactors 
(Koch et al., 2007). SUPT16H and SSRP1 are the two subunits of the facilitates chromatin 
transcription (FACT) complex, which is a histone chaperone implicated in nucleosome 
reorganization (Winkler & Luger, 2011). IFI16 is a nuclear protein involved in 
Identified in 3 out of 3 experiments 
Identified in 2 out of 3 experiments 












FACT complex SUPT16H SSRP1 
Gamma-interferon-inducible protein 16 IFI16 
14-3-3 proteins YWHAQ SFN 
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transcriptional regulation; in particular, it seems to be a transcriptional repressor that also 
binds the c-myc promoter, interfering with its transcription (Egistelli et al., 2009). 
YWHAQ and SNF are two members of the 14-3-3 family (14-3-3 theta and sigma 
respectively) of regulatory proteins: they can interact with many binding partners 
regulating their activity and thus being involved in many cellular functions such as cell 
cycle regulation, metabolism control, apoptosis and gene transcription (Obsilová et al., 
2008). Aiolos (IKZF3) and Ikaros (IKZF1) are lymphocyte specific transcription factors, 
able to interact with each other and considered tumor suppressors (Georgopoulos, 2017).  
 
3.1.4. Validation of Myc interactors 	  
We performed ChIP-WB experiments for a first validation of Myc interaction with the 
cofactors identified by MS. If we immunoprecipitate Myc, we can see a 
coimmunoprecipitation signal for Nucleolin (NCL), Ruvbl1 and Ifi16, thus, in these cases, 
the interaction seems to be validated (figure 14A). The specificity of the result is less clear 
for Aiolos, since a band appears also in the negative control and for ACLY, since it 
coimmunoprecipitates with Myc in a similar manner when Myc is present at high or low 
level. Finally, for DNA-PK, Rbbp4, Chd4, Parp1 and Ikaros, no interaction was visible, 
while for Ruvbl2, the signal could be masked by the heavy chain of the antibody used for 
the ChIP (figure 14A). We also tried the reciprocal approach by immunoprecipitating 
Ikaros and Aiolos: in this case, Myc clearly coimmunoprecipitates with both of them when 
present at high level (figures 14B and C). The same strategy could be tried also for the 
other candidates to understand if the lack of interaction signal was due to technical issues. 
Further ChIP-WB experiments, together with coimmunoprecipitations in native conditions 
are needed to set clear conclusions.  
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Figure	  14.	  Validation	  of	  Myc	   interactors	  by	  ChIP-­‐WB	   in	  p493-­‐6	   cells.	  ChIP-­‐WB	  after	  Myc	  (A),	  Aiolos	  (B)	  or	  Ikaros	  (C)	  immunoprecipitation	  in	  p493-­‐6	  cells	  with	  high	  (H)	  or	  low	  (L)	  Myc	  levels.	  FT=	  flowthrough.	  The	  loaded	  input	  and	  FT	  correspond	  to	  3%	  of	  the	  material	  used	  for	  the	  ChIP.	  Here it is shown one experiment representative 
of two replicates.	  	  
Since, according to the information found in literature, the putative interplay between Myc 
and Ikaros/Aiolos appeared to be particularly interesting and, in addition, the first ChIP-
WB validation of these interactions was promising, we decided to focus our attention on 
these two proteins, as exposed in the next paragraphs. 
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3.2. Ikaros, Aiolos and Myc interaction in p493-6 cells 	  
3.2.1. Ikaros and Aiolos coimmunoprecipitate with Myc 	  
In order to validate the interaction of Myc with Ikaros and Aiolos, we checked if these 
proteins coimmunoprecipitate also in native conditions, in absence of formaldehyde 
crosslinking. We thus performed a co-immunoprecipitation (coIP) experiment in p493-6 
cells with high (non-treated) or low (8h Tet) Myc levels. By immunoprecipitating either 
Ikaros or Aiolos, we could see their reciprocal interaction in either high or low Myc 
conditions, as expected (figure 15A and B); Myc was detected in the same immune-
precipitate, but not in the IgG control IP, only when expressed at high levels, indicating 
that its interaction with both proteins was specific. By immunoprecipitating Myc, instead, 
the results were not so clear: Aiolos was still visible but with a faint band, while Ikaros 
could not be distinguished from the background (figure 15C). This could be due to 
technical issues and/or to the fact that only a small part of the overexpressed Myc is bound 
by Ikaros and Aiolos, thus making it difficult to detect the interaction in this direction; in 
fact, although the bands corresponding to the immunoprecipitated Ikaros, Aiolos and Myc 
appeared to be similar in figure 15A and B, Ikaros and Aiolos levels in the input are much 
lower than Myc. Most noteworthy here, Ikaros and Aiolos protein levels did not change 
upon modulation of Myc (at least after 8h), suggesting that Ikaros and Aiolos are not 
regulated by Myc (figure 15). 
Myc and Aiolos coimmunoprecipitation was also visible by adding the Benzonase nuclease 
to the cell lysate, thus suggesting that the two proteins can interact in a DNA independent 
way. 
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Figure 15. Myc, Ikaros and Aiolos coimmunoprecipitation in p493-6 cells. Immunoprecipitation of the 
endogenous Ikaros (A) and Aiolos (B) in p493-6 cells with high (H) or low (L) Myc levels. (C) Myc 
immunoprecipitation in p493-6 cells with high (H) or low (L) Myc levels. The loaded input is 2.5% of the 
material used for the IP. Low Myc conditions are obtained treating cells for 8h with 200 ng/ml Tet. Here it is 
shown one experiment representative of several biological replicates. 
 
The interaction of Ikaros/Aiolos with Myc was also visible by coimmunoprecipitation in 
different lymphocytic cell lines such as Burkitt’s lymphoma cells (Daudi, Raji, Namalwa, 
Ramos) (figure 16A), Multiple Myeloma cells (H929, JJN3, KMS11) (figure 16B) and pre-
B ALL cells (697, REH, Sup-b15) (figure 16C). 
Altogether, these results confirmed that a protein-protein interaction does occur between 
Myc, Ikaros and Aiolos.  
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Figure 16. Myc, Ikaros and Aiolos coimmunoprecipitation in different cell lines. (A) 
Immunoprecipitation of endogenous Aiolos in Burkitt’s lymphoma cell lines. (B) Immunoprecipitation of 
endogenous Aiolos in Multiple Myeloma cell lines; in MM1S we could not detect the co-immunoprecipitated 
Myc. (C) Immunoprecipitation of endogenous Ikaros in pre-B ALL cell lines. (IK6: Ikaros dominant negative 
isoform 6). The loaded input corresponds to 2.5% of the material used for the IP. CoIPs shown in panels A 
and B were done as single experiments, while the coIP in panel C is representative of two replicates. 
 
Subsequently, we asked whether Ikaros and Aiolos were able to bind Myc independently 
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expressed at very low levels, such as REH and Sup-b15 pre-B ALL cell lines, the 
interaction between Ikaros and Myc was still visible (figure 16C). To answer this question 
more precisely, we set an ad hoc experiment taking advantage of HEK293T cells, which 
express neither of the two lymphocytic transcription factors. We thus cloned Ikaros and 
Aiolos cDNAs in the pcDNA3 vector, choosing the IKZF1.1 and IKZF3.1 isoforms, which 
are the most common of either factor. We transfected HEK293T cells with plasmids 
allowing the overexpression of FLAG-Myc, Ikaros and Aiolos alone or in different 
combinations and immunoprecipitated either FLAG-Myc, Ikaros or Aiolos in native 
conditions. When all the constructs were co-transfected, the three factors always co-
immunoprecipitated (figure 17). Similarly, Myc and Aiolos reciprocally co-precipitated 
with anti-Aiolos and anti-Myc antibodies when co-expressed, with or without co-
transfection of Ikaros. Most noteworthy, co-immunoprecipitation of Aiolos with FLAG-
Myc and, reciprocally, FLAG-Myc with Aiolos consistently decreased upon co-expression 
of Ikaros. Conversely, co-precipitation of FLAG-Myc and Ikaros was weak on its own, but 
reinforced by co-expression of Aiolos (figure 17). Altogether, these results suggested that, 
Aiolos homodimers can interact with Myc, while Ikaros may require dimerization with 
Aiolos for effective interaction. 
It is noteworther here that, in apparent contrast with the above conclusion, Ikaros and Myc 
interacted also in systems where Aiolos was present at very low levels, like REH and Sup-
b15 cells (figure 16C), as mentioned before; moreover no difference in Ikaros-Myc 
interaction was observed in Ba/f3 cells (where Aiolos was not detectable either at protein 
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Figure 17. Coimmunoprecipitations in HEK293T cells. HEK293T cells were transfected with the 
pcDNA3 vector overexpressing FLAG-Myc, Ikaros and Aiolos in different combinations, and the three 
factors were immunoprecipitated, as indicated, in native conditions. The loaded input corresponds to 2.5% of 
the material used for the IP. Here it is shown one experiment representative of three biological replicates.	  
	  
Figure 18. Coimmunoprecipitation in Ba/f3 cells. Ba/f3 were infected with vectors expressing a Tet-
inducible Ikaros, an OHT activatable MycER, and with or without a Tet-inducible Aiolos. Anti-Ikaros or 
anti-IgG antibodies were used for the immunoprecipitation in native conditions. The loaded input 
corresponds to 2.5% of the material used for the IP. This coIP was done as single experiment. 
Input IP: FLAG-Myc 
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3.2.2. Genome-wide distribution of Ikaros, Aiolos and Myc 	  
Since Ikaros and Aiolos were identified as Myc interactors on chromatin, we analyzed 
their genomic distribution in p493-6 cells through ChIP-seq experiments, using the cognate 
antibodies. We also performed ChIP-seq using an antibody recognizing acetylated lysine 
27 in histone 3 (H3K27Ac) to identify active chromatin regions, and in particular active 
promoters and enhancers (Creyghton et al., 2010). We collected p493-6 cells with high 
(non-treated) or low (8h Tet) Myc levels and crosslinked them with formaldehyde before 
proceeding with the ChIP protocol. Prior to sequencing, we verified Myc binding by qPCR 
at known target promoters (Nucleolin, IFRD2) and the absence of binding in the 
acetylcholine receptor (AchR) promoter, as we previously did for the ChroP. As expected, 
the binding was higher in high Myc conditions, reduced in low Myc conditions and close 
to zero in the negative controls (figure 19).  
	  
Figure 19. ChIP-qPCR on Myc-ChIP and H3K27Ac-ChIP. ChIP-qPCR on active chromatin regions 
bound by Myc (Nucleolin, IFRD2) and on an inactive, non-bound region (AchR) as a negative control. H= 
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After sequencing of the immunoprecipitated DNA and peak calling, we retrieved a total of 
22202 and 1555 peaks for Myc in high and low Myc conditions, respectively, and around 
20000 peaks for either Ikaros or Aiolos, in either high or low Myc conditions (figure 20). 
Thus, as expected, the number of Myc peaks strongly decreased at low Myc levels, while 
peak numbers for Ikaros and Aiolos remained essentially unchanged. As already reported, 
Myc peaks mostly localized at promoters (Lin et al., 2012; Sabò et al., 2014) even if, when 
present at high levels, the percentage of peaks at distal sites increased. Conversely, Ikaros 
and Aiolos peaks seemed to be equally distributed among promoters, gene bodies and 
intergenic regions (Ferreirós-Vidal et al., 2013; Schjerven et al., 2017; Schwickert et al., 
2014), in proportions that did not vary with Myc levels (figure 20).  	  
 
 
Figure 20. ChIP-seq peak numbers and annotation. Number of peaks retrieved in Myc (pvalue 10-5), 
Ikaros and Aiolos (pvalue 10-10) ChIP-seq and their localization in promoters, gene bodies or intergenic 
regions. Promoters: -2kb to +1kb from the TSS; gene body: more than 1kb away from the TSS; intergenic: 
all the rest; H= high Myc; L= low Myc.  
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Motif analysis of the sequences underlying the peak summits (200 bp) identified the 
known consensus for both Ikaros and Aiolos (Molnár & Georgopoulos, 1994) in Ikaros 
and Aiolos ChIP-seq peaks, and the E-box in Myc peaks, thus confirming the specificity of 
the identified regions (figure 21). 
 
 
Figure 21. Motif analysis on sequences underlying Ikaros, Aiolos and Myc peaks. 200 bp sequences 
around the peak summits are considered for each ChIP-seq and analyzed with de novo motif discovery 
programs. Here the enriched motifs identified by DREME are reported for all the sets of regions except for 
Myc (L) distal sites: in this case DREME did not identify any motif, while the E-box has been retrieved by 
MEME-ChIP. The e-value and the number of regions used for the analysis are reported. (H)=high Myc; 
(L)=low Myc. 
 
We then focused our attention on promoters and performed a functional analysis to identify 
the most enriched classes of genes bound by each transcription factor. Functional analysis 
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of Ikaros bound genes identified the main biological functions promoted by Ikaros in p493-
6. The top ten classes included, in particular, cell cycle regulation, apoptosis and genes 
related to the immune system (figure 22A and E). All these classes well describe Ikaros 
specific activity in lymphocytes and its role in the negative regulation of cell cycle, 
particularly at the G1-S transition. STAT5 signaling pathways (in top 15 results) are also 
enriched, in accordance with the evidence that Ikaros compete with this transcription factor 
to regulate common target genes (Katerndahl et al., 2017). Functional analysis of Aiolos 
bound genes identified mostly the same classes enriched for Ikaros targets, according to 
the fact that most of target genes are in common (figure 22B and F). Functional analysis on 
genes bound by Myc (when present at high level) identified classes of genes related to 
protein and RNA metabolism and ribosomal biogenesis, that were also identified in other 
cell lines (Sabò et al., 2014; Walz et al., 2014) (figure 22C and G). 
Since genes bound by all the three transcription factors are mostly a subset of Myc-bound 
genes (figure 22D), functional analysis of these common genes did not add relevant 
information. 
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Figure 22. Bound genes overlap and functional annotation. A) Venn diagram showing the overlap of the 
genes whose promoters is bound by Ikaros either in high (H) or low (L) Myc conditions. B) Intersection of 
genes, the promoter of which is bound by Aiolos in H and L Myc conditions. C) Intersection of the genes, the 
promoter of which is bound by Myc in H and L Myc conditions. (D) Intersection of genes whose promoter is 
bound by Ikaros HL, Aiolos HL and Myc H.  Functional annotations of genes bound by Ikaros HL (E), by 
Aiolos HL (F) or by Myc H (G); genes are ranked for their enrichment level and the top 2500 genes are used 
for the functional analysis.	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To further control the quality of the peaks identified for Ikaros and Aiolos, we selected 
some of the most enriched promoters in the ChIP-seq data (AMICA1, SYK, QPCTL) (figure 
23) and tested them by ChIP-qPCR. The enrichment was visible only in Ikaros- and 
Aiolos-ChIP and not in the negative control (IgG), thus providing a first validation of the 
ChIP-seq results (figure 24). Although the qPCR results suggested a higher Ikaros and 
Aiolos enrichment on their target genes when Myc was present at low levels, this effect 
was not significant at a genome-wide level (figure 25).  
	  
	  
Figure 23.  Target gene tracks. ChIP-seq tracks visualized with the genome browser, showing the 
enrichment of Ikaros, Aiolos, Myc and H3K27Ac on Ikaros/Aiolos target genes (AMICA1, QPCTL, SYK) and 
on one negative control region (AchR-CHRNA1)	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Figure 24. Validation of Ikaros and Aiolos bound regions by ChIP-qPCR. ChIP-qPCR on promoters 
bound by Ikaros and Aiolos (AMICA1, SYK, QPCTL) and on the non-bound region AchR. The oligos used 





Figure 25. Ikaros binding intensity in high and low Myc conditions. Box-plot representing the enrichment 
of Ikaros on its own peaks in high and low Myc  conditions. 	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Peak distributions in our ChIP-seq datasets were consistent with their numbers: in 
particular, Myc peaks identified in the low Myc condition were a subset of those identified 
at high Myc levels; Ikaros and Aiolos, instead, shared most of the bound regions in both 
conditions. Moreover, around 70% of Ikaros and Aiolos peaks on promoters were shared 
with Myc, while around 40% of the promoters bound by Myc in high Myc condition were 
also bound by Ikaros and Aiolos. These overlaps decreased when considering distal sites, 
with 20-30% of peaks in common between Ikaros/Aiolos and Myc (figure 26). 
The levels of overlap between the transcription factors and H3K27Ac is also visualized in 
figure 27. In all cases, the great majority of the peaks were found in active chromatin 
regions, as identified by H3K27Ac. If it is well established that Myc can only bind to 
already opened chromatin (Guccione et al., 2006), for Ikaros and Aiolos this is less clear: 
in fact, as we mentioned in the introduction, Ikaros was mainly known as transcriptional 
repressor and it was identified as bound to close chromatin regions, in particular at 
centromeric repeated sequences (Brown et al., 1997). In our cells, Ikaros and Aiolos 
appeared to be mostly bound to active promoters and enhancers, as reported also in other 
published datasets (Schwickert et al., 2014), nevertheless, they can  bind regions in which 
H3K27Ac is absent too, particularly at distal sites (figure 27). In summary, ChIP-seq 
results showed that Ikaros, Aiolos and Myc share most of bound regions, particularly at 
promoters, but also at distal sites. 
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Figure 26. Overlap of Ikaros, Aiolos and Myc peaks in p493-6 cells. Percentages of peaks overlapping 
among the different samples, considering all the peaks, only peaks on promoters or only peaks on distal sites. 
For each column, the percentage of peaks overlapping (at least 1 bp) with the reference sample is reported. In 
green rectangles, the percentage of Ikaros and Aiolos peaks also bound by Myc H are highlighted, while in 
red rectangles are Myc H peaks also bound by Ikaros and Aiolos. H=High Myc; L=low Myc.	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Figure 27. Intensity and distribution of ChIP-seq peaks. Each row of the heatmaps represents a genomic 
interval (3 kb width centered on the peak). Every annotated promoter (-2000/+1000 bp from TSS) or every 
distal site (non-promoter region) in chromosome 1, identified as Ikaros-, Aiolos- or Myc-associated by ChIP-
seq in at least one of the experimental samples is reported. For the same interval, distribution of Ikaros, 
Aiolos, Myc and H3K27Ac is indicated. The white-red color code of the read count part is referred to the 
coverage on each region (white: not enriched; pink: poorly enriched; red: enriched). In the peak calling part, 
red means that a peak is called by the MACS software, white means that no peaks are called. In the last two 
columns, annotated genes (exons in red, introns in pink; + sense, - antisense strand) are also reported. All the 
lanes are ranked on the basis of Myc H enrichment. H=high Myc; L= low Myc. 
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3.2.3. Identification of direct Myc-regulated genes. 	  
To identify direct Myc target genes we decided to couple DNA binding and transcriptional 
regulation and we performed RNA-seq in p493-6 cells with high and low Myc levels, 
preparing four biological replicates for each condition. We identified a total of 4447 
differentially expressed genes (DEGs), of which 2429 were downregulated genes 
(log2Foldchange lower than -0.5) and 2018 were upregulated genes (log2Foldchange 
higher than 0.5) (figure 28).  
	  
Figure 28. Myc deregulated genes in p493-6 cells. Volcano plot representing deregulated genes upon Myc 
downregulation (8h Tet). Genes are considered deregulated if they have an adjusted pvalue (padj)<0.05 and a 
log2(fold change) expression >0.5 (in red) or <-0.5 (in blue). –log 10 (Padj) values are saturated to a 
maximum value of 10. 
 
In this system, DEGs are defined as genes the expression of which changes upon Myc 
inhibition, thus the upregulated genes are Myc target genes that are repressed by Myc, and 
vice-versa. Functional analysis confirmed that the DEGs identified belong to classes of 
genes that are usually regulated by Myc (figure 29). 
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DEG DOWN 





TRANSMEMBRANE TRANSPORT OF SMALL MOLECULES 1.24E-08 
TRANSCRIPTION 3.64E-08 
RNA POL I RNA POL III AND MITOCHONDRIAL TRANSCRIPTION 5.23E-08 
METABOLISM OF VITAMINS AND COFACTORS 9.01E-08 
RNA POL I TRANSCRIPTION INITIATION 1.20E-07 
SLC MEDIATED TRANSMEMBRANE TRANSPORT 1.24E-07 
 
DEG UP 
Gene Set Name FDR q-value 
INTERFERON GAMMA RESPONSE 2.64E-40 
IMMUNE SYSTEM 4.03E-33 
INTERFERON ALPHA RESPONSE 1.81E-22 
ALLOGRAFT REJECTION 1.71E-17 
CYTOKINE SIGNALING IN IMMUNE SYSTEM 2.20E-15 
IL2 STAT5 SIGNALING 2.70E-15 
TNFA SIGNALING VIA NFKB 2.70E-15 
HALLMARK APOPTOSIS 2.00E-14 
DEVELOPMENTAL BIOLOGY 7.46E-14 
CXCR4 PATHWAY 2.91E-12 
 
Figure 29. Functional analysis of Myc DEGs in p493-6 cells. Upregulated and downregulated genes 
identified by RNA-seq in p493-6 cells, with high or low Myc levels, belong to classes that are usually related 
to Myc functions.	  
 
Subsequently, we combined ChIP-seq and RNA-seq data to determine the correlation 
between DNA binding and gene regulation. In figure 30, the percentages of DEGs and no 
DEGs that are bound by Myc, Ikaros or Aiolos in each experimental condition are 
represented. We can see that Myc preferentially binds genes that are downregulated upon 
its inactivation. This is in accordance with previous results reporting that an increase in 
Myc occupancy at promoters correlates with Myc target gene activation (de Pretis et al., 
2017; Walz et al., 2014). Conversely, the same does not seem to be true true for Ikaros and 
Aiolos.  
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We are currently performing knock down experiments for Ikaros and Aiolos to obtain the 
list of genes that transcriptionally respond to their modulation. By intersecting the ChIP-
seq data and the complete transcriptional data, we hope to identify genes directly regulated 
by Myc and Ikaros/Aiolos, in order to study possible regulatory interactions. 
 
	  
Figure 30. Percentages of DEGs and NO DEGs bound by Ikaros, Aiolos and Myc in p493-6 cells. The 
percentages of DEGs and NO DEGs identified by RNA-seq in p493-6 cells with high or low Myc, the 
promoter of which is bound by Ikaros, Aiolos or Myc are represented. H=high Myc level; L=low Myc level. 
	  
3.3. Combined activation of Ikaros and Myc in BH1 cells 	  
3.3.1. IkarosER and Tet-Myc inducible system 	  
p493-6 cells constituted a valid system at the beginning of this project; nevertheless, they 
showed some limitations during the validation of candidate Myc interactors. For example, 
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downregulation of which causes cell cycle arrest. Moreover, they also express high levels 
of Ikaros and Aiolos that are not easily modulated. 
For these reasons, we decided to take advantage of BH1 cells, a murine pre-B cell line 
expressing a conditional IkarosER chimera, in which Ikaros is fused to the ligand-binding 
domain of the extrogen receptor (IkarosER) (Heizmann et al., 2013). BH1 cells were 
originally derived from transgenic mice in which the last exon of the Ikaros allele was 
flanked by loxP sites, allowing a Cre-dependent deletion that creates an Ikaros null allele: 
inactivation of Ikaros allowed immortalization and expansion of pre-B cells in vitro in 
presence of interleukin 7 (IL-7), followed by transduction with a retroviral vector 
expressing the GFP marker and IkarosER. Since these cells appeared very sensible to 
Ikaros induction and died in few hours after OHT treatment, a second plasmid 
constitutively expressing Bcl2-dsRed was also introduced (figure 31) (Heizmann et al., 
2013). 	  
 
Figure 31. Generation of the BH1 cell line. BH1 cells derived from mice in which the endogenous Ikaros 
has been floxed out through Mb1 Cre recombinase. Ikarosf/f  cells obtained from the bone marrow of these 
mice were subsequently infected with vectors expressing IkarosER and Bcl2 (Heizmann et al., 2013). 
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We first verified that, in our hands, BH1 cells behaved as expected (Heizmann et al., 2013) 
and checked GFP expression, using parental cells without the IkarosER-GFP vector as 
negative control. All the cells were GFP positive, although two distinct populations with 
high and low levels of GFP were visible, corresponding presumably to high and low levels 
of IkarosER expression, respectively (figure 32). This could be due to a partial leakiness of 
the IkarosER protein: since it is reported that Ikaros induction blocks the cell cycle thus 
giving a disadvantage to the cells, it is possible that cells tend to lose the vector when kept 
in culture. In order to check this assumption, we sorted the different populations and tested 
them separately.  
 
Figure 32. GFP level in BH1 cells. All the BH1 cells were GFP positive compared to the negative control 
lacking the IkarosER-GFP vector. Nevertheless, two different populations with high or low GFP levels were 
identified and sorted. 
	  
We added ethanol or OHT to the medium of each population (high GFP, low GFP and the 
initial mixture) and followed cell counts over time: only cells with high GFP stopped 
proliferating upon IkarosER activation (figure 33), consistent with our hypothesis that low-
GFP cells had lost activity. In all subsequent experiments, we used only the bright GFP 
population. 
We also checked the effects of Ikaros activation in presence or absence of interleukin 7 
(IL7). As expected, while Ikaros activation per se blocked cell growth, in absence of IL7, 
the effect was even more dramatic whether or not Ikaros was activated (figure 34) 
(Heizmann et al., 2013). 
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We then checked the expression of some Ikaros target genes after 24h of OHT treatment 
(Ferreirós-Vidal et al., 2013; Heizmann et al., 2013): as expected Lig4, Syk and Blnk were 
upregulated upon IkarosER activation, while Igll1, Vpreb, Ccnd2 and endogenous Myc 
were downregulated. Moreover, we also observed that the transcriptional effects of Ikaros 
activation were increased in case of IL7 withdrawal (figure 35), as previously reported 
(Heizmann et al., 2013). 
	  
Figure 33. Effects of Ikaros levels on BH1 cell growth. Cells sorted for high or low GFP and the initial mix 
were treated with 400 nM OHT or ethanol and counted to perform a growth curve. Average and standard 
deviation of technical replicates are shown. This growth curve was done as a single experiment. 	  
	  
Figure 34. Effect of IL7 on BH1 cell growth. BH1 cells were grown in presence or absence of IL7 and 
activated or not with OHT to perform a growth curve. Average and standard deviation of technical replicates 
are shown. This growth curve was done as a single experiment. 
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  Figure 35. Regulation of Ikaros target genes in BH1 cells. BH1 cells were cultured in presence or absence 
of IL7 in the medium and treated with 400 nM OHT or ethanol; 24h later, cells were collected for RNA 
extraction and the expression of known Ikaros target genes was checked by RT-qPCR. Average and standard 
deviation of technical triplicates are shown. This was done as a single experiment.	  
  
In order to be able to modulate also Myc expression in this system, we transduced BH1 
cells with a pSLIK vector expressing a human Tet-inducible c-Myc cDNA. To test the 
efficiency of Tet-Myc induction, we treated cells with 400 ng/ml Dox for 24h, checking 
the level of the exogenous human Myc expression and the regulation of known Myc target 
genes (Nucleolin, St6galnac4 and Rrp9) by qPCR. The results showed that Myc was well 
induced upon Dox treatment and that its target genes were upregulated, as expected, 
compared to non-treated cells (figure 36).  
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Figure 36. Inducible expression of Tet-Myc in BH1 cells. BH1 cells transduced with Tet-Myc psLIK 
vector were treated with 400 ng/ml Dox for 24h. Cells were collected for RNA extraction and the expression 
of the exogenous human Myc and of known Myc target genes (Nucleolin, IFRD2, St6galnac4) was checked 
by qPCR. NT=non-treated cells; Dox=cells treated with Dox. Average and standard deviation of technical 
triplicates are shown. 
 
Once we established the system, we performed a coIP experiment to check if the 
Ikaros/Myc interaction was maintained in these cells and with the Ikaros protein fused to 
the ER domain. We thus treated cells with OHT to induce IkarosER activation and with 
Doxycycline (Dox) to induce Myc expression and we immunoprecipitated Ikaros. The 
result showed that Myc coimmunoprecipitated with IkarosER, thus confirming the 
possibility to use this system (figure 37). 
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Figure 37.	  IkarosER and Myc coimmunoprecipitation in BH1 cells. Cells were treated with 400nM OHT 
and 400 ng/ml Dox for 24h to activate IkarosER and induce Myc expression, respectively, and were collected 
to perform the coIP in native conditions. The loaded input is 2.5% of the material used for the IP. This coIP 
was done as a single experiment. 
 
Subsequently, we treated cells with OHT, with Dox or both to check the effects of the 
single and double activations at protein and mRNA level. By western blot analysis, we 
observed that IkarosER seemed to be stabilized by OHT addition; the level of 
overexpressed Myc was not much higher than the endogenous one and, finally, the 
endogenous Myc was clearly downregulated by IkarosER activation, in particular at 24h 
(figure 38A). By qPCR, we checked the expression levels of the exogenous Myc (hMyc), 
of the endogenous Myc (mMyc) and of some target genes specific for Myc (St6galnac4, 
Rrp9) and for Ikaros (Igll1, Lig4). The exogenous human Myc was specifically induced in 
presence of Dox at all the time points, with a decrease of the induction after 24h; the 
endogenous murine Myc was downregulated in presence of Tet-induced Myc and even 
more when IkarosER was active, particularly after 24h. qPCR results were in accordance 
with the western blot in terms of endogenous and exogenous Myc expression levels and all 
the tested target genes were regulated as expected (figure 38B) (Ferreirós-Vidal et al., 
2013; Heizmann et al., 2013).	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Figure 38. BH1 treatment controls. BH1 cells were left non-treated (NT) or treated with OHT, Dox or 
both. Cells were collected after 4h, 8h and 24h for RNA and protein extraction. (A) Western blot showing the 
levels of IkarosER, exogenous Myc (hMyc) and endogenous Myc (mMyc) in all the conditions. (B) RT-
qPCR to check the expression of the exogenous Myc (hMyc), endogenous Myc (mMyc), Ikaros target genes 
(Igll1, Lig4) and Myc target genes (Rrp9, St6galnac4). Average and standard deviation of technical replicates 
are shown. This experiment is representative of two biological replicates. 	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3.3.2. Ikaros and Myc have an opposite effect on cell proliferation 	  
In order to characterize the phenotypic effect of single versus combined activation of 
Ikaros and Myc in BH1 cells, we treated them with OHT, Dox or both, in presence or 
absence of IL7, and followed cell growth for ten days. In presence of IL7, as expected, 
IkarosER activation arrested cell proliferation, while Myc induction increased it. 
Interestingly, the activation of both Ikaros and Myc together resulted in an intermediate 
effect (figure 39A). Since it is known that Ikaros activation causes Myc downregulation 
(Ma et al., 2010) that can contribute to cell cycle arrest, it is reasonable that Myc 
overexpression is able to partially rescue the phenotype. Without IL7, we observed an 
initial decrease in cell number, possibly due cell death, even if more detailed analysis are 
needed to define it precisely; subsequently, non-treated cells or cells with activated 
IkarosER stopped growing, while Myc overexpression kept the cells proliferating, even if 
less than in presence of IL7, thus suggesting that Myc expression partially overcome the 
absence of survival and proliferative stimuli due to IL7 withdrawal (figure 39B).  
BH1 cells constitutively express Bcl2, thus the decrease in proliferation observed with the 
growth curves should be mainly due to a cytostatic effect rather than to apoptosis. To 
verify this, we also measured BrdU incorporation in the same conditions after 24h of 
treatments. As expected, when IkarosER was active, the entry into the S phase was reduced 
and cells accumulated in G1; Myc induction increased the percentage of cells in S phase, 
while the double activation resulted in an intermediate effect (figure 40A). Again, without 
IL7 in the medium, cells are completely blocked in G1, unless Myc is overexpressed 
(figure 40B). Apoptotic events are not present at a significant level and does not seem to 
change after 24h of treatments, with or without IL7, at least measuring the subG1 
population based on propidium iodide (PI) incorporation (figure 41); nevertheless, more 
specific assays are needed to study cell death in detail. 
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Figure 39. Growth curves upon IkarosER and/or Myc activation in BH1 cells. Cells are treated with 
OHT, Dox or both to perform the growth curves with (A) or without IL7 (B) in the medium. Average and 




Figure 40. BrdU incorporation. Cells were treated with OHT, Dox or both, with (A) or without (B) IL7 in 
the medium and BrdU incorporation after 24h of treatment was measured. The percentage of BrdU-positive 
cells in S phase, as well as in G1 and G2 phases is reported. Cells were previously gated to exclude debris 
and aggregates. This experiment is representative of three biological replicates. 
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Figure 41. Evaluation of cell death. Cells were treated with OHT, Dox or both, with (A) or without (B) IL7 
in the medium; 24h later, cells were subjected to a BrdU pulse and collected. While stained to measure BrdU 
incorporation, cells were incubated overnight with propidium iodide (PI) to determine the DNA content. In 
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3.3.3. Transcriptional effect of Ikaros and Myc induction 
  
In order to identify the transcriptional programs behind the observed phenotypes, we 
collected cells at 4h, 8h and 24h after treatment with OHT, Dox or both to analyze the 
complete transcriptional profile of Ikaros/Myc response. 
From an initial qPCR analysis of the samples, Ikaros and Myc target genes resulted to be 
regulated as expected; on the other hand, the effect of the double activation was not clear, 
at least for these selected target genes (figure 38B). 
Subsequently, we profiled the total RNA in all these conditions, performing RNA-seq in 
triplicate. 
Analysis of genes that were deregulated in treated cells at each time point compared to the 
relative non-treated control, showed a substantial effect of IkarosER, but very little effects 
of Myc activation alone on gene expression (figure 42). The latter was expected in the 
conditions used here, as the exogenous Myc was induced in proliferating cells that already 
expressed endogenous Myc, with relatively modest changes in total Myc levels (figure 
38A). However, co-activation of Tet-Myc and IkarosER allowed sustained Myc expression 
in the presence of IkarosER activity, causing significant effects on both cell growth (as 
described above, figure 39) and gene expression, especially at 24h (figures 43 and 44). In 
figure 43, all the samples were compared and clusterized according to the similarity of 
their expression profiles. In this heatmap, samples in which only Myc is induced (red) are 
close to non-treated samples (grey); conversely, samples in which only IkarosER (green) 
or both IkarosER and Myc (blue) are activated share a high similarity at 4h and 8h, while 
they are well separated at 24h.  
The effect of Myc on Ikaros response is described more precisely in figure 44, which 
compare the response to co-activation of both factors (Y-axes) relative to IkarosER alone  
(X-axes), revealing a decrease in the extent of gene expression changes in the presence of 
Myc, particularly at 24h. 
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Figure 42. DEGs identified in BH1 cells upon IkarosER and/or Tet-Myc induction. Volcano plots 
representing DEGs identified with RNA-seq experiments in BH1 cells. Only genes that were significantly 
deregulated (qvalue <0.05) were considered. DEGs with log2(fold change) <0.5 are downregulated genes (in 
blue), while DEGs with log2(fold change) >0.5 are upregulated genes (in red). –log10(padj) values are 
saturated at a maximum value of 10. 
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Figure 43. Correlation heatmap of RNA-seq samples upon IkarosER and/or Myc activation in BH1 
cells. Heatmap representing the correlation and clusterization of all RNA-seq replicates in BH1 cells upon 
activation of Myc and/or IkarosER. In the colored squares inside the heatmap the major clusters are 
highlighted: non-treated cells (NT) or cells with only Myc clusterize together at 4, 8 and 24h (red square 
inside the heatmap); samples in which only IkarosER or IkarosER plus Myc are induces appeared similar at 4 
and 8h (blue square inside the heatmap); conversely, at 24h, samples with only IkarosER or IkarosER plus 
Myc activated, clusterize separatly suggesting a major effect on the transcriptional activity (black square 
inside the heatmap). 	  
	  
 
Figure 44. Correlation plots of gene expression upon IkarosER or IkarosER plus Myc activation in 
BH1 cells. The effect due to the co-activation of IkarosER and Myc (Y-axes) relative to IkarosER alone  (X-
axes) at 4, 8 and 24h is represented. 
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This behavior suggests that after 24h we are observing a general effect probably due to the 
opposite transcriptional program promoted by the two transcription factors. Since we are 
particularly interested in studying variations directly caused by the protein-protein 
interaction between Ikaros and Myc, we decided to focus on target genes already regulated 
at early time points. 
We started considering genes that were deregulated upon IkarosER activation alone, 
reasonably corresponding to Ikaros target genes (figure 45A); among them, we identified 
the ones whom expression was also significantly different between the condition in which 
both IkarosER and Myc were activated and that with only IkarosER activation (figure 
45B). Finally, we focused our attention on the genes that were behaving in this way along 
the entire time course, that were presumably the most direct (being already modulated at 
earlier time points) and consistent, retrieving a total of 113 genes (figure 45C). 
By analyzing more in detail the change in the expression level of these target genes, we 
can observe that around 80% of them are anti-regulated by IkarosER and Myc and, in 
particular, the majority is positively regulated by IkarosER and more downregulated in 
presence of Myc (figure 46). The complete list of genes divided in the four classes 
depicted in figure 46 is reported in Table 2. In the supplementary table 1, the complete data 
relative to log2(FoldChange) of the 113 DEGs upon IkarosER and/or Myc activation at all 
the time points are available 
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Figure 45. Ikaros and Myc common target genes in BH1 cells. Among genes significantly deregulated 
upon IkarosER activation (pvalue<0.05, without treshold on the log2(FoldChange) values) (A), we selected 
genes that were deregulate when both IkarosER and Myc were activated compared to IkarosER activation 
alone (B). The overlap of the DEGs identified in each time point resulted in 113 genes (C).	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Figure 46. Genes anti-regulated and co-regulated by IkarosER and Myc in BH1 cells. The pie charts (on 
the left) represent the fractions of genes anti- or co-regulated by IkarosER and Myc; the same classes are also 
represented on the scatter plots (on the right) with the log2(fold change) of DEGs in the IkarosER plus Myc 
samples (y axis) compared to the log2(fold change) of DEGs in presence of IkarosER alone (x axis). Only 
DEGs with a qvalue <0.05 were considered. Three genes, Lbh, Prox1 and Trp53i11 showed a different 
behaviour at 24h compared to the other time points. 
 
Interestingly, among the genes antagonistically regulated by IkarosER and Myc, were 
genes involved in the regulation of cell cycle. In particular, Asb2 (Guibal et al., 2001), 
Btg1 (Zhu et al., 2013), Cdkn1b (Polyak et al., 1994) and Rbm5 (Sutherland et al., 2005), 
that favor cell cycle arrest, were upregulated by IkarosER and downregulated in presence 
of Myc, in accordance with the expectations; vice-versa, Ccnd1 (Baldin et al., 1993), that 
is required for the G1/S transition, was downregulated by IkarosER alone and less 
downregulated in presence of Myc. 
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Many antagonistically regulated genes were also related to lipid metabolism and transport: 
Abcd1 (Wiesinger et al., 2013), Acox3 (Ferdinandusse et al., 2017), Cerk (Ordoñez et al., 
2017), Pyct1a (Hoover-Fong et al., 2014) and Spns3 (Perland et al., 2017). Myc 
involvement in lipid metabolism has been reported in different systems: in general, Myc 
seems to favor fatty acid biosynthesis during cell growth and to influence the lipid 
composition of cells during tumorigenesis (Dang 2013; Edmunds et al., 2014; Hall et al., 
2016). Ikaros role in the regulation of these pathways had not been deeply investigated; a 
connection between Ikaros and cholesterol biosynthesis was only provided by experiments 
performed in pituatury gland cells, in which Ikaros seemed to upregulate the expression of 
LDL-R and to regulates other genes involved in cholesterol homeostasis such as SREBP2 
and HmGCoAR (Loeper et al., 2008).  
In addition, genes related to energy stress were also identified: Prkaa2 encodes for a 
catalytic subunit of the AMPK energy-stress sensor that is activated in low energy 
conditions (Ross et al., 2016), while Deptor encodes for an inhibitor of the mTORC1/2 
complexes (Catena & Fanciulli, 2017), thus blocking energy consuming pathways. Both of 
them were downregulated by IkarosER alone and less downregulated when also Myc is 
present. Ikaros implication in the regulation of cellular homeostasis was proposed by a 
recent study according to which Ikaros exerts its tumor suppressor function, at least in part, 
by acting as a metabolic gatekeeper. In particular, the suggested hypothesis would be that 
Ikaros can restrict glucose uptake and metabolism, thus limiting glucose and energy supply 
to levels not sufficient for malignant transformation. The identification of Foxo1, that 
promotes gluconeogenesis (Zhang et al., 2006), might be related to this concept, too; 
nevertheless, Foxo1 also plays crucial roles in early steps of B cell development as well as 
in peripheral immune functions (Dengler et al., 2008), thus the regulation of this gene 
exerted by IkarosER and Myc could have multiple implications. 
Due to the complex and still not completely disentangled mechanisms that regulate cell 
metabolism and to the multiple feedback loops that control cellular homeostasis, it is 
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difficult to predict, at a first glance, the direction in which we expect to find these target 
genes regulated by either Ikaros and Myc; nevertheless, the fact that many of them belong 
to classes of genes that are functionally related with the known activities of the two 
transcription factors suggests that it could be worth to investigate more in depth the 
meaning of these findings.  
Finally, genes that resulted co-regulated by IkarosER and Myc appeared to have in general 
a less defined function and no particular classes of genes emerged. 
In summary, these results are in accordance with the opposite functions exerted by Ikaros 
and Myc in pre-B cells, particularly in cell cycle regulation and metabolic pathways. 
Further studies are needed to investigate the mechanism behind the regulation of these 











2610008E11Rik Abcb1b Mtrr Alpk2 
Abcd1 Abcc1   Apba1 
Ackr4 Acy1   Atp6v0a1 
Acox3 Atg9b   Cd248 
Adamtsl2 Bcl11a   Cyth4 
Aim1 Ccnd1   Gab2 
Ankrd44 D8Ertd82e   Il5ra 
Ap3m2 Deptor   Kctd12b 
Arid3b Dfna5   Klf3 
Asb2 Fgd2   Pcdh17 
Atg9a Frrs1   Ppp1r18 
Baz2a Kdelc1   Rasgrp3 
Bcl2l1 Mmp15   Rgs2 
Btg1 Nr1d1   Rnf150 
Calcoco1 Nrp2   Slc37a2 
Cblb Pdzrn3   Tmem108 
Cd37 Prkaa2   Tmtc1 
Cdkn1b Prrg4   (Lbh) 
Cerk Ptpn14   (Prox1) 
Chd3 Rasd2   (Trp53i11) 
Cklf Sdc1     
Cpm Slc19a2     
Cr2 Slc39a10     
Dennd1c Tbkbp1     
Dgka Xxylt1     
Dopey2 Zfp365     
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Dyrk1b       
Endou       
Ero1lb       
Fam214a       
Fam63b       
Fchsd1       
Foxo1       
Gdi1       
Git2       
Gltscr1       
H2-Oa       
H2-Ob       
Ifi203       
Il16       
Jakmip1       
Kmt2e       
Map4k2       
Mbd4       
Natd1       
Neil1       
Pcyt1a       
Pecam1       
Pias3       
Pink1       
Plekhg2       
Pyhin1       
Rab43       
Rag1       
Rbm5       
Rprl1       
Serinc5       
Siglecg       
Slc12a6       
Spns3       
Tbx6       
Tuba1a       
Ypel3       
Zfp821       
Zfp831       
Zhx3       
(Lbh)       
(Prox1)       
(Trp53i11)       
	  
Table 2. Lists of genes anti-regulated and co-regulated by Ikaros and Myc. Ikaros and Myc common 
target genes are listed according to the direction of their regulation. Genes in brackets (Lbh, Prox1, Trp53i11) 
have a different behaviour at 24h compared to 4h and 8h. The complete table reporting the log2(FoldChange) 
upon Ikaros and/or Myc activation is available in the supplementary table 1. 
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4. DISCUSSION 
	  
4.1. Identification of new Myc interactors using a MS-based 
approach. 	  
Myc is a key transcription factor that regulates many physiological cell functions and with 
the diffusion of high throughput sequencing techniques, such as ChIP-seq and RNA-seq, 
Myc activity has been deeply studied at a genomic scale. Our group recently proposed that 
the process of Myc binding site recognition on chromatin initially occurs in a sequence-
independent manner (Sabò & Amati, 2014), probably supported by the interaction with 
other proteins (Richart et al., 2016; Thomas et al., 2015). This, together with the 
observation that Myc can bind most of the active chromatin sites, but only part of them is 
actually regulated, strengthens the idea that many cofactors can be implicated in supporting 
and regulating Myc activity on DNA. In this contest, the identification of Myc interactors 
becomes particularly interesting to better clarify the complex and largely unknown 
network of Myc cooperations (Tu et al., 2015). 
Myc interactors have been studied with different techniques, the most used of which are 
two-hybrid assay, in vitro pull-down and co-immunoprecipitation. With the advent of 
mass-spectrometry, new approaches have been exploited to identify Myc cofactors. Indeed, 
mass spectrometry introduced the possibility to gain a broader (-omic) idea of the dynamic 
interactions in cells and an easier way to detect not only associations within single 
proteins, but also within multiprotein complexes. 
Until now, three published studies used MS-based approaches to investigate the Myc 
interactome. In the first paper, Koch et al. performed Tag-affinity-immunoprecipitation 
experiments in colorectal cancer cells and identified 221 proteins, some of which were 
validated by co-immunoprecipitation and two-hybrid assay (H. Koch et al., 2007). In the 
second paper, Agrawal et al. used a similar approach in human fibroblasts. They performed 
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tandem-affinity-immunoprecipitation both in label free conditions and with the stable 
isotope labeling with amino acids in cell culture (SILAC) MS approach, identifying a total 
of 418 putative Myc interactors (Agrawal et al., 2010). Finally, in the third paper, Dingar 
et al used a different technique called BioID proximity-based biotin labeling: the protein of 
interest (in this case Myc) is fused with a mutant Escherichia coli biotin ligase that 
biotinilates the surrounding proteins so that they can be easily purified with a streptavidin-
sepharose matrix. With this method, they identified 134 proteins in 293T-Rex cells (Dingar 
et al., 2015). The comparison of the data obtained from these three different studies 
revealed that the overlap was quite small: only three proteins have been identified in all of 
them: MAX, TRRAP and EP400 (Dingar et al., 2015). This high variability is partly 
expected since they used different techniques: different methods can be more useful to 
identify particular type of proteins (soluble proteins with tag affinity purification or 
proteins in less soluble compartments with BioID). Even more important can be the type of 
cells that are used for the analysis, since many interactors can be cell-type specific. 
In our work, we used the ChroP technique (Soldi & Bonaldi, 2014b) to specifically 
identify Myc interactors on chromatin. The ChroP technique involves cell crosslinking 
with formaldehyde (FA): the FA crosslink has many advantages, in fact it can stabilize 
protein interactions with DNA and, being FA a very small molecule, it can also stabilize 
the interaction within very close aminoacids, thus allowing the use of stronger detergents 
during the washing steps of the immunoprecipitation protocol. The same concept was 
recently used to study the estrogen receptor interactome, with the rapid 
immunoprecipitation mass spectrometry of endogenous proteins (RIME) technique 
(Mohammed et al., 2013) and other similar methods have been used in mammalian cells 
(TChP, Pourfarzad et al., 2013), in Drosophila (ChIP-MS, Wang et al., 2013) as well as in 
yeast (CHAP-Ms, Byrum et al., 2012), highlighting the high potential of this kind of 
approach.   
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In our experiments, we have quite a high variability between biological replicates that 
could be due partly to the intrinsic variability of the MS technique, but also to the fact that, 
by crosslinking proteins to DNA, stochastic or weak interactions difficult to reproduce can 
be stabilized too. Moreover, the presence of the FA could affect the MS detection of some 
peptides and the immunoprecipitation efficiency by masking recognized epitopes 
(Mohammed et al., 2016). For example, unexpectedly, we only identified Max in the first 
replicate: this is probably a technical artifact, since its presence is instead visible by ChIP-
WB and Myc binding to DNA, that we detected by ChIP-qPCR (figure 10), is possible 
only through the interaction with Max (Amati et al., 1992). Nevertheless, we identified 24 
proteins in common between all the three biological replicates and 51 proteins in common 
between at least two out of three experiments (figure 12). Among them, we identified 10 
already known Myc interactors (WDR5, RUVBL1/2, TRRAP, EP400, MCM2/3/6/7, 
HDAC1), mostly detected in all three replicates; additionally, we found 10 other proteins 
(PSMA7, DDX17, TRIM28, PTBP1, PRKDC, CCT5, YBX1, PGD, FBL, UBC) that were 
already identified in the previously mentioned proteomic datasets (Agrawal et al., 2010; H. 
Koch et al., 2007), but not yet validated (figure 12). The complete list of the identified 
Myc interactors is reported in the supplementary table 2. In that table, Myc interactors 
identified in our and other published MS datasets are reported and ranked according to the 
number of times they have been identified (see also the Appendix). We can see that MAX, 
EP400 and TRRAP are actually at the top positions, since they have been retrieved in all 
(or most of) the cases (figure 53). 
Among the new putative interactors identified with the label free ChroP technique, we 
defined the top candidates, that were judged of particular interest according to the 
information found in literature (figure 13). In particular, Ifi16 is considered a potent 
transcriptional repressor and, being able to bind regulatory regions of Myc promoter could 
be involved in the auto-regulation of this oncogene. In fact, an increase of Myc level in 
cells induces a feedback loop to control Myc expression itself; although the exact 
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mechanism behind this autoregulation is still not clear, it can require the formation of 
complexes between Myc and other cellular factors (Egistelli et al., 2009; Penn et al., 1990). 
Of notice, we identified multiple proteins belonging to the same complexes. For example 
we found many subunits of the NuRD complex, some of which were already known to 
interact with Myc (HDAC1, TRIM28, CHD4), while RBBP4 has been identified for the 
first time here. YWHAQ and SFN are two members of the 14-3-3 family of scaffold 
proteins, involved in many cell functions among which cell cycle regulation, metabolism, 
apoptosis and gene transcription (Obsilová et al., 2008). Of particular interest is the 
identification of both subunits of the facilitate chromatin transcription complex (FACT), 
SUPT16H and SSRP. The FACT complex is a nucleosome chaperone implicated in 
chromatin remodeling and associated with the acceleration of tumorigenic transformation; 
in particular, it seems to exert its activity on genes related to cell proliferation, cell death 
and cell differentiation and it has been reported to regulate the expression of its target 
genes through the interaction with transcription factors such as Myc itself (Garcia et al., 
2013). Finally, Ikaros and Aiolos belong to the same family of transcription factors 
involved in lymphocyte development and differentiation, and are the candidates we chose 
for further validation and functional studies.  
 
 4.2. Interplay between Ikaros/Aiolos and Myc 	  
Among the newly identified Myc interactors, we focused our attention on Ikaros and 
Aiolos, that were found in two and three of our MS triplicates, respectively. The 
identification of two members of the same family, that are known to form either homo-or 
heterodimers, as putative Myc interactors suggests that a relevant complex can be formed. 
Interestingly, Ikaros/Aiolos and Myc seem to be implicated in the same cellular functions, 
but playing opposite roles. First of all, they all are transcription factors, able to either 
activate or repress genes (Schwickert et al., 2014; Wanzel, 2003). One of the main 
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functions that characterize Myc and Ikaros/Aiolos activity is the regulation of cell 
proliferation: while Myc induces cell cycle progression (Amati et al., 1998), Ikaros 
decreases cell proliferation by blocking cells in G1 phase (figure 40) (Gómez-del Arco et 
al., 2004). They also play crucial role in cell differentiation: Myc expression can affect this 
process depending on the cellular contest, for example it can block differentiation of 
plasma cells (Calame et al., 2000), while it promotes differentiation of HSC (Wilson et al., 
2004) and B-cell early progenitors (Habib et al., 2007). Ikaros and Aiolos, instead, tend to 
promote cell differentiation: Ikaros particularly at earlier stages of hematopoiesis 
(Heizmann et al., 2013), Aiolos mostly during maturation of B lymphocytes (Cortes and 
Georgopoulos, 2004). Moreover, it is well known that Myc regulates cell metabolism to 
favor energy supply, in particular during tumorigenesis (Hsieh et al., 2015), while recently, 
it has been proposed that Ikaros could, at least in part, act as a tumor suppressor by 
creating a metabolic barrier that keeps the energy supply under the level necessary for 
malignant transformation (Chan et al., 2017). These behaviors are examples of Myc 
oncogenic potential (Dang, 2012) in opposition to Ikaros and Aiolos that, instead, are 
mostly considered tumor suppressors (Winandy et al., 1995). Altogether these observations 
lead to the hypothesis that Ikaros/Aiolos and Myc could actually compete to regulate each 
other activities. 
Nevertheless, the picture could be even more complex since while Ikaros/Aiolos act as 
tumor suppressors in B cell progenitors, they could be oncogenic in mature B cells. Indeed, 
they are expressed at high levels in mature B cells and in the correspondent lymphomas, 
where Myc generally plays a crucial role in tumor proliferation, and their expression seems 
to be necessary for tumor maintenance (Bjorklund et al., 2015). For example, multiple 
myeloma, as well as other blood malignancy deriving from mature B cells, is treated with 
Lenalidomide, that specifically induces Ikaros and Aiolos ubiquitination and subsequent 
degradation (Kronke et al., 2014; Lu et al., 2014). For this reason, we cannot exclude that, 
at later stages of B lymphopoiesis, Ikaros/Aiolos and Myc could also cooperate. These 
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observations imply that we have to consider very carefully the system we choose for our 
studies because experiments performed at different stages of B cell development could 
potentially lead to opposite results. 
In this contest, the first system we used was the p493-6 cell line. P493-6 are human mature 
B cells expressing high levels of endogenous Ikaros and Aiolos, and with a highly 
overexpressed exogenous Tet-Myc.  
The second system we used, BH1 cells, are murine pre-B cells transduced with inducible 
Ikaros and Myc.  
Finally, pre-B ALL cell lines could also be considered as suitable models for future studies 
on Ikaros/Myc interaction in a pathological condition that is known to be strictly dependent 
on Ikaros activity (Mullighan et al., 2009). 
After the MS identification of Ikaros and Aiolos, we validated their interaction with Myc 
by co-immunoprecipitation in native conditions. Of particular interest is the fact that Myc 
interaction with Ikaros/Aiolos is observed not only by overexpressing all the transcription 
factors in a host system (HEK293T cells, figure 17), but also at an endogenous level in 
different lymphocytic cell lines such as, p493-6, Burkitt’s lymphoma (Daudi, Raji, 
Namalwa, Ramos), multiple myeloma (H929, JJN3, KMS11), pre-B ALL (697, REH, Sup-
b15), Ba/f3 and BH1 cells, strengthening the idea that it is quite conserved across different 
B cell subtypes and differentiation stages (figures 15, 16 and 18).  
We tried to define more precisely the interplay of the three proteins by testing Myc 
interaction with Ikaros and Aiolos separately. Overall the results we obtained suggested 
that Aiolos is able to bind Myc also in the absence of Ikaros, while the vice-versa is still 
not completely clear (figures 17 and 18). 
The identification of the domains responsible for Ikaros/Aiolos/Myc interaction would be 
very interesting to better understand the structure of this complex and for further functional 
studies. Although we tried some preliminary experiments in that direction, we did not 
obtained reliable results, thus a more detailed analysis is needed. 
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ChIP-seq data in p493-6 cells also supported the idea of a co-binding between Ikaros, 
Aiolos and Myc on chromatin. Indeed, the overlap of the sites bound by Ikaros, Aiolos and 
Myc is quite high, both on promoters and distal sites (figures 26-27). Of notice is the fact 
that Ikaros and Aiolos distribution on chromatin does not seem to be macroscopically 
influenced upon Myc modulation, thus we exclude a broad effect on their DNA-binding 
ability. In order to explore a possible correlation between Ikaros/Aiolos co-binding with 
Myc and transcriptional regulation, we also performed RNA-seq in p493-6 cells with high 
and low Myc levels, to define Myc target genes in this system. From the integration of 
ChIP-seq and RNA-seq data in these conditions we observed that, while Myc preferentially 
binds to Myc-induced target genes, as expected (de Pretis et al., 2017), Ikaros/Aiolos 
enrichment is the same on promoters of Myc target and non-target genes (figure 30). Taken 
these observations together, the most probable scenario is that Myc interaction with 
Ikaros/Aiolos could only affect a subset of common target genes. To verify this hypothesis 
and to identify the putative common target genes, we are planning to perform RNA-seq 
experiments in p493-6 cells, in presence or absence of Ikaros/Aiolos so that, together with 
the dataset that we already have, we would be able to identify genes that are bound and 
regulated by all the factors in an antagonistic or common direction. 
We also tried to define Myc and Ikaros common target genes in BH1 cells, where we were 
able to easily modulate both Ikaros and Myc levels. Myc induction in this system appeared 
to be less efficient than expected (figures 38 and 42); nevertheless, we observed the 
opposite effect exerted by Ikaros and Myc on cell proliferation (figures 39 and 40) and on 
the regulation of their transcriptional programs (figures 43 and 44). The fact that Ikaros is 
able to repress Myc by directly binding to its promoter (Ma et al., 2010) imposes to be very 
careful in the interpretation of the obtained data, to distinguish between a general effect 
due to the transcriptional interplay of these factors and the direct effects possibly 
dependent on a protein-protein interaction. RNA-seq data allowed us to select genes that 
were regulated by both Ikaros and Myc at short time points, thus presumably coinciding 
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with direct target genes (figure 45). Interestingly, most of these genes were anti-regulated 
by Ikaros and Myc, while a smaller percentage was constituted by co-regulated genes 
(figure 46). Among the anti-regulated targets, we found genes involved in cell cycle 
control (Asb2, Btg1, Cdkn1b, Rbm5, Ccnd1), in metabolism of lipids (Abcd1, Acox3, Cerk, 
Pyct1a, Spns3, Nr1d1) and in the regulation of energy homeostasis (Prkaa2, Deptor, 
Foxo1). These classes of genes are consistent with the key role played by Ikaros and Myc 
in cell cycle regulation and can also be related to the newly suggested role of Ikaros as a 
metabolic gate keeper and a regulator of energy metabolism. (Chan et al., 2017). In some 
cases, such as for targets involved in cell cycle regulation, the direction of Ikaros- and 
Myc-dependent regulation is clear and in accordance with the expectations. In the other 
cases, the meaning of Ikaros/Myc antagonistic regulation needs to be investigated more in 
depth.  
Moreover, once we will have the complete datasets of RNA-seq and ChIP-seq in both our 
systems (p493-6 and BH1 cells), it would be interesting to compare Ikaros transcriptional 
activity in mature B cells and pre-B cells and, particularly, the interplay between Ikaros 
and Myc at different B cell developmental stages.  
Further studies on the mechanisms that drive the expression of these common target genes 
will shed light on the role of Ikaros-Myc interaction in transcriptional regulation. For 
example, Myc-mediated transcriptional repression has been suggested to occur also by 
antagonizing the activity of other transcription factors such as Miz-1: Myc binding to Miz-
1 would cause the release of Miz-1 cofactors p300 and Npm, and the recruitment of 
chromatin repressors (Staller al., 2001; Brenner et al., 2005). Similarly, Ikaros can regulate 
its target genes by competing with other transcription factors, such as STAT5, in different 
ways: either by binding to the same DNA motif or by recruiting on chromatin histone 
modifier that can promote transcriptional activation or repression (Katerndahl et al., 2017). 
Thus it is reasonable that the interaction between Myc and Ikaros/Aiolos on promoters of 
common target genes could imply similar mechanisms to determine the final direction of 
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transcriptional regulation. To assess this idea, we will select a subset of the antagonistically 
regulated genes (according to their fold change variation, biological function, presence of 
Ikaros and Myc motifs in their promoters) for which we will accurately characterize the 
dynamic of Myc and Ikaros binding to their promoters along with their transcriptional 
response, both by ChIP- and RT-qPCR and by Luciferase assays. 
In conclusion, we identified an interaction between Myc, Ikaros and Aiolos, and are 
working to better define its biological role. By unveiling the mechanism driving Myc-
Ikaros interplay, we would also be able to consider if and how targeting Ikaros (and 
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5. APPENDIX 
5.1. Experimental design 	  
Besides the label-free ChroP, we also performed a Stable Isotope Labeling by Amino acids in 
Cell culture (SILAC) ChroP experiment, in p493-6 cells, with the aim of increasing the 
accuracy of Myc interactors identification using different MS techniques. 
For the SILAC approach, two cell populations are grown separately in medium containing 
light (L) (12C6 and 14N4) or heavy (H) (13C6 and 15N4) lysine (Lys) and arginine (Arg). 
After the ChIP, the two samples are mixed in a 1:1 proportion and analyzed together: the 
m/z ratio obtained with the MS analysis will reveal to which population each protein 
belongs (figure 47) (Soldi & Bonaldi, 2013). 
Moreover, differently from the label-free ChroP, for the SILAC ChroP we performed the 
Myc-ChIP in both high and low Myc conditions. Indeed, this technique should be 
particularly sensible in comparing the proteome deriving from two different conditions, 
since the two samples are mixed and analyzed together. We performed it in two replicates 
called forward (FWD) and reverse (REV): in the forward experiment, the high Myc cell 
population was associated with heavy Arg and Lys and the low Myc condition with light 
aminoacids, while in the reverse experiment it was the opposite. We expected specific Myc 
interactors to be more abundantly immunoprecipitated when Myc was present at high level  
and thus to be identified as proteins with a heavy/light (H/L) (FWD experiment) or 
light/heavy (L/H) (REV experiment) ratio greater than 1.   
Subsequently, we compared the results that we obtained with the SILAC and label-free 
approaches together with previously published datasets in which Myc interactors were 
identified with other MS-based techniques. 
From this comparison we retrieved a list of the most reliable Myc cofactors candidates to 
test them with a functional siRNA-based screen. 
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The functional screen will allow us to identify Myc cofactors implicated in Myc’s 
transcriptional activity. To this aim, we used a 3T9 cell line, expressing an exogenous 
human MycER chimaera that can be activated adding OHT to the medium (Littlewood et 
al., 1995). These cells have been engineered using the CRISPR-Cas9 technique (Ran et al., 
2013) to insert the NanoLuc luciferase reporter gene under the control of a Myc target gene 
promoter and thus, if we transfect cells with an siRNA able to silence a cofactor which is 
necessary for Myc transcriptional activity, we should see a variation of the NanoLuc signal 
upon OHT activation. 
 
	  
Figure 47. SILAC ChroP scheme. Two different cell populations are separately grown in SILAC medium 
containing light or heavy aminoacids. The cell lisates are fragmented with the MNase enzyme and the Myc 
antibody is added to perform the ChIP. Immunocomplexes are recovered with the beads and washed. The 
material recovered from the two samples are mixed in a 1:1 proportion and processed for MS analysis. After 
the MS analysis, each peptide could be associated to the heavy or light population according to its m/z ratio 
(adapted from Soldi & Bonaldi, 2013). 
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5.2. Materials and methods 
 
5.2.1. Cell culture 	  
P493-6 cells were grown for at least eight replication cycles in RPMI medium with 10% 
Tet-free dyalized fetal bovin serum, 2 mM glutamine, 100 U/ml penicillin/streptomycin 
and 0.1 mM non-essential amino acids (NEAA, Lonza), with the addition of light (12C6 
and 14N4) or heavy (13C6 and 15N4) Lys (146 mg/L) and Arg (84 mg/L). For Low Myc 
conditions, p493-6 cells were treated with 200 ng/ml tetracycline (Tet) (Sigma) for 8h. 
BZ1 cells were grown in DMEM medium with 10% fetal bovine serum, 2 mM glutamine, 
10 U/ml penicillin/streptomycin.  
 
5.2.2. SILAC ChroP 	  
The ChroP protocol was followed as described in previous material and methods session. 
Myc-ChIP in cells with high or low Myc conditions were performed separately but the 
recovered material was then mixed in a 1:1 proportion before being loaded on gel and 
processed for MS analysis. 
 
5.2.3. MS analysis 	  
In-gel digestion and MS analysis were performed as previously described. 
 
5.2.4. siRNA tranfection 	  
2500 BZ1 cells were plated in each well of a white 96 multiwell plate and transfected with 
3 pmol siRNA and 0.3 µl RNAiMax transfection reagent. 
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5.2.5. Luciferase and resazurin measurement 	  
Resazurin was resuspended at a final concentration of 100 µM in PBS. The transfection 
medium was taken out of the wells except for 50 µl to which was added the same volume 
of the resazurin solution. Cells are left in the incubator for 2h and then, after 30 minutes at 
room temperature, the resazurin luminescence was read with a Tecan spectrophotometer 
(excitation λ: 535 nm; emission λ: 590 nm). 
After the resazurin measurement, 50 µl of solution per well were substituted with 50 µl of 
the Nanoglo mix (buffer+reagent) (Nano-Glo® Luciferase Assay System, Promega), the 
plate was shacked for few minutes and the nanoLuc luminescence was read with the Tecan 
spectrophotometer. 
 
 	    
	   114	  
5.3. Results 	  
5.3.1. Setting of the SILAC ChroP 	  
Since cells need to be cultured in the SILAC medium, we performed a growth curve to 
check if this could affect their growth. We plated and counted separately cells with the 
normal medium, with the SILAC medium containing light aminoacids and with the SILAC 




Figure 48. Growth curve with SILAC medium. P493-6 cells were cultured with normal medium, with the 
SILAC medium containing light aminoacids or with the SILAC medium containing heavy aminoacids and 
counted every two days to perform the growth curve. 
 
The next step consisted in verifying if the incorporation of heavy aminoacids by the cells 
actually occurred. To this aim, we collected cells grown in heavy and light SILAC medium 
after eight replication cycles, we prepared the cell lysates and part of the material was used 
to obtain an heavy:light 1:1 mix; the samples were then loaded on acrylamide gel and 
processed for the MS analysis (figure 49A). The distribution of proteins identified with a 
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H/L ratio in the mixed sample confirmed that it was actually a 1:1 mix, thus half of the 
material incorporated heavy aminoacids (figure 49C). Moreover, more than 96% of the 
peptides identified in the heavy sample fully incorporated heavy aminoacids indicating that 
the labeling was working efficiently (figure 49B).  
 
	  
Figure 49. Incorporation test. (A) Protein lysates obtained from cells grown in light medium (L), heavy 
medium (H) or a 1:1 mix of light and heavy lysates (H/L) have been separated by SDS-PAGE and dyed with 
Coomassie Blue. The red squares indicate the bands that have been cut and analyzed by MS. (B) Summary of 
the peptides identified in the Heavy sample: more than 96% of the peptides incorporated the heavy 
aminoacids. (C) Distribution of the proteins with a H/L ratio, identified in the H/L sample: the low standard 
deviation (SD) indicates that it is actually a 1:1 mix of light and heavy protein lysates. 
 
We controlled the efficiency of the ChIP by western blot and ChIP-qPCR. As expected, the 
enrichment of Myc-bound regions (Nucleolin, IFRD2) observed by ChIP-qPCR was 
correlated to the Myc protein level detected by western blot (figure 50). The rest of the 
material was mixed in a 1:1 heavy:light ratio and loaded on the gel for Coomassie Blue 
staining and sample processing. 
	   116	  
	  
Figure 50. Myc enrichment in SILAC ChroP experiments. Myc enrichment evaluated by ChIP-WB 
(upper part) and ChIP-qPCR (lower part) in forward (A) and reverse (B) experiments; Nucleolin and IFRD2 
are known Myc-bound promoters used as positive controls, while the acetylcholine receptor promoter 
(AchR) is not bound by Myc and used as negative control. The loaded input corresponds to 2.5% of the 
material used for the IP. IP=immunoprecipitated proteins. 
 
5.3.2. SILAC MS results 	  
The number of peptides identified in the input was similar in both forward (FWD) and 
reverse (REV) experiments; conversely, analysis of reverse Myc-ChroP resulted in lower 
number of proteins compared to the forward experiment. However, in both replicates Myc 
has been identified with a good number of peptides (9 and 12 for FWD and REV, 
respectively) and has a good and comparable H/L ratio value in the two experiments (log 2 
H/L ratio FWD=2.34; log2 H/L ratio REV=-3.2). Moreover, the majority of the proteins 
identified in REV experiment are present also in the FWD experiment (86%) (figure 51). 
Of the 44 proteins identified in both the replicates, 22 had a H/L higher than 1 (log2=0) 
and can be considered “enriched” . 
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Figure 51. SILAC MS results. In the forward experiments, a higher number of proteins have been identified 
compared to the reverse replicate; nevertheless, the overlap in quite good. Of the 44 proteins in common, 22 
have a H/L ration >0 and can be considered “enriched”. 	  
We enlarged our list of candidates considering not only the common ones, but all the 
proteins identified in the FWD experiment with a H/L ratio >1 and all the proteins 
identified in the REV experiment with a H/L ratio <1 in the reverse replicate, retriving a 
total of 68 proteins. 
 
5.3.3. Integration of the MS data 	  
The number of putative candidates identified with the SILAC technique (68 proteins in 
total) was much lower than the one identified with the label-free approach (468 proteins). 
Nevertheless, 27 candidates were in common within the two approaches, some of which 
were already known Myc interactors (i.e. Max, WDR5, TRRAP, MCM3) (figure 52). 
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Figure 52. Label-free and SILAC MS results. Total number of putative Myc interactors identified with the 
label free and SILAC ChroP. The 27 proteins reported on the right were identified with both SILAC and 
label free techniques. Already known interactors are highlighted in blue, while proteins identified as putative 
Myc interactors in other MS datasets (Koch et al., 2007; Agrawal et al., 2010), even though the interaction 
was not yet validated, are highlighted in green. 	  
 
To enlarge our dataset, we decided to consider all the interactors identified with both our 
label-free and SILAC experiments and to include the already published MS datasets 
(Agrawal et al., 2010; Dingar et al., 2015; Koch et al., 2007) and the Myc interactors 
reported in the Human Protein Reference Database (HPRD) (http://www.hprd.org/) (Peri et 
al., 2003). We ranked all these proteins according to the number of times they were 
identified and selected the ones that were identified at least twice, of which at least once in 
our data (figure 53). 
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Figure 53. Enlarged list of Myc interactors. Part of the Supplementary 2 table in which are reported all the 
putative Myc interactors identified in our data and in already published datasets (Koch et al., 2007; Agrawal 
et al., 2010; Dingar et al., 2015; Peri et al., 2003). All the proteins were ranked according to the number of 
times they have been identified. The ones identified at least twice and at least once in our datasets, were 
selected to be tested with the functional screen. Green= identified; white= not identified. 
 
5.3.4. Functional screen set up 	  
In order to functionally assess the role of the identified Myc interactors on its 
transcriptional activity we decided to set up a siRNA-based screen. 
We took advantage of immortalized murine fibroblasts, the BZ1 cell line, in which the 
exogenous human MycER is under the control of the Rosa26 promoter. The MycER 
protein is a chimaera that can be activated adding OHT to the medium, inducing its 
translocation from cytoplasm to nucleus and thus a rapid activation of Myc transcriptional 
activity (Littlewood et al.,1995). These cells have been further engineered using the 
CRISPR-Cas9 technique to insert the NanoLuc luciferase reporter gene under the control 
of the promoter of a Myc induced gene, St6galnac4. In this system, Myc activation by 
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OHT will lead to the upregulation of the reporter gene, which is easily readable thanks to 
the luminescence properties of the luciferase. Knock down of the selected candidates will 
lead to a decrease or increase in luminescence if they co-activate or antagonize Myc 
activity on that promoter (figure 54) 
We decided to activate cells for 24h with a low dose of OHT (25 nM) to avoid the 
saturation of the system. Moreover, we used resazurin as a normalizer for cell number and 
viability. 
Preliminary controls in non-transfected cells and in cells transfected with a siRNA against 
Myc, treated with OHT for 24h confirmed that the nanoLuc signal of the reporter gene 
strongly increases with MycER activation, while it does not change when cells are 
transfected with the siMyc (figure 55A). Conversely, the resazurin signal remains constant, 
as expected from a normalizer (figure 55B). We concluded that the system is working and 
can be used to test our siRNA library. 
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Figure 54. Functional screen setup. (A) BZ1 fibroblasts expressing an exogenous hMycER were 
engineered to have the NanoLuc luciferase reporter gene under the control of the St6galnac4 Myc target 
gene. (B) Screen model: the reporter gene is expressed at a basal level in normal conditions and is 
upregulated when OHT is added to the medium; if cells are transfected with an siRNA which silences a Myc 
cofactor, a change in the luciferase levels should be observed.   
 
 
	   122	  
	  
Figure 55. Preliminary controls. Non-transfected cells (NT) and cells transfected with an siRNA against 
Myc were treated with OHT for 24h. As expected, the NanoLuc signal significantly increases upon induction 
in non-transfected cells, while it does not change when the siMyc is present (A). Conversely, the resazurin 
signal remains constant, thus it can be used as normalizer for cell number and viability (B). 
 
5.4.5. Screen results 	  
We bought an siRNAs library against our list of candidates and performed the screen in 
two replicates. We plated cells in 96 multiwell plates and transfected them with the 
siRNAs. The day after, we added OHT to the medium (or ethanol in control cells) and after 
24h we read the nanoLuciferase signal by spectrophotometer to evaluate the induction of 
the reporter gene in Myc activated cells respect to controls. Unfortunately, the two 
replicates we prepared did not seem to correlate very well and it was hard to identify real 
candidates for further validation. Moreover, the few siRNAs that induced a consistent 
downregulation of the reporter signal in both replicates were, apart from the positive 
controls (siMyc and siMax), mostly against ribosomal proteins, so we could not distinguish 
if the effect was specific for Myc activity or due to a more general impairment in protein 
translation (figure 56). 
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Figure 56. Functional screen results. The results obtained from the two replicates (dark blue and light blue) 
do not correlate so well. Moreover, most of the siRNAs that induce a reduction of the reporter signal in both 
the experiments are targeting ribosomal proteins (*).	  
 
In conclusion, we set up a system that is potentially very useful as a functional screen to 
identify genes implicated in Myc activity, but we still need to fix some technical problems. 
Along this line we are preparing another cell line bearing an additional reporter (Renilla 
luciferase) under the control of a housekeeper gene that can be used as an internal 
normalizer for unspecific effects on transcription/translation. 
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Ptpn14 -0.650917374 -0.367236577 0.142805585 -0.896763603 -0.547986964 -0.12388203 -1.659730785 -1.029373077 0.031047087
Rasd2 -0.612418467 0.273948692 0.562358866 -0.629118707 0.106771571 0.609617885 -2.987740467 -1.515128672 0.208425051
Sdc1 -0.397878646 -0.136001221 0.188787304 -0.480566105 -0.190159826 0.264730716 -1.206517686 -0.670325873 0.047351102
Slc19a2 -0.304549181 0.068604407 0.275187327 -0.239532718 0.065564373 0.331971194 -0.599326294 -0.094261403 0.063348583
Slc39a10 -0.364382052 -0.116368547 0.107505163 -0.460215788 -0.257433793 0.066274624 -1.000963508 -0.680207834 -0.034724542
Tbkbp1 -0.762768417 -0.388254184 0.130250817 -1.014564681 -0.631607537 0.054071424 -2.536515278 -1.541562631 0.031556706
Xxylt1 -0.232515615 0.086011027 0.261982785 -0.354623657 -0.071656127 0.150379574 -1.181429565 -0.437652861 0.064783841
Zfp365 -0.4765213 0.042104217 0.233033793 -0.788003655 0.02055114 0.422793221 -2.283282166 -0.922617796 0.059439355
Mtrr 0.434770417 0.763893694 0.175150946 0.530736128 0.762467315 0.244713147 0.364612018 0.749203731 0.079741556
Ikaros DOWN/Myc DOWN
Alpk2 -1.426335259 -1.88752649 -0.319627808 -1.176703152 -1.654744764 -0.239229409 -0.29855436 -0.98114671 -0.061948622
Apba1 -0.762656193 -1.117967683 -0.148785936 -0.840174272 -1.307008669 -0.256465534 -0.448686014 -0.793923282 -0.145107055
Atp6v0a1 -0.73154847 -1.401545957 -0.532376938 -0.541484159 -1.453752004 -0.542292661 -0.335130251 -1.224142744 -0.208085066
Cd248 -1.475301339 -1.938394988 -0.192461626 -1.560271083 -1.943126261 -0.167923687 -1.617721289 -2.211667853 -0.118544988
Cyth4 -0.886793002 -1.206087561 -0.145945273 -0.965086728 -1.44049949 -0.220207531 -0.847889923 -1.118676155 -0.038473492
Gab2 -0.28950398 -0.523894029 -0.321910506 -0.528706855 -0.803477502 -0.407050395 -0.385461821 -0.632870101 -0.064198646
Il5ra -0.632477561 -1.162258407 -0.471660104 -0.869582167 -1.200495237 -0.29849865 -0.522231825 -0.834319061 -0.059543823
Kctd12b -0.738823444 -1.418245289 -0.466055301 -1.341569229 -1.929589771 -0.403021609 -1.394546539 -1.816019033 -0.063506767
Klf3 -0.670024793 -1.179970811 -0.483589263 -1.042523567 -1.599853212 -0.454149949 -0.962287053 -1.43563299 -0.152244381
Pcdh17 -0.915155321 -1.409217751 -0.409188493 -0.867673956 -1.539116669 -0.371615541 -1.15709451 -1.893561933 -0.111486341
Ppp1r18 -0.502738992 -0.912453698 -0.242333997 -0.57873491 -0.9291964 -0.207746162 -0.199596052 -0.621621187 -0.107963077
Rasgrp3 -1.486339227 -1.964708975 -0.27312871 -1.593951708 -2.454725632 -0.28168211 -2.211261325 -2.964153072 -0.161319603
Rgs2 -0.910897416 -1.225557774 -0.224093734 -0.846268948 -1.244782489 -0.10379063 -0.605289228 -1.252903822 -0.02570328
Rnf150 -0.532716238 -0.834189176 -0.19415426 -0.681265437 -0.912480978 -0.284346849 -0.677465796 -0.912257961 -0.057020884
Slc37a2 -0.886279517 -1.293429398 -0.228107173 -1.137962483 -1.430609704 -0.182402357 -1.335788951 -1.552427043 -0.116521589
Tmem108 -0.857858236 -1.369222423 -0.335726382 -1.178782561 -1.763946746 -0.450419917 -1.497990405 -1.910468357 -0.133727539
Tmtc1 -2.218849408 -3.004033171 -0.526997123 -2.680723347 -3.6553773 -0.683938153 -2.572485486 -3.402741933 -0.146307076
Lbh -0.188292491 -0.414779482 -0.148277353 -0.261468675 -0.480387109 -0.123531595 0.191131659 -0.165278682 -0.088308909
Prox1 -0.494972479 -1.246143491 -0.510061212 -0.614856401 -1.393404554 -0.586538758 0.237854541 -0.424295567 -0.135758323







Ikaros UP/Myc DOWN Ikaros DOWN/ Myc UP Ikaros UP/Myc UP Ikaros DOWN/Myc DOWN






































































Gene symbol Extended name Function
Antagonistic UP
2610008E11Rik unidentified /
Abcd1 ATP Binding Cassette Subfamily D Member 1 ABC transporter ikely involved in the peroxisomal transport or catabolism of very long chain fatty acids
Ackr4 Atypical Chemokine Receptor 4 Receptor for C-C type chemokines. This receptor has been shown to bind dendritic cell- and T cell-activated chemokines
Acox3 Acyl-CoA Oxidase 3, Pristanoyl Desaturation of 2-methyl branched fatty acids in peroxisomes
Adamtsl2 ADAMTS Like 2 Secreted glycoprotein that binds the cell surface and extracellular matrix
Aim1 CRYBG1, Crystallin Beta-Gamma Domain Containing 1 May function as suppressor of malignant melanoma. It may exert its effects through interactions with the cytoskeleton.
Ankrd44 Ankyrin Repeat Domain 44 Putative regulatory subunit of protein phosphatase 6 (PP6) that may be involved in the recognition of phosphoprotein substrates
Ap3m2 Adaptor Related Protein Complex 3 Mu 2 Subunit Subunit of the heterotetrameric adaptor-related protein comlex 3 (AP-3).The AP-3 complex plays a role in protein trafficking to lysosomes and specialized organelles
Arid3b AT-Rich Interaction Domain 3B Member of the ARID (AT-rich interaction domain) family of DNA-binding proteins. Members of the ARID family have roles in embryonic patterning, cell lineage gene regulation, cell cycle control, transcriptional regulation and possibly in chromatin structure modification
Asb2 Ankyrin Repeat And SOCS Box Containing 2 subunit of a multimeric E3 ubiquitin ligase complex that mediates the degradation of actin-binding proteins. This gene plays a role in retinoic acid-induced growth inhibition and differentiation of myeloid leukemia cells
Atg9a Autophagy Related 9A Involved in autophagy and cytoplasm to vacuole transport (Cvt) vesicle formation
Baz2a Bromodomain Adjacent To Zinc Finger Domain 2A Essential component of the NoRC complex. It plays a central role by being recruited to rDNA and by targeting chromatin modifying enzymes such as HDAC1, leading to repress RNA polymerase I transcription.
Bcl2l1 BCL2 Like 1 Potent inhibitor of cell death
Btg1 BTG Anti-Proliferation Factor 1 Member of an anti-proliferative gene family that regulates cell growth and differentiation. Expression of this gene is highest in the G0/G1 phases of the cell cycle and downregulated when cells progressed through G1.
Calcoco1 Calcium Binding And Coiled-Coil Domain 1 Functions as a coactivator for aryl hydrocarbon and nuclear receptors (NR). Involved in the transcriptional activation of target genes in the Wnt/CTNNB1 pathway
Cblb Cbl Proto-Oncogene B Negatively regulates TCR (T-cell receptor), BCR (B-cell receptor) and FCER1 (high affinity immunoglobulin epsilon receptor) signal transduction pathways.
Cd37 Cell Differentiation Antigen 37 Mediate signal transduction events that play a role in the regulation of cell development, activation, growth and motility
Cdkn1b Cyclin Dependent Kinase Inhibitor 1B Binds to and prevents the activation of cyclin E-CDK2 or cyclin D-CDK4 complexes, and thus controls the cell cycle progression at G1. The degradation of this protein is required for the cellular transition from quiescence to the proliferative state.
Cerk Ceramide Kinase Converts ceramide to ceramide 1-phosphate (C1P), a sphingolipid metabolite
Chd3 Chromodomain Helicase DNA Binding Protein 3 Components of a histone deacetylase complex referred to as the Mi-2/NuRD complex
Cklf Chemokine Like Factor Chemoattractant for neutrophils, monocytes and lymphocytes
Cpm Carboxypeptidase M Arginine/lysine carboxypeptidase. Its expression is associated with monocyte to macrophage differentiation
Cr2 Complement C3d Receptor 2 Eceptor for Epstein-Barr virus (EBV) binding on B and T lymphocytes
Dennd1c DENN Domain Containing 1C Guanine nucleotide exchange factor, regulates endosomal membrane trafficking and is involved in actin polymerization
Dgka Diacylglycerol Kinase Alpha Upon cell stimulation converts the second messenger diacylglycerol into phosphatidate, initiating the resynthesis of phosphatidylinositols and attenuating protein kinase C activity.
Dopey2 Dopey Family Member 2 May be involved in protein traffic between late Golgi and early endosomes
Dyrk1b Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1BDual-specificity kinase which possesses both serine/threonine and tyrosine kinase activities. Enhances the transcriptional activity of TCF1/HNF1A and FOXO1. promotes expression of the gluconeogenic enzyme glucose-6-phosphatase (G6PC)
Endou Endonuclease, Poly(U) Specific Endoribonuclease that cleaves single-stranded RNAs at uridylates and releases products that have 2-3-cyclic phosphate termini
Ero1lb Endoplasmic Reticulum Oxidoreductase 1 Beta Oxidoreductase involved in disulfide bond formation in the endoplasmic reticulum.
Fam214a Family With Sequence Similarity 214 Member A /
Fam63b MINDY Lysine 48 Deubiquitinase 2 Can remove ubiquitin from proteins
Fchsd1 FCH And Double SH3 Domains 1 /
Foxo1 Forkhead Box O1 Transcription factor that is the main target of insulin signaling and regulates metabolic homeostasis in response to oxidative stress
Gdi1 GDP Dissociation Inhibitor 1 Regulate the GDP-GTP exchange reaction of members of the rab family that are involved in vesicular trafficking of molecules between cellular organelles
Git2 GIT ArfGAP 2 GIT proteins regulate cytoskeletal dynamics and participate in receptor internalization and membrane trafficking.
Gltscr1 Glioma Tumor Suppressor Candidate Region Gene 1 May play a role in BRD4-mediated gene transcription.
H2-Oa Heterodimer encoded by H2-Oa and b in the MCH II class region, shown to be physically associated with H2-M in B cells and to downregulate its function
H2-Ob Heterodimer encoded by H2-Oa and b in the MCH II class region, shown to be physically associated with H2-M in B cells and to downregulate its function
Ifi203 interferon activated gene 203 /
Il16 Interleukin 16 Chemoattractnt, ligand for CD4
Jakmip1 Janus kinase and microtubule interacting protein 1 Associates with microtubiles and may play a role in the microtubule-dependent transport of the GABA-B receptor. May play a role in JAK1 signaling and regulate microtubule cytoskeleton rearrangement
Kmt2e Lysine MEthyltransferase 2E Histone methyltransferase that specifically mono- and dimethylates Lys-4 of histone G. REgulator of hematopoiesis, cell cycle regulator, required to suppress inappropriate expression of S-phase-promoting genes; overexpression inhibits cell cycle progression
Map4k2 Mitogen-Activated PRotein Kinase Kinase Kinase Kinase 2SEr/Thr kinase. REquired for efficient sctivation of JNKs
Mbd4 Methyl-CpG Binding Domain 4, DNA Glycosylase Mismatch-specific DNA N-glycosylase involved in DNA repair
Natd1 N-Acetyltransferase Domain Containing 1 /
Neil1 Nei Like DNA Glycosylase 1 Acts as DNA glycosylase that recognizes and removes damaged bases. 
Pcyt1a Phosphate Cytidylyltransferase 1, Choline, Alpha Involved in the regulation of phosphatidylcholine biosynthesis
Pecam1 Platelet And Endothelial Cell Adhesion Molecule 1 The encoded protein is a member of the immunoglobulin superfamily and is likely involved in leukocyte migration, angiogenesis, and integrin activation.
Pias3 Protein Inhibitor Of Activated STAT 3 E3-type small ubiquitin-like modifier (SUMO) ligase;  role as a transcriptional coregulation in various cellular pathways, including the STAT pathway and the steroid hormone signaling pathway.
Pink1 PTEN Induced Putative Kinase 1 Serine/threonine protein kinase that localizes to mitochondria. It is thought to protect cells from stress-induced mitochondrial dysfunction. 
Plekhg2 Pleckstrin Homology And RhoGEF Domain Containing G2RhoGTPase that can activate CDC42 by promoting exchange of GDP for GTP on CDC42
Pyhin1 Pyrin And HIN Domain Family Member 1 Tumor suppressor activity of IFN in breast cancer cells. Promotes ubiquitination and subsequent degradation of MDM2, which leads to p53/TP53 stabilization.
Rab43 RAB43, Member RAS Oncogene Family Rab are key regulators of intracellular membrane trafficking
Rag1 Recombination Activating 1 Involved in activation of immunoglobulin V-D-J recombination
Rbm5 RNA Binding Motif Protein 5 Plays a role in the induction of cell cycle arrest and apoptosis through pre-mRNA splicing of multiple target genes including the tumor suppressor protein p53. 
Rprl1 ribonuclease P RNA-like 1 /
Serinc5 Serine Incorporator 5 Enhances the incorporation of serine into phosphatidylserine and sphingolipids
Siglecg sialic acid binding Ig-like lectin G B1 cell inhibitory receptor
Slc12a6 Solute Carrier Family 12 Member 6 Mediates electroneutral potassium-chloride cotransport.
Spns3 Sphingolipid Transporter 3 Sphingolipid transporter
Tbx6 T-Box 6 Role in the determination of the fate of axial stem cells: neural vs mesodermal
Tuba1a Tubulin Alpha 1a Major components of microtubules
Ypel3 Yippee Like 3 Involved in proliferation and apoptosis in myeloid precursor cells.
Zfp821 Zinc Finger Protein 821 /
Zfp831 Zinc Finger Protein 831 /
Zhx3 Zinc Fingers And Homeoboxes 3 Acts as a transcriptional repressor. Involved in the early stages of mesenchymal stem cell (MSC) osteogenic differentiation
Antagonistic DOWN
Abcb1b ATP-binding cassette, sub-family B, member 1B ABC transporter  involved in multidrug resistance.
Abcc1 ATP Binding Cassette Subfamily C Member 1 ABC transporter  involved in multidrug resistance.
Acy1 Aminoacylase 1 Function in the catabolism and salvage of acylated amino acids.
Atg9b Autophagy Related 9B Involved in autophagy and cytoplasm to vacuole transport (Cvt) vesicle formation
Bcl11a B-Cell CLL/Lymphoma 11A Transcription factor associated with the BAF SWI/SNF chromatin remodeling complex 
Ccnd1 Cyclin D1 This cyclin forms a complex with and functions as a regulatory subunit of CDK4 or CDK6, whose activity is required for cell cycle G1/S transition.
D8Ertd82e / /
Deptor DEP Domain Containing MTOR Interacting Protein Negative regulator of the mTORC1 and mTORC2 signaling pathways
Dfna5 Non-syndromic hearing impairment protein 5 /
Fgd2 FYVE, RhoGEF And PH Domain Containing 2 May play a role in leukocyte signaling and vesicle trafficking in antigen-presenting cells in the immune system
Frrs1 Ferric Chelate Reductase 1 Reduce ferric to ferrous iron before its transport from the endosome to the cytoplasm
Kdelc1 KDEL Motif Containing 1 Proteins carrying this motif are bound by a receptor in the Golgi apparatus so that the receptor-ligand complex returns to the endoplasmic reticulum.
Mmp15 Matrix Metallopeptidase 15 Involved in the breakdown of extracellular matrix
Nr1d1 Nuclear Receptor Subfamily 1 Group D Member 1 Transcriptional repressor which coordinates circadian rhythm and metabolic pathways in a heme-dependent manner. Also regulates genes involved in metabolic functions, including lipid and bile acid metabolism, adipogenesis, gluconeogenesis and the macrophage inflammatory response
Nrp2 Neuropilin 2 May play a role in cardiovascular development, axon guidance, and tumorigenesis
Pdzrn3 PDZ Domain Containing Ring Finger 3 E3 ubiquitin-protein ligase
Prkaa2 Protein Kinase AMP-Activated Catalytic Subunit Alpha 2 Catalytic subunit of the AMP-activated protein kinase (AMPK
Prrg4 Proline Rich And Gla Domain 4 /
Ptpn14 Protein Tyrosine Phosphatase, Non-Receptor Type 14 May play a role in the regulation of lymphangiogenesis, cell-cell adhesion, cell-matrix adhesion, cell migration, cell growth 
Rasd2 RASD Family Member 2 Activator of mechanistic target of rapamycin 1 
Sdc1 Syndecan 1 Participates in cell proliferation, cell migration and cell-matrix interactions via its receptor for extracellular matrix proteins
Slc19a2 Solute Carrier Family 19 Member 2 High-affinity transporter for the intake of thiamine.
Slc39a10 Solute Carrier Family 39 Member 10 May act as a zinc-influx transporter.
Tbkbp1 TBK1 Binding Protein 1 Adapter protein which constitutively binds TBK1 and IKBKE playing a role in antiviral innate immunity.
Xxylt1 Xyloside Xylosyltransferase 1 /
Zfp365 Zinc Finger Protein 365 May play a role in uric acid excretion.
Synergic UP
Mtrr 5-Methyltetrahydrofolate-Homocysteine Methyltransferase ReductaseFunctions in the synthesis of methionine by regenerating methionine synthase to a functional state.
Synergic DOWN
Alpk2 Alpha Kinase 2 Kinase that recognizes phosphorylation sites in which the surrounding peptides have an alpha-helical conformation.
Apba1 Amyloid Beta Precursor Protein Binding Family A Putative function in synaptic vesicle exocytosis
Atp6v0a1 ATPase H+ Transporting V0 Subunit A1 Required for assembly and activity of the vacuolar ATPase
Cd248 CD248 Molecule May play a role in tumor angiogenesis.
Cyth4 Cytohesin 4 Promotes the activation of ARF factors through replacement of GDP with GTP.
Gab2 GRB2 Associated Binding Protein 2 They act as adapters for transmitting various signals in response to stimuli through cytokine and growth factor receptors
Il5ra Interleukin 5 Receptor Subunit Alpha Receptor for interleukin-5.
Kctd12b Potassium Channel Tetramerization Domain Containing 12Auxiliary subunit of GABA-B receptors that determine the pharmacology and kinetics of the receptor response
Klf3 Kruppel Like Factor 3 Binds to the CACCC box of erythroid cell-expressed genes. May play a role in hematopoiesis
Lbh Limb Bud And Heart Development Transcriptional activator which may act in mitogen-activated protein kinase signaling pathway.
Pcdh17 Protocadherin 17 Potential calcium-dependent cell-adhesion protein.
Ppp1r18 Protein Phosphatase 1 Regulatory Subunit 18 Protein phosphatase-1
Prox1 Prospero Homeobox 1 May play an essential role during development
Rasgrp3 RAS Guanyl Releasing Protein 3 Guanine nucleotide exchange factor (GEF) for Ras and Rap1.
Rgs2 Regulator Of G Protein Signaling 2 Regulates G protein-coupled receptor signaling cascades
Rnf150 Ring Finger Protein 150 /
Slc37a2 Solute Carrier Family 37 Member 2 Inorganic phosphate and glucose-6-phosphate antiporter. 
Tmem108 Transmembrane Protein 108  Regulates the organization and stability of the microtubule 
Tmtc1 Transmembrane And Tetratricopeptide Repeat Containing 1Endoplasmic reticulum adaptor protein
Trp53i11 Tumor Protein P53 Inducible Protein 11 /
Supplementary table 2. In this table, all Myc interactors identified in our experiments (label free and 
SILAC) or in already published datasets (Koch et al, 2007; Agrawal et al, 2010; Dingar et al, 2015; HPDR, 
Peri et al, 2003) are reported. Each column represents one dataset and cells are colored in green if the 
corresponding protein has been identified in that experiment. The proteins are ranked according to the 
number of times they have been identified considering all the datasets ("TOT" column). The number of 
times each protein has been identified in our datasets is also reported ("TOT in our data" column).
 not identified
 identified































































































































































































































































































































































































































































































































































































































































SH3P9; BIN1 1 0
SMAD2 1 0
TFAP2B 1 0
SMARCB1 1 0
P73 1 0
CCNT1 1 0
MAPK7 1 0
TUBA2 1 0
TUBA1B 1 0
CDC6 1 0
DNMT3A 1 0
SUP73H 1 0
PAF350/400 1 0
SMAD3 1 0
NMI 1 0
ZNF151 1 0
TUBA8 1 0
MYCBP 1 0
RAGE-1 1 0
MYCBP2 1 0
SPAG9 1 0
MINA 1 0
UBB 1 0
CDKN2A 1 0
GCN5L2 1 0
ERK1 1 0
NFYC 1 0
MXI1 1 0
SNIP1 1 0
BCL2 1 0
GCN5L1 1 0
ZNF281 1 0
HECTH9 1 0
DBC-1 1 0
MYBBP1A 1 0
BAF53A 1 0
H2B 1 0
SMARCA6 1 0
MMS19L 1 0
GTF3C1 1 0
GTF3C2 1 0
GTF3C3 1 0
U5-200kD 1 0
U5-116kD 1 0
HNRPF 1 0
HNRPK 1 0
NOL5A 1 0
HSA9761 1 0
ARHGEF2 1 0
DDX15 1 0
DDX20 1 0
DDX52 1 0
HNRPA0 1 0
IMP-1 1 0
IMP-2 1 0
KIAA0332 1 0
RNGTT 1 0
U5-102kD 1 0
XRN1 1 0
AKAP8L 1 0
POLE 1 0
LTAg 1 0
CHTF18 1 0
SMC2L1 1 0
SMC4L1 1 0
KU70 1 0
FANCD2 1 0
ERCC3 1 0
KU80 1 0
MSH3 1 0
EIF3S2 1 0
EF1G 1 0
EIF4ENIF1 1 0
MARS 1 0
MRPS22 1 0
MRPS34 1 0
PELO 1 0
SKP1A 1 0
PSMA1 1 0
PSMA2 1 0
PSMA5 1 0
PSME4 1 0
UBE3C 1 0
UBR2 1 0
FBX29 1 0
PRSS15 1 0
PSMC3 1 0
PSMD4 1 0
SQSTM1 1 0
BCR 1 0
PPP6C 1 0
ARL1 1 0
GCS1 1 0
GSG2 1 0
IRAK1 1 0
MEP50 1 0
NEK9 1 0
PLK1 1 0
RPN1 1 0
DNAJA2 1 0
DNAJB6 1 0
TCP1 1 0
CCT2 1 0
DNAJA3 1 0
CCT4 1 0
CCT6A 1 0
CCT8 1 0
HSPH1 1 0
IRS4 1 0
C1QBP 1 0
IKBKAP 1 0
CYR61 1 0
RIN1 1 0
SHOC2 1 0
14-3-3 1 0
TUBAL1 1 0
COPG 1 0
COPG2 1 0
KPNB1 1 0
MYO9B 1 0
NUP133 1 0
SLC25A12 1 0
SLC25A13 1 0
XPO1 1 0
ABCB7 1 0
ARF4 1 0
ATP1A1 1 0
ATP2A2 1 0
DNCH1 1 0
IPO13 1 0
IPO9 1 0
KPNA4 1 0
MYO5C 1 0
MYO9A 1 0
NUP153 1 0
PLEKHC1 1 0
RANBP2 1 0
SEC61A2 1 0
SLC25A1 1 0
SLC25A11 1 0
TUBG1 1 0
TUBGCP2 1 0
XPOT 1 0
ALDH1B1 1 0
NDUFS3 1 0
OAT 1 0
P4HA1 1 0
AASS 1 0
ASS 1 0
CEPT1 1 0
GCDH 1 0
IDH3A 1 0
IDH3G 1 0
NDUFA5 1 0
NDUFA8 1 0
NDUFS1 1 0
PLOD3 1 0
PPT1 1 0
PTE1 1 0
PTGES2 1 0
SPTLC1 1 0
GCN1L1 1 0
IQGAP3 1 0
C1ORF25 1 0
FLJ20272 1 0
HIGD1A 1 0
ILVBL 1 0
SLIT2 1 0
SSR4 1 0
ZNF121 1 0
LMO7 1 0
TTN 1 0
IK 1 0
MFGE8 1 0
NAV2 1 0
AMOTL2 1 0
ARSB 1 0
ASPM 1 0
ATAD3B 1 0
C9orf79 1 0
CSPP1 1 0
DOCK7 1 0
FAM122B 1 0
IKZF2 1 0
IL4R 1 0
IQCE 1 0
KIF25 1 0
KNDC1 1 0
LECT1 1 0
MICALL2 1 0
MIPEP 1 0
MLH3 1 0
NLRX1 1 0
NRXN3 1 0
PDZD2 1 0
RCOR3 1 0
RIN3 1 0
ROBO2 1 0
SCO2 1 0
SDK1 1 0
SEC31B 1 0
SPEG 1 0
XDH 1 0
ZCCHC11 1 0
DNAJB11 1 0
RBPJ 1 0
CHCHD3 1 0
SDF2L1 1 0
ACTG1 1 0
CTNND1 1 0
TRIM21 1 0
TFAM 1 0
TCF12 1 0
FOXP1 1 0
EEF1G 1 0
NDUFAF3 1 0
PHLDB2 1 0
AKAP6 1 0
CDYL 1 0
RNF130 1 0
SSBP1 1 0
CYC1 1 0
AFAP1 1 0
PDLIM7 1 0
SRP9 1 0
FHL2 1 0
RARS 1 0
RBMS2 1 0
IGF2BP3 1 0
ADIPOR1 1 0
FOSL1 1 0
MZT2B 1 0
RCN1 1 0
CALM1 1 0
CANK2D 1 0
CTPS 1 0
OPA1 1 0
ERC1 1 0
HELZ 1 0
OBFC2B 1 0
MRPL53 1 0
TP53 1 0
LEPRE1 1 0
SH3BP4 1 0
SSR1 1 0
ECSIT 1 0
SNRPC 1 0
MYCN 1 0
LOX 1 0
HIST1H2BM 1 0
MAP1A 1 0
AGPAT1 1 0
CDC26 1 0
CSMD2 1 0
HIST1H2AE 1 0
HSD17B4 1 0
PREX2 1 0
TNFRSF18 1 0
WIPF1 1 0
CALCOCO2 1 0
TEX2 1 0
CEP55 1 0
KANK2 1 0
TUBB6 1 0
ARID5B 1 0
RPL26L1 1 0
AHNAK 1 0
DYNC1LI1 1 0
FOSL2 1 0
LUZP1 1 0
ACACA 1 0
ATM 1 0
CENPV 1 0
CHAF1B 1 0
CNOT4 1 0
DDX51 1 0
FANCM 1 0
FZD10 1 0
NPTX2 1 0
OBSCN 1 0
OPHN1 1 0
PDLIM4 1 0
SGOL2 1 0
SNRPF 1 0
ABCA1 1 0
ABRA 1 0
ADAMTS20 1 0
ANLN 1 0
AP4B1 1 0
ARG1 1 0
ASXL1 1 0
ATP6V1D 1 0
BAT2 1 0
BCMO1 1 0
BPTF 1 0
C14orf43 1 0
C18orf22 1 0
C20orf160 1 0
C20orf20 1 0
C2orf89 1 0
C3orf15 1 0
CEP192 1 0
CPSF2 1 0
CYP2U1 1 0
DENND3 1 0
DHX58 1 0
DIP2B 1 0
DIRAS2 1 0
EHHADH 1 0
ETV6 1 0
EXOSC1 1 0
FAM117B 1 0
FRMD6 1 0
FZR1 1 0
H3F3B 1 0
HCFC2 1 0
HIRA 1 0
HOXB5 1 0
IL1B 1 0
INSM1 1 0
ITGAL 1 0
KALRN 1 0
KCNG3 1 0
KIAA0922 1 0
KIAA1274 1 0
KLF10 1 0
LBX2 1 0
LRP1B 1 0
MAGEB10 1 0
MAP3K1 1 0
MAP3K7 1 0
MATN4 1 0
MCF2L2 1 0
MCTP2 1 0
MED12L 1 0
MIB1 1 0
MKL1 1 0
MRPL14 1 0
MTRF1 1 0
MYO18A 1 0
NAIP 1 0
NCOR1 1 0
NPC1L1 1 0
PLEKHH1 1 0
POP4 1 0
PPA2 1 0
PPP2R3B 1 0
PRG4 1 0
PRKAR1B 1 0
PRR11 1 0
RAG1 1 0
RALGAPA1 1 0
RUNX2 1 0
SAMD9L 1 0
SETX 1 0
SH3RF1 1 0
SHANK2 1 0
SIPA1L3 1 0
SNX19 1 0
ST3GAL3 1 0
ST6GALNAC6 1 0
TAF2 1 0
TENC1 1 0
TRAK1 1 0
USP10 1 0
WDFY3 1 0
ZBTB40 1 0
ZC3H7B 1 0
ZFHX3 1 0
ZNF354B 1 0
ZNF541 1 0
ZNF586 1 0
ZNF703 1 0
ZNF740 1 0
IGF2BP2 1 0
RBM9 1 0
PDS5B 1 0
NCOR2 1 0
IMMT 1 0
GFPT1 1 0
PHF6 1 0
ATP5O 1 0
SMC6 1 0
YAF2 1 0
CDC42EP1 1 0
CLEC11A 1 0
HIST1H1A 1 0
JUN 1 0
KIAA0319 1 0
NOMO2 1 0
PLOD2 1 0
SDF4 1 0
TPP1 1 0
TRPM1 1 0
ZC3H18 1 0
BAHCC1 1 0
C2orf29 1 0
CACNA1G 1 0
CALD1 1 0
CROCC 1 0
DACT1 1 0
DYNLRB1 1 0
FAF2 1 0
FAM116B 1 0
FASTKD1 1 0
FLJ45139 1 0
GLTSCR1 1 0
IL16 1 0
KARS 1 0
KIAA2026 1 0
KIF20B 1 0
LGALS7 1 0
LIMS1 1 0
MAGI1 1 0
MUC5AC 1 0
OTUD4 1 0
PDHA2 1 0
PHF20 1 0
PLA2G4A 1 0
PPIP5K2 1 0
RPS21 1 0
RRP1B 1 0
SEC11C 1 0
SHE 1 0
SMYD4 1 0
TBL2 1 0
TDG 1 0
UQCRFS1 1 0
ZFP106 1 0
HOXA10 1 0
CDV3 1 0
MAST4 1 0
MUC3A 1 0
TUBB3 1 0
ABCA9 1 0
ABCB1 1 0
ACACB 1 0
AGK 1 0
AHNAK2 1 0
AIFM2 1 0
AJAP1 1 0
ALPK3 1 0
ARFGAP1 1 0
ARID4B 1 0
BRWD1 1 0
BUB1 1 0
C2orf16 1 0
CDK5RAP2 1 0
CLSTN1 1 0
CNTN5 1 0
CSF1 1 0
CTBP1 1 0
CYBA 1 0
DDX47 1 0
DNAH8 1 0
DUSP15 1 0
ELFN1 1 0
ERP44 1 0
EXPH5 1 0
FERMT3 1 0
FLJ44674 1 0
FOXC2 1 0
FRMPD4 1 0
GABRR1 1 0
GEMIN5 1 0
GPR158 1 0
HK1 1 0
KIF12 1 0
LCN12 1 0
MAP3K5 1 0
MAP7D1 1 0
MFHAS1 1 0
MYO1D 1 0
NAV3 1 0
NFIL3 1 0
NPR1 1 0
NRD1 1 0
NUP98 1 0
ODZ2 1 0
PADI2 1 0
PITX2 1 0
POLG 1 0
POLR3A 1 0
RFX2 1 0
RRM1 1 0
SACS 1 0
SBNO2 1 0
SDHA 1 0
SLC25A10 1 0
SUCLG2 1 0
TMPRSS11A 1 0
TNR 1 0
TPH1 1 0
TRAP1 1 0
UBA1 1 0
USP36 1 0
USP48 1 0
XKRX 1 0
ZNF238 1 0
ZZEF1 1 0
ZBTB33 1 0
TAFL6 1 0
BRD4 1 0
TAF9B 1 0
FAM48A 1 0
TAF5L 1 0
EPC2 1 0
TADA1 1 0
VPS72 1 0
DIDO1 1 0
ARID1A 1 0
PPP1R10 1 0
SUPT7L 1 0
CCDC101 1 0
ING3 1 0
SUPT3H 1 0
TAF10 1 0
MED1 1 0
TAF12 1 0
YEATS4 1 0
KDM3B 1 0
CHD8 1 0
RBM27 1 0
RDBP 1 0
TRIM24 1 0
SIN3B 1 0
MBTD1 1 0
YEATS2 1 0
SPEN 1 0
TASA2B 1 0
PES1 1 0
TADA3 1 0
SNW1 1 0
MGA 1 0
LRWD1 1 0
ARID3B 1 0
TRIM33 1 0
TAF9 1 0
BAG2 1 0
SETD1A 1 0
BAP1 1 0
ZMYM2 1 0
ATXN7L2 1 0
WDR36 1 0
VBP1 1 0
SUGP1 1 0
SMARCE1 1 0
ARID1B 1 0
THAP11 1 0
TCF20 1 0
ZMYND8 1 0
PFDN6 1 0
WHSC2 1 0
UTP14A 1 0
NOC3L 1 0
XAB2 1 0
KANSL3 1 0
MGEA5 1 0
MLL4 1 0
HMGXB4 1 0
CCDC99 1 0
ZC3H14 1 0
WAC 1 0
MEAF6 1 0
JMJD1C 1 0
CDC73 1 0
CCNK 1 0
CFDP1 1 0
IRF2BP2 1 0
TPX2 1 0
LIN54 1 0
LUC7L3 1 0
USP22 1 0
NFRKB 1 0
PPIL1 1 0
DPY30 1 0
NUP50 1 0
ELAC2 1 0
NFIA 1 0
WIZ 1 0
WRNIP1 1 0
DGCR14 1 0
HEXIM1 1 0
WDR3 1 0
NCAPH 1 0
MED23 1 0
TBPL1 1 0
CPSF7 1 0
PRPF3 1 0
TLE3 1 0
